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ABSTRACT 
 
 
 
Otitis Media is one of the most common childhood diseases. 
Recurrent acute otitis media (RAOM) is characterized by 
repeated episodes of inflammation of the middle ear in 
conjunction with middle ear fluid, and often with an inflamed or 
bulging eardrum. Defective clearance by the Eustachian tube 
results in mucus build-up and is characteristic of otitis media 
with effusion (OME). Streptococcus pneumoniae, Haemophilus 
influenzae, Moraxella catarrhalis, respiratory syncytial virus, and 
rhinovirus are the most common contributors to otitis media 
pathogenesis. In New Zealand, OME has been implicated with 
conductive hearing loss in childhood and has been shown to 
significantly impact on speech and language development. New 
Zealand Maori and Polynesian children have displayed 
significantly higher hearing test failure rates than European-
Caucasian children. 
 
The collectins, Surfactant Protein (SP)-A and –D are encoded by 
three genes (SP-A1, SP-A2, and SP-D) and are host defense 
proteins present in the middle ear and Eustachian tube. Single 
nucleotide polymorphisms (SNPs) in SP-A1 and SP-A2 have been 
associated with increased or decreased susceptibility to otitis 
media, meningococcal disease, and range of respiratory 
diseases. Using allele-specific primers and real-time PCR with 
SYBR® Green I melting curve analysis, four groups of individuals 
were genotyped for eleven SP-A1, SP-A2, and SP-D SNPs: 
European-Caucasian individuals with RAOM/OME; New Zealand 
Abstract iii
Maori/Polynesian individuals with RAOM/OME; individuals with 
meningococcal disease; and a control group. The computer 
program, Haploview, was employed to perform χ2 analyses and 
identify statistically significant associations of alleles/haplotypes 
with RAOM/OME or meningococcal disease. 
 
In the European-Caucasian population, two SP-A1 alleles, one 
SP-A2 allele, and four haplotypes (CGAGC, 1A3, 1A9, and 1A10) 
were found to be associated with increased risk of RAOM/OME (P 
< 0.05). Conversely, haplotypes 6A2 and 1A2 were found to be 
protective against susceptibility to RAOM/OME (P < 0.05). In 
New Zealand Maori and Polynesian individuals, two SP-A1 alleles, 
three SP-A2 alleles, one SP-D allele, and four haplotypes (6A8, 
6A10, 1A3, and 1A10) were found to be associated with increased 
risk of RAOM/OME (P < 0.05). An additional four haplotypes 
(6A2, 1A0, 1A2, and TA) were determined to be protective against 
susceptibility to RAOM/OME (P < 0.05). However, protective 
SPA1/SPA2/SPD haplotype 6A2-1A0-TA was significantly under-
represented in the New Zealand Maori and Polynesian population 
(P < 0.05). A single allele and haplotype were associated with 
increased risk of meningococcal disease (P < 0.05). 
 
The findings of this study confirm that specific genetic variants of 
SP-A and SP-D are associated with either increased or decreased 
risk of developing RAOM and/or OME. Furthermore, it was 
demonstrated that New Zealand Maori and Polynesian individuals 
appear to exhibit more haplotypes susceptible to RAOM/OME. 
This may provide a partial explanation for the higher 
RAOM/OME-related failure rates of hearing tests in New Zealand 
Maori and Polynesian children. However, there are numerous 
socio-economic and environmental factors that also contribute to 
otitis media pathogenesis which were not considered in this 
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study. The effects of the SP-A1, SP-A2, and SP-D alleles and 
haplotypes on the bacterial/viral binding efficiencies of SP-A and 
SP-D need to be investigated by further research, using a large 
population, to confirm the association with susceptibility or 
resistance with RAOM/OME. 
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CHAPTER ONE 
 
INTRODUCTION AND LITERATURE 
REVIEW 
 
 
1.1 Otitis Media 
 
Otitis Media (OM) is one of the most common childhood diseases 
and is responsible for the majority of doctor’s visits, antibiotic 
treatment, and related surgery for children in developed 
countries (Freid et al., 1998). Acute otitis media is characterized 
by rapid onset of inflammation of the middle ear and the 
presence of middle ear fluid, often coupled with an inflamed 
and/or bulging tympanic membrane (eardrum). Recurrent acute 
otitis media (RAOM) is regarded as at least three or four 
episodes of acute otitis media in the past six or twelve months, 
respectively. Evidence of serous or mucoid fluid in the middle 
ear, without acute symptoms, is characteristic of otitis media 
with effusion (New Zealand District Health Board, 2004). 
 
Otitis media often occurs secondary to respiratory infections and 
is mostly caused by bacterial and viral infections that start in the 
nasopharynx and rapidly spread through to the Eustachian tube 
and the middle ear cavity (Kodama et al., 2005) as depicted in 
Figure 1.1. Streptococcus pneumoniae, Haemophilus influenzae, 
and Moraxella catarrhalis are the most common bacterial 
pathogens responsible for otitis media, while respiratory 
syncytial virus and rhinovirus are the most predominant viral 
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contributors (Chonmaitree et al., 2000; Pitkaranta et al., 1998a, 
1998b, 1998c). 
 
Outer Ear Inner EarMiddle 
Ear
Eustachian Tube
Eardrum 
(Tympanic Membrane)
 
 
Figure 1.1. Location of the middle ear cavity and Eustachian tube within the 
human auditory system. Diagram adapted from Regional Hearing Services Ltd 
(2006). 
 
During infection, the mucosa of the middle ear undergoes 
extensive hyperplasia where the monolayer of mostly simple 
squamous epithelium is transformed to a pseudostratified 
respiratory epithelium by the addition of cells, including goblet 
and ciliated cells (Ryan et al., 2005). Otitis media with effusion 
(OME) occurs when the mucociliary clearance system provided 
by the Eustachian tube becomes defective. 
 
Normally, the Eustachian tube clears the pathogen-binding 
mucus secretions produced by mucosal epithelial cells into the 
neighbouring nasopharynx, maintaining a healthy environment in 
the middle ear. However, when this system is compromised, 
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mucus production continues and builds up within the middle ear 
cavity (e.g. ‘glue-ear’) often causing conductive hearing loss 
(Ryan et al., 2005). Current management of these conditions 
includes repeated courses of antibiotics and often operations to 
drain fluid and ventilate the middle ear. 
 
OME has been implicated in hearing loss which often occurs 
during the most critical stage of language development in 
childhood (National Audiology Centre, 2003). In New Zealand, 
the conductive hearing loss associated with bilateral OME has 
been shown to have a significant impact on language and speech 
development, reading ability, and classroom behaviour in 
children up to eleven years old (Chalmers et al., 1989). Results 
from the Dunedin Multidisciplinary Health and Development 
Study (1996) calculated that nearly 20% of New Zealand five 
year olds exhibited OME in at least one ear. 
 
A New Zealand hearing screening programme carried out 
between July 2001 – June 2002, found that the overall failure 
rates of tympanometry tests for new school entrants and three 
year olds were both 7.8%. However, three year old Pacific Island 
and Maori children had significantly higher failure rates compared 
to their European counterparts with 14.9% and 11.8% 
respectively. Maori and Pacific Island new school entrants had 
12.1% and 17.1% failure rates (National Audiology Centre, 
2003). Additionally, a recent longitudinal study of Pacific Island 
children living in New Zealand revealed that approximately 25% 
of Pacific Island 2 year olds suffered from acute otitis media or 
OME (Paterson et al., 2006). 
 
A variety of factors contribute to the pathogenesis of otitis media 
including: age, bacterial and viral exposure, innate and adaptive 
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immunity status, Eustachian tube structure and function (Zheng 
et al., 2006). A range of environmental factors such as day care, 
season of year, older siblings, parental smoking, 
housing/crowding, and breast feeding influence an individual’s  
level of pathogen exposure and immunity (Homoe et al., 1999; 
Rovers et al., 2004). Additionally, compelling evidence presented 
by Casselbrant et al (1999) suggested that otitis media 
susceptibility is genetically inherited. In their twin and triplet 
study, a significantly higher concordance rate of OME in 
monozygotic twins compared with dizygotic twins was observed. 
 
 
1.2 Surfactant 
 
In the lungs, a lipoprotein surfactant is synthesized to reduce the 
surface tension at the alveolar air-liquid interface and 
consequently prevents the lungs from collapsing. Pulmonary 
surfactant is composed of phospholipids (80%), cholesterol 
(~10%), and four surfactant proteins (~10%): SP-A, SP-B, SP-
C, and SP-D (McGuire, 2002). This surfactant and its associated 
proteins have also been found to be present in many other 
tissues, including oral epithelium; gastric and intestinal 
mucosae; mesothelial tissues; synovial cells; salivary glands; 
pancreas; reproductive and urinary tracts; Eustachian tube and 
middle ear mucosae (Bourbon and Chailley-Heu, 2001; Dutton et 
al., 1999). 
 
Phosphatidylcholine (PC) was found by Paananen and colleagues 
(2002) to be the main phospolipid in both Eustachian tube 
lavage fluid (ETLF) and bronchoalveolar lavage fluid (BALF). 
However, the molecular species of PC in each location was 
different: palmitoyloleoyl PC was the most prevalent in ETLF, and 
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dipalmitoyl PC in BALF. This difference corresponded with a 
significantly reduced efficiency of the ETLF for lowering surface 
tension, suggesting that another function predominates for 
Eustachian tube surfactant.  
 
Eustachian tube epithelium is morphologically similar to lower 
airway epithelium and specialized microvillar epithelial cells have 
been identified which express and secrete the surfactant 
proteins, facilitated by cytoplasmic electron-dense granules, 
homologous to those seen in Type II pneumocytes located in 
pulmonary alveoli (Paananen et al., 2001). Evidence for the 
presence of SP-A and SP-D has been provided by in situ 
hybridization, reverse-transcriptase polymerase chain reaction 
(RT-PCR), electron microscopy, and immunoelectron microscopy 
(Dutton et al., 1999; Paananen et al., 1999, 2001; Yamanaka et 
al, 1991). In addition, SP-A was found to be the most abundant 
surfactant protein in the middle ear, as also seen in pulmonary 
surfactant (Paananen et al., 2001).  
 
SP-B and SP-C are hydrophobic proteins that are essential for 
lowering surface tension in the lungs by enhancing adsorption 
and spreading of surfactant phospholipids at the air-liquid 
interface (Nogee, 1998). A SP-B deficiency that occurs frequently 
in premature babies typically leads to lethal neonatal respiratory 
disease (Floros et al., 1995). Detection of SP-B and SP-C mRNAs 
in the middle ear has been performed with RT-PCR, however the 
presence of these proteins in the middle ear has not been 
confirmed and it has been proposed that they are lung-specific 
(Dutton et al., 1999). 
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1.2.1  Structure of SP-A and SP-D 
 
In contrast, SP-A and SP-D are hydrophilic proteins and belong 
to the collectin family of calcium-dependent carbohydrate 
binding proteins, which also includes mannose-binding lectin 
(MBL) and conglutinin (Floros et al., 1998; Crouch et al., 2001). 
Members of the collectin family are characterised by N-terminal 
collagen-like domains and C-terminal carbohydrate recognition 
domains (CRD) which allows them to bind to various types of 
macromolecules, including carbohydrates, phospholipids, and 
proteins (Shepherd, 2002).  
 
Both SP-A and SP-D are oligomers of trimeric subunits (Crouch, 
2000, 2001) as illustrated in Figure 1.2. SP-A has ‘bouquet-like’ 
oligomers of the closely related chains SP-A1 and SP-A2, 
arranged as octadecamers with closely spaced CRDs (20nm). 
Both SP-A1 and SP-A2 protein molecules consist of 248 amino 
acids (aa) and usually only differ within the collagen-like domain: 
Met66, Asp73, Ile81, and Cys85 for SP-A1, and Thr66, Asn73, Val81, 
and Arg85 for SP-A2 (Karinch and Floros, 1995). 
 
SP-D (375 aa) exists as a dodecamer, with more widely spaced 
CRDs (100nm). Spacing between the CRDs in SP-D is five times 
greater than for SP-A, possibly contributing to the greater ability 
of SP-D to aggregate microbial ligands (Shepherd, 2002). 
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Figure 1.2. The structural organization of SP-A and SP-D. Both proteins are 
members of the collectin family which are characterized by the presence of an 
N-terminal collagen-like domain and CRD (Sano and Kuroki, 2005). 
 
 
1.2.2  Function of SP-A and SP-D 
 
Recent publications have established that SP-A and SP-D are 
important components of the innate immune system in the lungs 
(Crouch and Wright, 2001; Shepherd, 2002). They combat 
infections caused by bacteria, viruses, and fungi by promoting 
destruction of these pathogens by phagocytic cells and it is 
therefore probable that they also play this role in the middle ear.   
 
It has been proposed that SP-A and SP-D promote phagocytosis 
by two different mechanisms (Ding et al., 2004). The first 
involves binding of the collectins to pathogens and promoting 
their recognition for phagocytic clearance by macrophages and 
neutrophils (Crouch and Wright, 2001).   
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Both SP-A and SP-D are positively-charged proteins that can 
bind to lipopolysaccharide (LPS), a negatively-charged cell wall 
component of all gram-negative bacteria, which consists of core 
oligosaccharides, an amphipathic lipid A domain, and a variable 
O-antigen polysaccharide domain. The C-terminal domains of SP-
A and SP-D interact in a Ca2+ and Na+ dependent manner with 
LPS at the lipid A domain and the core oligosaccharides/O-
antigen domain, respectively, (Kalina et al., 1995; Sano et al., 
1999; Van Iwaarden et al., 1994). In addition, it was observed 
that SP-D uses its CRD to bind to lipoteichoic acid (LTA) and 
peptidoglycan (PepG) in a calcium-dependent manner. LTA and 
PepG are major cell wall components of gram-positive bacteria 
which can induce an inflammatory response and in some cases, 
initiate septic shock (van der Wetering et al., 2001). In the same 
study, SP-A did not bind to LTA or PepG in a specific manner, but 
it was hypothesized that the protein may interact with other 
glycoconjugates present on the cell wall surface. 
 
Numerous in vitro and in vivo studies have examined the 
interactions between SP-A and SP-D with microbial pathogens 
including H. influenzae, S. pneumoniae, Influenza A virus, and 
respiratory syncytial virus, confirming that they can be bound, 
aggregated, and promoted for phagocytosis by the collectins 
(Crouch et al., 1998, 2000, 2001). 
 
SP-D was also found to aggregate and/or bind to several 
bacterial strains of E. coli, Salmonella enterica and S. 
pneumoniae significantly greater than the other collectin family 
members MBL and conglutinin (Hartshorn et al., 2002). Jounblat 
and associates (2004) used enzyme-linked immunosorbent assay 
(ELISA) to examine the interaction between SP-D and S. 
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pneumoniae and found that both recombinant truncated SP-D 
and native full-length SP-D bound to all strains of bacteria. 
 
One study using SP-A null mice found delayed pulmonary 
clearance of H. influenzae and respiratory syncytial virus (LeVine 
and Whitsett, 2001).  However, the addition of purified SP-A 
enhanced the binding and uptake of respiratory syncytial virus 
by peripheral blood monocytes and alveolar macrophages (Barr 
et al., 2000). Furthermore, they found SP-A also had an effect 
on the macrophage production of the pro-inflammatory cytokine, 
tumour necrosis-factor alpha, and the anti-inflammatory 
cytokine, interleukin 10. 
 
The second mechanism by which SP-A and SP-D may facilitate 
destruction of pathogens involves a direct interaction between 
SP-A or SP-D and the phagocytic cells themselves, stimulating 
their activity. Schagat and co-workers (2001) determined that 
SP-A and SP-D could bind to polymorphonuclear neutrophils 
(PMNs), which are recruited to a specific site of infection and 
undergo apoptosis, which dramatically increases their 
phagocytosis by resident macrophages. Furthermore, 
intrapulmonary administration of truncated human recombinant 
SP-D also reduced the amount of apoptotic and necrotic alveolar 
macrophages in a SP-D null mouse model (Clark et al., 2002). 
Enhanced removal of apoptotic macrophages in an area of 
inflammation, e.g. Otitis media, is necessary for returning the 
affected tissue back to normal, as extended exposure to the 
expelled components of apoptosis can prolong inflammation and 
hinder the healing process (Matalon and Wright, 2004). 
 
In addition, there has been evidence to suggest that SP-A and 
SP-D may also interact and/or stimulate members of the 
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adaptive immune system. Both native and recombinant forms of 
SP-A and SP-D   were shown to interact with recombinant Toll-
like receptors (TLR) 2 (Murakami et al., 2002) and TLR4 (Ohya 
et al., 2006), which detect specific pathogen associated 
molecular patterns (PAMPS) and modulate cytokine expression 
(Bohlson et al., 2007). Nadesalingam and colleagues (2005) 
employed ELISA to reveal that SP-D binds to various types of 
immunoglobulins, including secretory-IgA, IgE, IgG, and IgM. It 
was also determined that SP-D binds to IgG in a calcium-
dependent manner, aggregates IgG-coated beads and enhances 
their phagocytosis by mouse-derived macrophages. These 
results therefore suggest SP-D as a mediator of the innate and 
adaptive immune systems. 
 
Overall, the literature provides evidence that both SP-A and SP-
D facilitate the destruction of various bacteria and viruses that 
are commonly known to cause otitis media in the middle ear. Not 
only do these collectins contribute to innate immunity in the 
middle ear but they also interact with the adaptive immune 
system in order to alleviate infection and inflammation in an 
attempt to restore tissue homeostasis. 
 
 
1.2.3  SP-A and SP-D genes 
 
The human SP-A locus has two functional, highly homologous 
genes (SP-A1 and SP-A2) in opposite transcriptional orientation 
with one pseudogene between these two genes. They are all 
located at chromosome 10q22-q23 in a cluster along with the 
SP-D and MBL genes (Kishore et al., 2006) as shown in Figure 
1.3.  
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Physical and radiation hybrid mapping has provided evidence 
that SP-A1, SP-A2, SP-D, and the SP-A pseudogene (MBL1P1) 
are in linkage disequilibrium (Floros et al., 1996; Hoover and 
Floros, 1998).    
 
Interestingly, baboons are the only other species to have two 
SP-A genes, whilst all other mammals have only one SP-A gene. 
Floros and colleagues (1993, 2005) speculated that gene 
duplication may have occurred approximately 26 million years 
ago due to greater demands imposed upon the organism as a 
consequence of an increasing number of pathogens, irritants and 
other environmental challenges. 
 
In contrast to previous publications, the latest reference copy of 
the human genome shows two copies of both SP-A1 and SP-A2 
approximately 300kb apart, but only a single copy of SP-D 
(Ensemble Human, release 40). This evidence suggests that 
individuals may have different gene copy numbers of SP-A1 and 
SP-A2, possibly leading to gene dosage effects. However, the 
effects of SP-A1 and SP-A2 copy number variations on the 
expression of these genes, and any association with disease, has 
not yet been investigated. 
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1.2.4  Association of SP-A and SP-D with disease 
 
Some alterations in SP-A1, SP-A2, and SP-D are known to be 
associated with a range of pulmonary diseases. For example, it 
was determined that a methionine at amino acid position 11 in 
SP-D (Lahti et al., 2002) and a lysine at residue 223 in SP-A2 
(Lofgren et al., 2002) are associated with severe infection by 
respiratory syncytial virus, a common respiratory tract pathogen 
of infancy.  
 
Saxena and co-workers (2003) identified two exonic and two 
intronic polymorphisms in the collagen region of SP-A1 and SP-
A2 that were significantly associated with increased risk of 
allergic bronchopulmonary aspergillosis. A tryptophan at amino 
acid position 219, instead of arginine in SP-A1, was found to be 
significantly related to the development of idiopathic pulmonary 
fibrosis (Selman et al., 2003).  
 
Certain genetic variants of SP-A1 and SP-A2 were 
overrepresented in premature infants with respiratory distress 
syndrome, a major cause of newborn mortality and morbidity 
(Ramet et al., 2000). Similar results were obtained by Seifart 
and colleagues (2005) who found that some SP-A1/SP-A2 
variants were associated with risk for pulmonary cancer, 
including small cell lung carcinoma, adenocarcinoma, and 
squamous cell carcinoma. 
 
In addition, specific SP-A1, SP-A2, and SP-D alleles correlated 
with increased or decreased risk for tuberculosis (Floros et al., 
2000), and decreased levels of the proteins have been detected 
in the lungs of patients with cystic fibrosis (Postle et al., 1999). 
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This observation may explain the compromised pulmonary innate 
immunity commonly seen in cases of cystic fibrosis. 
A recent study investigated the distribution of polymorphisms in 
SP-A1, SP-A2, and SP-D among patients diagnosed with 
meningococcal disease (Jack et al., 2006). They found that a 
lysine instead of a glutamine at amino acid position 223 of SP-A2 
was associated with increased risk of meningococcal disease. 
However, variations in SP-A1 and SP-D were not associated with 
increased or decreased risk of the disease. 
 
This research project proposes that any unfavourable change in 
the ability of SP-A and SP-D to deal with the pathogens 
previously discussed, and others, may predispose an individual 
to middle ear infections and persistent middle ear effusions. 
Such a change could occur within the protein’s coding DNA, 
where a single nucleotide substitution may result in an altered 
protein primary sequence, thus affecting the protein’s ability to 
bind and aggregate its targets. 
 
 
1.3 Genetic diversity of SP-A and SP-D 
 
Human SP-A1 and SP-A2 exhibit extensive genetic heterogeneity 
across individuals (Floros et al., 2005). This has been seen in the 
range of 5’ untranslated exon splice variants, sequence 
variability in the 3’ untranslated region (UTR), and single 
nucleotide polymorphisms in the coding regions. Karinch and 
Floros (1995) investigated the alternative splicing of the four 5’ 
UTR exons (A-D) in SP-A1 and SP-A2, and found that all possible 
variants for both genes were translated in vivo. However, the 
relative levels and translation efficiency of the splice variants 
differed amongst individuals, with AD’ presenting as the most 
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frequent splice variant for SP-A1 and ABD for SP-A2. Wang and 
co-workers (2005) later found that 5’ UTR splice variants of SP-
A1 and SP-A2 also modulate mRNA stability, with four specific 
variants enhancing gene expression. In addition, sequence 
variations in the 3’ UTR were also found to influence the 
expression of SP-A1 and SP-A2 (Wang et al., 2003). However, 5’ 
UTR splice variants and 3’ UTR sequence variants of SP-D, and 
their influence on expression and translation have not yet been 
fully characterized. 
 
SP-A1, SP-A2, and SP-D have all been found to be polymorphic 
(Liu et al., 2003; Pantelidis et al., 2003). Gelehrter and 
colleagues (1990) considered a particular locus to be 
polymorphic if the less frequent allele has a population frequency 
of no less than 1%, and a heterozygosity frequency of at least 
2%. Single nucleotide polymorphisms (SNPs) occur when a 
single nucleotide (purine or pyrimidine) in a DNA sequence is 
substituted with a different nucleotide. A SNP may either result 
in a synonymous or non-synonymous amino acid substitution, 
where the amino acid coded for is the same or different, 
respectively (Crawford and Nickerson, 2005).  
 
The linkage of SP-A1, SP-A2, SP-D, and MBL1P1 allows for all the 
polymorphisms to be assembled into haplotypes: combinations 
of alleles of different SNPs along the same chromosome which 
can be inherited as a unit (Crawford and Nickerson, 2005). As 
Homo sapiens are diploid, each individual has two haplotypes for 
a particular part of their genome, corresponding to the paternal 
and maternal chromosomes. The SNP loci making up a particular 
haplotype on a chromosome will be passed on from parent to 
offspring as a unit unless separated by recombination.  
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The probability of recombination occurring within a haplotype 
partially depends on the physical distance between the SNP loci. 
Closely spaced loci are therefore less likely to be separated and 
are described as being in linkage disequilibrium. Consequently, if 
the genotype of one SNP is known, the genotype of another SNP 
may be predicted if there is a high level of linkage disequilibrium 
between the two SNPs. 
 
This research project investigated previously described SNPs in 
the SP-A and SP-D genes as depicted in Figure 1.4. 
SP-A1 
SP-A2 
SP-D 
 
 
Figure 1.4. Location of the SP-A and SP-D gene polymorphisms. Exons and 
introns are represented by black boxes and straight lines, respectively. Amino 
acid positions of the SNPs are labelled. Modified from Pantelidis et al., 2002. 
 
Within the exons of SP-A1 there have been five biallelic SNPs 
documented, corresponding with amino acid positions 19, 50, 62, 
133, and 219 (DiAngelo et al., 1999). Two of these SNPs are 
silent (aa62 and aa133), whereas the remainder result in non-
conservative amino acid substitutions, as described in Table 1.1. 
Observed patterns of the SNPs from previously published 
research have provided 19 and 15 haplotypes for SP-A1 (6An) 
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and SP-A2 (1An), respectively (DiAngelo et al., 1999). However, 
only four SP-A1 haplotypes and six SP-A2 haplotypes made up 
almost 99% of the haplotypes present in the Finnish population 
(Hoover and Floros, 1998; Rämet et al., 2001).  
 
 Amino Acid No 
Haplotype 19 50 62 133 219 
6A C C G G C 
6A2 T G A A C 
6A3 T C A A C 
6A4 T C G A T 
 
GCG 
(Ala) 
 
GTG 
(Val) 
CTC 
(Leu) 
 
GTC 
(Val) 
CCG 
(Pro) 
 
CCA 
(Pro) 
ACG 
(Thr) 
 
ACA 
(Thr) 
CGG 
(Arg) 
 
TGG 
(Trp) 
 
Table 1.1. Single Nucleotide Polymorphisms and amino acid differences in SP-
A1. The amino acid number in SP-A1 and their corresponding nucleotide 
changes are shown. Both possible codons are shown at the bottom with the 
encoded amino acid. Modified from Floros et al (2005). 
 
Within the SP-A2 there are three exonic SNPs which result in a 
non-synonymous amino acid change: aa9, aa91, aa223. While at 
aa140, a synonymous change can occur (Table 1.2).  
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 Amino Acid No 
Haplotype 9 91 140 223 
1A C C C C 
1A0 A G C C 
1A1 C G T A 
1A2 C G C C 
1A3 A G T A 
1A5 C C T C 
 
AAC 
(Asn) 
 
ACC 
(Thr) 
CCT 
(Pro) 
 
GCT 
(Ala) 
TCC 
(Ser) 
 
TCT 
(Ser) 
CAG 
(Gln) 
 
AAG 
(Lys) 
 
Table 1.2. Single Nucleotide Polymorphisms and amino acid differences in SP-
A2. The amino acid number in SP-A2 and their corresponding nucleotide 
changes are shown. Both possible codons are shown at the bottom with the 
encoded amino acid. Modified from Floros et al (2005). 
 
In comparison, DiAngelo and colleagues documented only two 
SNPs (Table 1.3) in SP-D that result in non-synonymous amino 
acid changes located at aa11 (Threonine to Methionine) and 
aa160 (Threonine to Alanine). 
 
 Amino Acid No 
Allele 11 160 
Major T G 
Minor C A 
 
Table 1.3. Single Nucleotide Polymorphisms in SP-D. 
 
Interestingly, recent research has indicated that differential allele 
expression of SP-A1, SP-A2, and SP-D occurs in a tissue-specific 
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manner (Lin and Floros, 2002; Lin et al, 2004). All three genes 
exhibited balanced biallelic expression in lung tissue, but 
imbalanced biallelic expression in middle ear tissue of 
heterozygous rats. These findings demonstrate further 
complexity to the genes’ already existing genetic variability. 
 
 
1.3.1  SP-A Haplotypes 
 
A previous study by Rämet et al. (2001) reported a difference in 
the frequencies of specific SP-A haplotypes between Finnish 
children diagnosed with recurrent otitis media and a control 
population. Using a PCR/restriction fragment length 
polymorphism technique to detect the SNPs in SP-A1 and SP-A2, 
they found an over-representation of the 6A4-1A5 haplotype 
within the recurrent otitis media patients. A subset of infants 
who had their first diagnosed case of acute otitis media before 
the age of six months also had an under-representation of the 
6A2-1A0 haplotype. In addition, the frequency of the homozygous 
SP-A1 haplotype 6A2/6A2 was significantly greater in the case 
population than the control population. 
 
However, contrasting findings were presented by Pettigrew and 
co-workers (2006) in an American population.  Amongst a subset 
of American-Caucasian infants, the 6A4-1A5 haplotype was 
protective against Otitis media, corresponding with a 76% 
reduced risk during the first twelve months of life. They also 
determined that the SNP at codon 19 in the SP-A1 gene was 
associated with prevalence of otitis media. An alanine at position 
19 corresponded with a significantly greater chance of otitis 
media within the first year of life. 
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The allele and haplotype frequencies for SP-A1, SP-A2, and SP-D 
within a New Zealand population are currently unknown. Given 
that the prevalence of RAOM/OME is a significant problem in 
European-Caucasian children, and even more so in New Zealand 
Maori and Pacific Island children, it is important to characterize 
whether changes in an individual’s SP-A and SP-D are associated 
with their susceptibility to RAOM/OME. 
 
 
1.4 Genetic Techniques and Data Analysis 
 
The present research project investigated the association of the 
eleven previously described SNPs in SP-A1, SP-A2, and SP-D, as 
single markers (SNPs) and as haplotypes, in patients who 
presented with recurrent acute OM (RAOM) and/or OM with 
effusion (OME) at Waikato Hospital (Hamilton, New Zealand). 
Volunteers donating blood at the New Zealand Blood Service 
(Waikato) Donor Centre comprised the control group for the 
study. 
 
Using allele-specific primers and real-time polymerase chain 
reaction (PCR) with SYBR® Green I melting curve analysis, DNA 
samples from patients undergoing surgery for RAOM/OME were 
screened for the minor and/or major alleles for each SNP. 
Genotype and haplotype frequencies for both populations were 
calculated and compared. 
 
 
1.4.1  Real-time PCR 
 
Real-time PCR is a rapid and high-throughput molecular 
technique for amplification of a particular region of DNA between 
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two predetermined positions, and is distinguished by its high 
level of sensitivity. The chemistry of PCR results from the action 
of the enzyme DNA Taq polymerase, originating in the 
thermophile Thermus aquaticus, a bacterium that inhabits hot-
springs and therefore expresses heat-stable enzymes.  
 
DNA amplification is facilitated by the addition of Taq polymerase 
to a reaction mix containing template DNA and primers 
(oligonucleotides) complementary to sequences flanking either 
side of the target region. The reaction is then exposed to a 
program of temperature cycles as described below: 
 
The first cycle begins with an initial denaturation step at a high 
temperature which promotes the double stranded DNA (dsDNA) 
to dissociate into single strands. The temperature is reduced to a 
level less than the melting temperature of the primers to allow 
for annealing.  
 
The annealing step facilitates the hybridization of the primers to 
their complementary sequences on the single stranded template 
DNA. The allele-specific primers used in this present study were 
designed with the 3’ end nucleotide complementary to the 
nucleotide variants at a particular SNP location.  
 
In order to circumvent the appearance of spurious smaller sized 
amplicons in the PCR product spectrum, Don et al. (1991) 
devised a simple strategy that involved increasing the annealing 
temperature of the PCR. Their proposed solution assumed that 
the problem was due to mispriming by one or both of the 
oligonucleotide primers with the target template or with each 
other; and due to their smaller size these are preferentially 
amplified, with the effects compounding during reaction cycling. 
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This also suggests that the mispriming annealings are less stable 
than the specific ones due to different degrees of mismatch.  
 
Don et al. proposed that any difference in the melting 
temperature between the incorrect and the correct annealings 
would give an advantage of 2x/cycle, or 4x/°C, to the correct 
product, all else being equal. By initially increasing the annealing 
temperature to 10°C greater than the expected annealing 
temperature, followed by a reduction (‘touchdown’) of 1°C per 
cycle for 11 cycles (e.g. 65-55°C), the correct product will be 
amplified before the smaller, spurious product, therefore 
obtaining a competitive edge that will be maintained for the rest 
of the thermal cycling.  
 
Following the touchdown annealing step, the temperature is 
raised to the optimum temperature for Taq polymerase activity, 
where the enzyme uses the primers as starting points for 
synthesising DNA complementary to the region specified. The 
heating/cooling steps are repeated for approximately 40 cycles 
and, theoretically, at the end of each cycle the number of DNA 
strands containing the target sequence should have doubled, 
resulting in millions of copies of the region of interest. 
 
The addition of a fluorescent dye which binds to dsDNA (e.g. 
SYBR® Green I) to the reaction allows the researcher to observe 
the amplification of the target sequence in real-time, given that 
the accumulation of fluorescence is proportional to the 
accumulation of amplification products (Higuchi et al., 1993) as 
shown in Figure 1.5. 
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Figure 1.5. Real-time PCR amplification curves. Amplification curves for 72 
reactions showing the exponential increase in fluorescence detection as a 
function of thermocycling progress. 
 
 
1.4.2  SYBR® Green I Melting Curve Analysis 
 
Previously utilized techniques for the detection of single base 
changes in particular regions of the genome included PCR, 
restriction fragment length polymorphism (RFLP) analysis, and 
gel electrophoresis. More recently, due to their high level of 
sensitivity and visualisation, fluorescence-based methods have 
found favour within the scientific community. 
 
The assay employed in this study used the intercalating dye 
SYBR® Green I, which incorporates into dsDNA during 
thermocycling in real-time PCR. Melting of the dsDNA into single 
strands was then monitored by fluorescence detection 
(470nm/510nm) during slow and steady heating. The 
dissociation of dsDNA was coupled with a loss in detected 
fluorescence due to the release of bound SYBR® Green I. The 
point at which the amplification products dissociate was labelled 
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the melting temperature (Tm) and is a function of the product 
sequence properties (i.e. GC%) and length.  
 
The fluorescence data obtained was subsequently translated into 
melting curves by removal of background fluorescence and any 
confounding influence of temperature on fluorescence, then 
plotted (Figure 1.6) as the negative derivative of fluorescence, -
dF, with reference to temperature, T, (Ririe et al., 1997). 
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A 
B 
Major Allele
Minor Allele
 
 
Figure 1.6. SYBR® Green I melting curves. A) Melting curves for an individual 
whose genome was screened for both the major (red) and minor (blue) alleles 
for a particular SNP. The presence of a peak at the appropriate melting 
temperature (~90°C) for the major allele, but not for the minor allele 
indicates that the individual is homozygous for the major allele. B) Melting 
curves for an individual which show detection of both the major and minor 
alleles for the SNP; both reactions show a PCR product peak with a melting 
temperature of 90°C, thus suggesting heterozygosity. The amplified target 
regions for both alleles differ by only one nucleotide, therefore they have 
similar melting temperatures and the peaks are almost perfectly 
superimposed. 
 
 
1.4.3  Haploview 
 
The characterization of haplotypes in the human genome and 
their association with specific diseases has become a standard 
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tool of many medical association studies in recent years. This 
has since led to the establishment of the Human Haplotype Map 
project (HapMap) which allows for genotype data to be available 
to all medical genetics researchers (International HapMap 
Consortium, 2003).  
 
Raw genotype data from both the case group and the control 
group for SP-A1, SP-A2, and SP-D were analyzed, interpreted, 
and visualized using the software package, Haploview (Barrett et 
al., 2005). Haploview calculated linkage disequilibrium 
information, constructed haplotypes, and estimated population 
allele and haplotype frequencies. Further analysis involved 
simple χ2 tests for each single marker and subsequent 
haplotypes. The program is freely available as an open source 
project (http://sourceforge.net/projects/haploview/). 
 
 
1.4.4  PolyPhen  
 
The potential effect of each non-synonymous SNP on SP-A1, SP-
A2, or SP-D’s protein structure and function was predicted using 
the PolyPhen (Polymorphism Phenotyping) server 
(http://www.bork.embl-heidelberg.de/PolyPhen/). PolyPhen 
analyzes the amino acid change by investigating 3D protein 
structures, multiple alignments of homologous sequences, and 
amino acid contact information from a range of protein structure 
databases, and then estimates position-specific independent 
counts (PSIC) scores for each of the two variants (major and 
minor). The difference in the PSIC scores between the two 
variants is then calculated. The greater the PSIC score 
difference, the greater the putative functional effect the amino 
acid change will have on the protein (Ramensky et al., 2002). 
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From this information, any association between allele/haplotype 
frequencies and their functional effects was investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter One: Introduction and Literature Review 28
1.5 Study Objectives 
 
 
1.5.1  Objective One  
 
Investigate whether a significant difference in population allele 
and haplotype frequencies, for all eleven markers in SP-A1, SP-
A2, and SP-D, exists between the case (patients with RAOM or 
OME) and control populations. 
 
1.5.2  Hypothesis One 
 
It was hypothesized that specific alleles and haplotypes of SP-
A1, SP-A2 and SP-D would be more or less frequent in the 
RAOM/OME individuals, confirming findings of previous studies 
(Pettigrew et al., 2006; Rämet et al., 2001). 
 
1.5.3  Objective Two  
 
Compare observed SP-A1, SP-A2, and SP-D alleles and haplotype 
frequencies between the New Zealand Maori and Pacific Island 
case population and the control population. 
 
1.5.4  Hypothesis Two 
 
It was hypothesized that allele and haplotype frequencies would 
be significantly different between the New Zealand Maori and 
Pacific Island case population and the control population. In 
addition, it was expected that this population would exhibit more 
RAOM/OME associated alleles and haplotypes than the total case 
population. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
 
2.1 Blood Samples 
 
Ethical approval for this study was obtained from the University 
of Waikato School of Science and Engineering Human Research 
Ethics Committee and the Northern Y Regional Ethics Committee, 
Ministry of Health (Ethics Reference Number: NTY05/05/030). 
Ethical approval information is presented in Appendix I. 
 
Four millilitre blood samples were obtained from 136 patients 
undergoing surgery involving ventilation tube insertion of the 
tympanic membrane at Waikato Hospital and Southern Cross 
Hospital, Hamilton, New Zealand. Blood samples from a control 
population were obtained from 160 participants donating blood 
at the New Zealand Blood Service (Waikato) Donor Centre, 
Hamilton, New Zealand. Additionally, blood samples from three 
patients diagnosed with meningococcal disease were obtained. 
 
Informed consent was obtained from each participant and basic 
personal and medical details were recorded including: age; sex; 
ethnicity; operation type; previous number of ventilation tubes 
inserted; presence of right and left middle ear fluid; previous 
adenoidectomy; and professional medical diagnosis. Blood 
samples were stored in EDTA containing Vacutainer® tubes (BD) 
at 4°C until used for isolating genomic DNA.  
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2.1.1  Isolation of Genomic DNA 
 
Genomic DNA from each blood sample was isolated for use in 
this study using the following protocol: 
 
Labelled 1.7 ml microcentrifuge tubes (Axygen) were filled with 1 
ml of sterile MQ-H2O (Barnstead), 130 μl of 10x red blood cell  
(RBC) lysis solution (1.44 M NH4Cl, 0.1 M NH4HCO3, 1 mM 
Na2EDTA), and 250 μl of each blood sample. Tubes were placed 
onto a rotator wheel (Labinco) for 5 - 10 minutes until lysis of 
the RBCs, indicated by a reduction in turbidity, and then 
centrifuged (5415R Bench Top Centrifuge, Eppendorf) at 13,000 
rpm for 5 minutes. After centrifugation, the supernatant and 
most of the RBC membranes were carefully pipetted off to leave 
a white pellet containing the white blood cells, at the bottom of 
the tube.  
 
The pellet was resuspended in the remaining solution, followed 
by the addition of 300 μl of DNA lysis buffer (0.1 M Tris pH 9, 
0.05 M EDTA, 0.1 M NaCl, 1% (w/v) SDS). After thorough 
mixing, the tubes were placed in a thermomixer (Eppendorf) at 
95°C for 5 - 10 minutes. Once removed from heat, 300 μl of 5 M 
lithium chloride (Ajax Chemicals) was introduced. The tubes 
were shaken vigorously and then placed onto the rotator wheel 
again for approximately 10 minutes. After mixing, 750 μl of 
chloroform (Ajax Chemicals) was added and the solutions 
vortexed for 20 seconds to form an emulsion before being 
returned to the rotator wheel for a further 15 - 30 minutes. The 
tubes were then centrifuged at 10,000 rpm for 10 minutes to 
separate the phases. The top phase containing the DNA 
(approximately 500 μl) was transferred using a transfer pipette 
to a new labelled tube along with an equal volume of isopropanol 
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(Ajax Chemicals), inverted to mix and then left overnight to 
allow DNA precipitation.  
 
On the following day, the tubes were centrifuged at 13,000 rpm 
for 20 minutes, gathering the precipitated DNA at the bottom of 
the tube. The alcohol was carefully poured off the pelleted DNA 
and washed with 70% v/v ethanol (Ajax Chemicals). Using an 
autopipette, the remaining ethanol was removed from the 
bottom of the tube, avoiding the white DNA pellet, and the pellet 
then air dried. Finally, 50 μl of tris (hydroxymethyl) amino-
methane (TE: 10 mM Tris, 1 mM EDTA pH 8) buffer was added to 
each tube and mixed at 37°C for 30 minutes to dissolve the 
DNA.  
 
 
2.1.2  DNA Concentration and Integrity 
 
DNA concentration and purity of each sample was determined by 
using 2 μl for analysis using a ND-1000 spectrophotometer 
(Nanodrop). The concentration of nucleic acids in each sample 
was measured by absorbance at 260 and presented as ng/μl. 
The ratio of sample absorbance at 260 and 280 nm was used to 
assess the purity of the DNA. A 260/280 ratio of 1.8 – 2.0 was 
considered ideal. The genomic DNA samples were then stored at 
4°C until required. 
 
 
2.2 Genotyping of SP-A1, SP-A2, and SP-D. 
 
Based on previous publications (Pantelidis et al., 2003), allele-
specific primer pairs were synthesized (Sigma-Aldrich) with the 
3’ end nucleotide complementary to the wild-type or mutant 
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nucleotide variants seen at each particular polymorphism 
location within SP-A1, SP-A2, and SP-D. These primer pairs are 
listed in Table 2.1.  
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A 
SNP Forward Primer (5’- 3’) Reverse Primer (5’- 3’) 
Length 
(bp) 
SPA1-19 
1- AAACGTCCTTCACTTCGCACA 
2- AACGTCCTTCACTTCGCACG 
AGTGAGTGAGTGACCTGACTAA 
516/515 
SPA1-50 
1- GCCAGGGTCTCCTTTGAC 
2- GCCAGGGTCTCCTTTGAG 
AGTGAGTGAGTGACCTGACTAA 
605 
SPA1-62 
1- GACATGGCATTTCTCCAGGT 
2- GACATGGCATTTCTCCAGGC 
AGTGAGTGAGTGACCTGACTAA 
959 
SPA1-133 
1- TGCAGGGCTCCATAATGACA 
2- TGCAGGGCTCCATAATGACG 
TACCTGGCCTTCTAACCTCAT 
937 
SPA1-219 
1- ACACACTGCTCTTTTCCCCG 
2- ACACACTGCTCTTTTCCCCA 
ATAGGAAAGCAAGTTCTCCACC 
577 
B 
SNP Forward Primer (5’- 3’) Reverse Primer (5’- 3’) 
Length 
(bp) 
SPA2-9 1- GGCTGCCATCAAGATGAGGT 
2- GCTGCCATCAAGATGAGGG 
GTGCCAGATGATGCTTGGAATT 235/234 
SPA2-91 1- TGGAGAGAAGGGGGAGG 
2- TGGAGAGAAGGGGGAGC 
CCTGATCACACCATCTGCCT 400  
SPA2-140 1- TAGGAGAGAAGGTCTTCTCC 
2- GTAGGAGAGAAGGTCTTCTCT 
AAACTGAAGGCCAGACAGGAT 395/396 
SPA2-223 1- TGTGTACATCTCCACACACTG 
2- CTGTGTACATCTCCACACACTT 
AAGAAAGCAAGTTCTCTGCCTG 588/589 
C 
SNP Forward Primer (5’- 3’) Reverse Primer (5’- 3’) 
Length 
(bp) 
SPD-11 1- AGACCTACTCCCACAGAACAAT 
2- ACCTACTCCCACAGAACAAC 
AGAGTTGCTGGGCTAGTTACA 200  
SPD-160 1- GTGGAGTCCCTGGAAACG 
2- CGTGGAGTCCCTGGAAACA 
CACTTTCTCCCTTTGCTCCTT 577  
 
Table 2.1. Allele-specific primers for genotyping SP-A1, SP-A2, and SP-D. A) 
Forward and reverse primers for both the major (1) and minor alleles (2) of 
the five SNPs in SP-A1. B) Primers for both alleles of the four SNPS in SP-A2. 
C) Primers for both alleles of the two SNPs in SP-D. The base-pair (bp) 
lengths of the amplified target regions are given. 
 
Original primer concentrations ranged between 59.2 - 149.4 
nmol and were subsequently diluted with TE (10 mM Tris, 1 mM 
EDTA pH 8) buffer to 200 pmol/μl. For each SNP, working primer 
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solutions (forward and reverse primers) were made for both 
alleles to a 20 pmol/μl concentration.  
 
 
2.2.1  PCR Optimization 
 
Optimal annealing temperatures and extension times for each 
set of allele-specific primers were determined using gradient 
PCR. Twenty-five microlitre reactions were made with PCR 
mastermix (10x HotMaster® Reaction Buffer (Eppendorf), 250 
μM deoxynucleotide triphosphates (Invitrogen), 2.5 mM MgCl2 
pH 8.5), 0.5 U of HotMaster® Taq DNA Polymerase (Eppendorf), 
10 pmol of allele-specific primers, and approximately 200 ng of 
genomic DNA.  
 
DNA Taq polymerase synthesized DNA complementary to the 
template at approximately 1000 bp per minute during the 
extension step of the thermocycling program, thus it was 
necessary to group allele-specific reactions based on similar PCR 
product base-pair lengths. Accordingly, the 22 allele-specific 
reactions were divided into three groups, with estimated optimal 
extension times (Table 2.2). 
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A 
Group One Group Two Group Three 
Allele PCR product (bp) Allele 
PCR product 
(bp) Allele 
PCR product 
(bp) 
SPA1-19T 516 SPA2-9A 235 SPA1-62A 959 
SPA1-19C 515 SPA2-9C 234 SPA1-62G 959 
SPA1-50C 605 SPA2-91G 400 SPA1-133A 937 
SPA1-
50G 
605 SPA2-
91C 
400 SPA1-133G 937 
SPA1-
219C 577 
SPA2-
140C 395 - - 
SPA1-
219T 577 
SPA2-
140T 396 - - 
SPA2-
223C 
588 SPD-11T 200 - - 
SPA2-
223A 589 
SPD-
11C 200 - - 
SPD-
160A 577 - - - - 
SPD-
160G 
577 - - - - 
 
B  
Primer 
Group 
PCR product length 
(bp) 
Approx extension 
time for Taq DNA 
Polymerase (secs) 
Group 
One 515 - 605 40 
Group 
Two 
200 - 400 30 
Group 
Three 
937 - 959 60 
 
Table 2.2. Grouping of the 22 allele-specific reactions based on PCR product 
length. A) Group One contains allele-specific primers which amplify a DNA 
region between 515 – 605 base-pairs (bp) in length. Group Two contains 
allele-specific primers which amplify a DNA region between 200 – 400 bp in 
length. Group Three contains allele-specific primers which amplify a DNA 
region between 937 959 bp in length. B) Approximate extension times needed 
for Taq DNA polymerase for complementary DNA synthesis were calculated 
(1000 bp per minute) for each Primer Group based on the length of the 
amplified genomic region. 
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Thermocycling was conducted using a Peltier Thermal Cycler 
(PTC) 200 (MJ Research) and consisted of the following steps: 
 
 1.  Initial denaturation at 95°C for 2 minutes 
 2.  94°C for 20 seconds 
 3.  Annealing temperature gradient of 52 - 64°C 
4.      Extension: i)  Group One: 68°C for 40 seconds 
ii)   Group Two: 68°C for 30 seconds 
iii)   Group Three: 68°C for 60 seconds 
 5.  Repeat steps 2 - 4 in 39 more cycles 
 6.  Final extension at 68°C for 5 minutes 
 
 
2.2.2  Agarose Gel Electrophoresis 
 
Gradient PCR products were then electrophoresed to determine 
which annealing temperature produced the most efficient 
amplification of the target genomic region. 
 
 A 2% (w/v) agarose gel (USB) was cast with 1x sodium borate 
buffer (0.05 M boric acid, 0.01 M NaOH pH 8.5) and 1.5 μg/ml of 
ethidium bromide using a Owl gel electrophoresis system. Ten 
microlitres of the amplified product from each PCR reaction was 
loaded into the wells of the gel. The products were then 
electrophoresed for 30 minutes at 120 V and 30 mA. Product 
bands were visualised using a GIBCO BRL ultra-violet 
transilluminator (Life Technologies) at 312 nm, photographed 
using a COHU High Performance CCD camera and printed with a 
Sony Digital Graphic Printer UP-D890. Confirmation of product 
band base-pair lengths were made by comparison with a 100 bp 
DNA ladder (Invitrogen). 
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The optimal annealing temperature for each set of allele-specific 
primers was determined by the presence of a single high 
intensity product band in the agarose gel at the appropriate 
base-pair length, and the absence of extra bands of other 
inappropriate lengths. 
 
 
2.2.3  Real-Time PCR 
 
Real-time PCR reactions were performed in 100 μl thin walled 
tubes (Corbett Research) and monitored using a Rotor-GeneTM 
6000 (Corbett Research). Each 20 μl reaction mixture contained 
Real-time PCR Mastermix (10x Thermostart® Reaction Buffer (AB 
Ltd), 1/20,000 dilution of SYBR® Green I (Invitrogen), 250  μM 
deoxynucleotide triphosphates (Invitrogen),  5 mM MgCl2 pH 
8.5), 0.5 U of ABGene Thermostart® DNA Polymerase (AB Ltd), 5 
pmol of allele-specific primers, and approximately 200 ng of 
genomic DNA.  
 
Touchdown thermocycling steps were as follows: 
 
1.  Initial denaturation at 95°C for 10 mins  
2. 94°C for 20 seconds 
3.  Annealing temperature started at 70°C for 20 
seconds and then decreased at 1°C/cycle for 20 
seconds for the first 15 cycles, staying at 56°C for 
the remaining cycles 
4.  Extension at 68°C for 30 – 60 seconds (Table 4) 
5.  Fluorescence acquisition step at 80°C for 15 seconds 
(excitation at 470 nm, detection at 510 nm) 
6.  Repeated steps 2 - 5 in 44 more cycles 
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2.2.4  SYBR® Green I Melting Curve Analysis 
 
Following amplification, PCR products were heated from 75°C to 
99°C in 0.5°C increments every 5 seconds. The denaturing 
conditions dissociated the dsDNA into single strands as the 
melting temperatures (Tms) were reached for each specific PCR 
product.  
 
The consequential reduction in fluorescence from the release of 
the SYBR® Green I dye was detected, and the derivative of the 
raw data produced a melt curve, with the peak representing the 
Tm for the product. The absence or presence of the appropriate 
melt curves were used to assign whether the wild-type, mutant, 
or both alleles were present in an individual’s genome. 
 
Real-time PCR products were analyzed by 2% (w/v) agarose gel 
electrophoresis as previously described in section 2.2.2, and 
product band lengths noted to confirm that the correct target 
genomic region had been amplified. 
 
 
2.2.5  Sequencing of SP-A1, SP-A2, and SP-D PCR Products 
 
Sequencing of the allele-specific PCR products amplified from SP-
A1, SP-A2, and SP-D was also employed to confirm that the 
correct region had been targeted and that no incorrect 
amplification had occurred.  
 
Genomic DNA from sample M1 (meningococcal group) and case 
sample 26 was used as a template for amplification of the 22 
(two alleles for each SNP) previously described alleles in SP-A1, 
SP-A2, and SP-D by PCR. Fifty microlitre reactions consisted of 
PCR mastermix (10x HotMaster® Reaction Buffer (Roche), 250  
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μM deoxynucleotide triphosphates (Invitrogen), 2.5 mM MgCl2 
pH 8.5), 0.5 U of HotMaster® Taq DNA Polymerase (Eppendorf), 
10 pmol of allele-specific primers, and approximately 200 ng of 
genomic DNA. 
 
The thermocycling protocol for amplification of the 22 alleles was 
as follows:   
 
1. Initial denaturation at 95°C for 2 minutes 
2. 94°C for 20 seconds 
3. 60°C for 20 seconds 
4. Extension: i)  Group One: 68°C for 40 seconds 
ii) Group Two: 68°C for 30 seconds 
iii)  Group Three: 68°C for 60 seconds 
5. 39 more cycles of steps 2 - 4 
6. Final extension at 68°C for 5 minutes 
 
Following thermocycling, all PCR products were purified by 
selective precipitation with polyethylene glycol (PEG) 6000 as 
previously published by Schmitz and Riesner (2006). The amount 
of reagents added to each 50 μl reaction was different for each 
group of allele-specific reactions, as seen in Table 2.3. 
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Group 
EDTA 
(0.5 M, 
pH 8) 
50% (w/v) 
PEG 6000 5 M NaCl 
Group 
One 1.6 μl 21.0 μl 8.1 μl 
Group 
Two 
1.9 μl 34.0 μl 9.6 μl 
Group 
Three 1.4 μl 12.0 μl 7.0 μl 
 
Table 2.3. Volume of reagents added to each 50μl allele-specific PCR reaction 
for purification of PCR products for subsequent sequencing. The amounts of 
purification reagents added was altered according to the base pair length of 
the expected PCR product, as seen across Group One, Two, and Three. 
 
Following addition of the purification reagents, the solutions were 
mixed well and incubated at room temperature for 10 minutes. 
Post-incubation, the solutions were centrifuged at 16,000 x g for 
10 minutes to allow the DNA to sediment. The supernatant was 
then removed and the remaining DNA pellet washed with 125 μl 
of 70% (v/v) ethanol. Finally, the ethanol was also removed and 
the pellet solubilized in 15 μl of deionised water. The solutions 
were then sent to the University of Waikato Sequencing 
Laboratory (Hamilton, New Zealand) for sequencing, using the 
allele-specific forward and reverse primers as sequencing 
primers. 
 
Product sequences for each allele-specific reaction were entered 
into the NCBI website in FASTA format to facilitate a BLAST 
search which allowed confirmation that the correct region within 
SP-A1, SP-A2, or SP-D had been amplified. 
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2.3 Analysis of Genotype Data 
 
Raw genotype data for both the case and control populations 
were analyzed with Haploview software (Barrett et al., 2005). A 
simple tab-delimited text file (.txt) containing sample numbers, 
gender, case/control status, and SNP genotypes were input into 
Haploview. A separate input file which contained the names and 
chromosomal position for each SNP was also loaded. 
 
Initially, the software performed a number of SNP genotyping 
quality measures including the percentage of individuals 
successfully genotyped for each particular SNP, and a test of 
conformance with Hardy-Weinberg equilibrium. These 
parameters were then used to filter out any SNPs which fell 
below a preset threshold. 
 
 
2.3.1  Haplotype Construction 
 
Haploview constructed haplotypes using an accelerated 
Expectation-Maximization algorithm similar to that described by 
Qin et al (2002) and generated the following: 
 
- pairwise measures of linkage disequilibrium  
- population allele frequencies 
- population haplotype frequencies  
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2.3.2  χ2-Tests for RAOM/OME Association 
 
Simple χ2-tests for single SNPs and the constructed haplotypes 
were carried out to calculate any association with recurrent acute 
otitis media or otitis media with effusion.  
 
 
2.3.3  Protein Phenotype Predictions 
 
The amino acid sequences of SP-A1, SP-A2, and SP-D were 
entered into the PolyPhen server (Ramensky et al., 2002) in 
FASTA format. Individually, the sequence position and the two 
amino acid variants for each SNP were included, from which the 
software could identify any deleterious alleles. 
 
To calculate whether the substitution in question occurred at a 
specific site, PolyPhen used: 
 
- the TMHMM (Krogh et al., 2001) algorithm to predict 
transmembrane regions, 
- the Coils2 program (Lupas et al., 1991) to predict 
coiled coil regions, 
- the SignalP program (Bendtsen et al., 2004) to predict 
signal peptide regions of the protein sequence. 
 
Using a BLAST search of the non-redundant database (NRDB), 
homologues of the input protein sequences were identified and 
used by the PSIC software to calculate profile scores for the 
allelic variants at each SNP position. The difference between the 
scores of both variants was calculated. A further BLAST search of 
the Protein Data Bank (Berman et al., 2000) and the Protein 
Quaternary Structure database (Henrick and Thornton, 1998) for 
homologues allowed PolyPhen to estimate whether the 
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substitutions affected the hydrophobic core of the protein and/or 
electrostatic and ligand interactions. The DSSP database (Kabsch 
and Sander, 1983) provided information on the proteins’ 
secondary structures and solvent accessible areas. 
 
Finally, PolyPhen analyzed the various structural properties and 
profile scores obtained to compare the protein variants, and 
predict whether the structural and functional consequences of 
the minor allele at each particular SNP were benign or damaging. 
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CHAPTER THREE 
 
RESULTS 
  
 
 
3.1 Isolation of Genomic DNA 
 
Genomic DNA was isolated from 4 ml blood samples from 136 
patients with recurrent acute otitis media (RAOM) or otitis media 
with effusion (OME), 160 control participants, and 3 
meningococcal disease patients. Sample information is presented 
in Appendix II. The DNA was resuspended in 50 μl of TE buffer 
and 5 μl loaded into a 2% (w/v) agarose gel and 
electrophoresed, as depicted in Figure 3.1. Migration of the 
genomic DNA through the agarose gel, followed by ethidium 
bromide staining and UV visualization allowed for band intensity 
analysis. From this information, a crude estimation of the sample 
DNA concentration could be made. 
 
 
1      2      3      4      5      6      7  
Figure 3.1. Genomic DNA samples electrophoresed in a 2% (w/v) agarose gel. 
To ensure isolated genomic DNA samples were of similar concentrations, 5 μl 
of the samples were loaded into the 2% (w/v) agarose gel, electrophoresed 
and the band intensity assessed. This gel photo contains samples 1 – 7 from 
the case population. 
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In order to obtain accurate measurements of DNA concentration 
and integrity, 2 μl of each sample was analyzed by a Nanodrop® 
ND-1000 spectrophotometer. A small subset of 
spectrophotometer results are presented in Table 3.1. The 
nucleic acid concentration for each genomic DNA sample was 
given in ng/μl, and sample absorbance was measured at 230 
nm, 260 nm, and 280 nm. The ratio of a sample’s 260 nm and 
280 nm absorbance measurements were used to determine the 
purity of the DNA sample. A 260/280 ratio of greater than or 
equal to 1.8 was considered “pure” DNA, and devoid of 
contaminants. 
 
 
Sample ID ng/μl A260 260/230 260/280 
 
120 
793.48 15.87 2.06 1.90 
 
121 999.64 19.99 2.08 1.90 
 
122 
959.99 19.20 2.10 1.90 
 
123 246.62 4.93 1.49 2.09 
 
124 
304.69 6.09 1.76 2.04 
 
125 1067.10 21.34 2.11 1.89 
 
126 
1625.90 32.52 2.21 1.87 
 
127 
319.51 6.39 1.71 2.02 
 
Table 3.1. Example of Nanodrop readings for samples 120 – 127 of the case 
population. Nucleic acid concentrations are presented in ng/μl. 
  
 
3.2 Gradient PCR 
 
To determine the optimal annealing temperature for the allele-
specific primers used to amplify the major (Mj) and minor (mi) 
alleles for each SNP, gradient PCR was used. During the 
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thermocycling, the peltier thermal cycler (PTC-200) established a 
temperature gradient across the plate where the reactions are 
placed. Identical reactions for all 22 allele-specific primers were 
placed into the PTC-200 which provided a temperature gradient 
between 52°C – 64°C at the annealing step.  
 
Once the thermocycling was completed, 10 μl of each reaction 
was loaded into a 2% (w/v) agarose gel supplemented with 
ethidium bromide and electrophoresed as previously described in 
section 2.2.2. Migrated PCR products were then visualized with a 
UV transilluminator and compared to a 100 bp DNA ladder, from 
which product band intensity, length and quality could be 
determined. Figures 3.2 – 3.4 show the results of the gradient 
PCR for the allele-specific primers targeting regions in SP-A1, 
SP-A2, and SP-D in one sample. 
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SPA1-50G (Mj)SPA1-62A (Mj)
°C  55.4 53.1 52.0   N    63.8 62.2 59.2 55.4 53.1 52.0    N     L 
°C  63.8  62.2  59.2 55.4 53.1 52.0    N   63.8 62.2 59.2    L 
SPA1-62A (Mj) SPA1-62G (mi)
 
 
 
Figure 3.2. Gradient PCR products amplified from case sample 24 using allele-
specific primers SPA1-50G (Mj), SPA1-62A (Mi), and SPA1-62G (mi). Identical 
25 μl PCR reactions were run at different annealing temperatures (52.0 – 63.8 
°C), and 10 μl of each reaction was loaded into a 2% agarose (w/v) gel and 
electrophoresed. Single product bands of 605 bp, 959 bp, and 959 bp were 
expected, respectively. Lane N: negative template control; Lane L: 100 bp 
ladder. 
 
Spurious smaller bands were present in most reactions at an 
annealing temperature of 52.0°C. For example, the primers that 
targeted the SP-A1 allele, 62G (Figure 3.2), amplified the correct 
959 bp region and five smaller regions, ranging between 150 – 
450 bp. However, the presence of these smaller erroneous bands 
diminished as the annealing temperature was increased, with 
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none present in reactions with an annealing temperature 
between 59.2°C – 63.8°C. 
 
Figure 3.3 shows the agarose gel electrophoresis results for the 
gradient PCR products amplified with the allele-specific primers 
SPA1-140T, SPA2-223C, and SPA2-223A. Small erroneous 
product bands of approximately 300 bp were seen to be 
amplified at lower annealing temperatures by allele-specific 
primers and SPA2-223A and SPA2-223C in addition to the 
correct products of 589 and 588 bp, respectively. These extra 
products disappeared at higher annealing temperatures. 
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SPA2-223C (Mj) SPA2-223A (mi)
°C  63.8  62.2  59.2 55.4 53.1 52.0    N  63.8 62.2 59.2    L 
SPA1-140T (mi)
    °C  55.4 53.1 52.0    N    63.8 62.2 59.2 55.4 53.1 52.0    N     L  
SPA2-223C (Mj) 
 
Figure 3.3. Gradient PCR products amplified from case sample 24 using allele-
specific primers SPA1-140T (mi), SPA2-223C (Mj), and SPA2-223A (mi). 
Identical 25 μl PCR reactions were run at different annealing temperatures 
(52.0 – 63.8 °C), and 10 μl of each reaction was loaded into a 2% agarose 
(w/v) gel and electrophoresed. Single product bands of 396, 588, and 589 bp 
were expected, respectively. Lane N: negative template control; Lane L: 100 
bp ladder. 
 
Interestingly, the reactions that amplified the SPD-11C (200 bp) 
and SPD-11T alleles (200 bp) also amplified a larger region of 
approximately 300 and 450 bp respectively, at the lower 
annealing temperatures (Figure 3.4). This larger product was not 
present in reactions exposed to the higher annealing 
temperatures. 
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SPD-160A (mi)
°C      63.8   62.2   59.2 55.4  53.1 52.0    N    63.8 62.2 59.2      L 
 SPD-11C (mi) 
 
 
SPD-11T (Mj)SPD-11C (mi)
°C    55.4 53.1  52.0    N     63.8 62.2 59.2 55.4 53.1 52.0    N       L 
 
 
Figure 3.4. Gradient PCR products amplified from case sample 24 using allele-
specific primers SPD-11T (Mj), SPD-11C (mi), and SPD-160A (mi). Identical 
25 μl PCR reactions were run at different annealing temperatures (52.0 – 63.8 
°C), and 10 μl of each reaction was loaded into a 2% agarose (w/v) gel and 
electrophoresed. Single product bands of 200 bp, 200 bp, and 577 bp were 
expected, respectively. Lane N: negative template control; Lane L: 100 bp 
ladder. 
 
Table 3.2 displays the optimal annealing temperatures for all of 
the allele-specific primers tested by gradient PCR. In contrast to 
some of the allele-specific primers that misprimed at lower 
annealing temperatures, some primers did not amplify any other 
regions except the targeted region. For instance, primers SPA1-
19T (Mj) and SPA1-19C (mi) amplified only the specified 
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515/516 bp region for the entire range of annealing 
temperatures tested. 
 
Major Allele Minor Allele 
Primer Pair Annealing Temp (°C) Primer Pair Annealing Temp (°C) 
SPA1-19T 52.0 - 63.8 SPA1-19C 52.0 - 63.8 
SPA1-50G 59.2 - 63.8 SPA1-50C 62.2 - 63.8 
SPA1-62A 59.2 - 63.8 SPA1-62G 59.2 - 63.8 
SPA1-133A 59.2 - 63.8 SPA1-133G 59.2 - 63.8 
SPA1-219C 56.9 - 62.7 SPA1-219T 60.7 - 62.7 
SPA2-9A 60.7 - 62.7 SPA2-9C ~60.7 
SPA2-91G ~62.7 SPA2-91C ~62.7 
SPA2-140C ~62.2 SPA2-140T 56.9 - 62.7 
SPA2-223C 59.2 - 63.8 SPA2-223A 59.2 - 62.2 
SPD-11T 59.2 - 63.8 SPD-11C 62.2 - 63.8 
SPD-160G 59.2 - 63.8 SPD-160A 59.2 - 63.8 
 
Table 3.2. Optimal annealing temperature ranges for the allele-specific 
primers that amplify the major and minor alleles for each SNP. Using gradient 
PCR, the optimal annealing temperature (°C) ranges for the major and minor 
allele-specific primer pairs of each SNP were determined.  
 
 
3.3 Genotyping  
 
 
3.3.1 Real-Time PCR and SYBR® Green I Melting Curve 
Analysis 
 
Case and control DNA samples were genotyped for the major 
and minor alleles for the SP-A1, SP-A2, and SP-D SNPs using 
real-time PCR and SYBR® Green I melting curve analysis. 
Separate real-time PCR reactions were made for detection of the 
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major and minor alleles, and the products melted slowly between 
75 - 99°C. The resulting melt curve for each reaction was used 
to determine whether the alleles were present or absent. Figures 
3.5 – 3.15 show the melt curves produced for both the major 
and minor alleles for each SNP. The PCR products for each allele 
had precise melting temperatures (Tm) influenced by product 
length and GC% (GC pairings have three hydrogen (H)-bonds, 
while AT pairings have only two H-bonds to dissociate) thus 
allele-specific melt curves could be distinguished from other 
spurious products due to mispriming.  
 
The primers that amplified the major and minor alleles for each 
SNP differed only by the final 3’ end nucleotides, which were 
homologous for the corresponding allele present in an 
individual’s genome. Amplification of the targeted region only 
occurred if the correct allele was present for the specific primers 
used. Therefore, the PCR products for both the major and minor 
alleles of a particular SNP were almost identical in size and 
melting curve Tm. For example, Figure 3.5 shows the melt 
curves for the allele-specific primers SPA1-19T (Mj) and SPA1-
19C (mi) for control samples 144 – 148. The Tm for both the 
major and minor allele PCR products was approximately 
91.75°C, however nonspecific product curves can also be seen 
between 82 - 90°C. 
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Figure 3.5. SYBR® Green I melting curves for multiple reactions containing 
SPA1-19T (red) and SPA1-19C (orange) allele-specific primers. The melting 
temperature for the allele-specific products is indicated by the black arrow. 
Nonspecific PCR product melting curves are present between 82 - 90°C. 
 
 
 
 
 
 
Figure 3.6. SYBR® Green I melting curves for multiple reactions containing 
SPA1-50C (green) and SPA1-50G (turquoise) allele-specific primers. The 
melting temperature for the allele-specific products is indicated by the black 
arrow. Nonspecific PCR product melting curves are present between 82 - 
90°C. 
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Figure 3.7. SYBR® Green I melting curves for multiple reactions containing 
SPA1-62A (red) and SPA1-62G (purple) allele-specific primers. The melting 
temperature for the allele-specific products is indicated by the black arrow. 
Nonspecific PCR product melting curves are present between 75 - 90°C. 
 
 
 
 
 
 
Figure 3.8. SYBR® Green I melting curves for multiple reactions containing 
SPA1-133A (torquoise) and SPA1-133G (green) allele-specific primers. The 
melting temperature for the allele-specific products is indicated by the black 
arrow. Nonspecific PCR product melting curves are present between 75 - 
85°C. 
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Figure 3.9. SYBR® Green I melting curves for multiple reactions containing 
SPA1-219C (blue) and SPA1-219T (pink) allele-specific primers. The melting 
temperature for the allele-specific products is indicated by the black arrow. 
Nonspecific PCR product melting curves are present between 75 - 87°C. 
 
 
 
 
 
 
Figure 3.10. SYBR® Green I melting curves for multiple reactions containing 
SPA2-9A (red) and SPA2-9C (green) allele-specific primers. The melting 
temperature for the allele-specific products is indicated by the black arrow. 
Nonspecific PCR product melting curves are present between 75 - 87°C. 
 
 
 
 
 
 
 
 
Chapter Three: Results 56
 
 
Figure 3.11. SYBR® Green I melting curves for multiple reactions containing 
SPA2-91G (red) and SPA2-91C (blue) allele-specific primers. The melting 
temperature for the allele-specific products is indicated by the black arrow. 
Nonspecific PCR product melting curves are present between 75 - 87°C. 
 
 
 
 
 
 
Figure 3.12. SYBR® Green I melting curves for multiple reactions containing 
SPA2-140C (blue) and SPA2-140T (orange) allele-specific primers. The 
melting temperature for the allele-specific products is indicated by the black 
arrow. Nonspecific PCR products were absent between 75 - 85°C, as also 
demonstrated by the absence of spurious bands seen in the amplification of 
SPA2-140C in samples 128 and 129 (Figure 3.17). 
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Figure 3.13. SYBR® Green I melting curves for multiple reactions containing 
SPA2-223C (pink) and SPA2-223A (purple) allele-specific primers. The 
melting temperature for the allele-specific products is indicated by the black 
arrow. Nonspecific PCR product melting curves are present between 75 - 
85°C, and correspond with the spurious 500 bp product band amplified in 
addition to SPA2-223C in samples 128 and 129 seen in Figure 3.16.  
 
 
 
 
 
 
Figure 3.14. SYBR® Green I melting curves for multiple reactions containing 
SPD-11T (pink) and SPD-11C (purple) allele-specific primers. The melting 
temperature for the allele-specific products is indicated by the black arrow. 
Nonspecific PCR product melting curves are present between 75 - 85°C. 
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Figure 3.15. SYBR® Green I melting curves for multiple reactions containing 
SPD-160G (pink) and SPD-160A (blue) allele-specific primers. The melting 
temperature for the allele-specific products is indicated by the black arrow. 
Nonspecific PCR product melting curves are present between 75 - 87°C. 
 
The approximate Tms obtained by SYBR Green I melting curve 
analysis for the major and minor allele-specific real-time PCR 
products are shown in Table 3.3.  
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Gene Allele-specific product (Mj/mi) 
Tm 
(°C) 
19T/C 91.75 
50G/C 91.75 
62A/G 91.50 
133A/G 89.40 
SP-A1 
219C/T 88.95 
9A/C 91.45 
91G/C 90.30 
140C/T 88.40 
SP-A2 
223C/A 88.65 
11T/C 90.50 
SP-D 
160G/A 89.15 
 
Table 3.3. Melting temperatures for allele-specific products amplified from SP-
A1, SP-A2, and SP-D. For each SNP, both the major and minor allele products 
had similar melting temperatures.  
 
 
3.3.2  Confirmation by Agarose Gel Electrophoresis 
 
To confirm that the regions amplified by the allele-specific 
primers were those targeted, 10 μl of each reaction was loaded 
into a 2% (w/v) agarose gel supplemented with ethidium 
bromide to stain the nucleic acid. The samples were 
electrophoresed through the gel and visualized by UV 
transillumination. The results from case samples 128 and 129 
with the allele-specific primers SPA1-19T/C, SPA1-50G/C, SPA1-
219C/T, and SPA2-223C/A are shown in Figure 3.16. 
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  19C           19T         50C         50G        219C 
 L     A     B        A     B       A     B     A     B       A     B 
L       A     B      A     B      A     B     N1   N2   N3   N4 
    219T       223C       223A    
 
 
Figure 3.16. Real-time PCR products amplified from case samples 128 and 
129 with SPA1-19T/C, SPA1-50G/C, SPA1-219C/T, and SPA2-223C/A allele-
specific primers. Samples 128 (A) and 129 (B) had identical genotypes for the 
SNPs occurring at amino acids 19, 50, and 219 in SP-A1, and amino acid 223 
of SP-A2. Negative template controls (NTCs) for 19C, 19T, 50C, and 50G are 
shown in lanes N1 – N4. The NTCs for the remaining four allele-specific 
primers were not run on the gel as they produced no melting curves during 
the SYBR® Green I melting curve analysis. 
 
Samples 128 and 129 were found to be heterozygous for the 
major/minor alleles at codons 19 and 50 of SP-A1, as indicated 
by allele-specific product bands in the agarose gel depicted in 
Figure 3.16. However, a cytosine (Mj) only was detected at 
codon 223 of SP-A2 for both samples. Furthermore, an allele-
specific band representing SPA1-219T (mi) was apparent for 
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sample 128 only, while SPA1-219C (Mj) was detected in sample 
129.  
 
Multiple product bands were seen in some lanes of the agarose 
gel (Figure 3.16). The smaller spurious products corresponded 
with the nonspecific products seen in the lower temperatures of 
the SYBR® Green I melting curve analysis, as depicted in 
Figures 3.5, 3.6, 3.9, and 3.13. 
 
Real-time PCR products for case samples 128 and 129 with the 
allele-specific primers SPA2-9A/C, SPA2-91G/C, SPA2-140C/T, 
and SPD-11T/C were also electrophoresed in a 2% (w/v) agarose 
gel and are presented in Figure 3.17. 
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       9A          9C            91G          91C           140C 
 L     A     B      A     B        A      B     A      B       A     B 
L       A     B      A     B      A      B     N1    N2   N3    N4 
    140T        11T          11C 
 
 
 
Figure 3.17. Real-time PCR products for allele-specific primers SPA2-9A/C, 
SPA2-91G/C, SPA2-140C/T, and SPD-11T/C for case samples 128 and 129. 
Samples 128 (A) and 129 (B) were found to have identical genotypes for the 
SNPs at amino acids 9, 91, and 140 in SP-A2, and amino acid 11 in SP-D. 
NTCs for 9A, 9C, 91G, and 91C are shown in lanes N1 – N4. NTCs for the 
remaining four primers were not run on the gel, and did not produce a SYBR® 
Green I melt curve. 
 
It was confirmed from the agarose gel that both samples 128 
and 129 were heterozygous at SNP loci SPA2-9 and SPD-11. 
Sample 128 was also heterozygous at SPA2-140 but only a 
cytosine (Mj) could be detected in sample 129. Allele-specific 
product bands in the gel were only seen for the minor allele 
(91C) of SPA2-91, in both the samples. 
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3.3.3  Confirmation by DNA Sequencing 
 
SP-A1, SP-A2, and SP-D allele-specific PCR products amplified 
from meningococcal sample M1 and RAOM/OME sample 26 were 
purified by selective precipitation with polyethylene glycol 6000 
(Schmitz and Riesner, 2006). The 22 (two alleles for eleven 
SNPs) purified PCR products were then sequenced, using the 
allele-specific forward and reverse primers as sequencing 
primers, in order to confirm that the correct genomic regions 
were being amplified by the allele-specific primers. The regions 
amplified by the major and minor allele-specific primers for each 
SNP (e.g. SPA1-19T and SPA1-19C) were identical. The forward 
primers differed only in the final 3’ end nucleotide which is 
complementary to the appropriate allele, while the reverse 
primers were identical. Therefore, the complementary strands 
produced by DNA polymerase are the same for both the major 
and minor allele-specific primers. Subsequent BLAST searches 
with the obtained sequences confirmed that the regions amplified 
by the allele-specific primers were from the correct locations 
within SP-A1, SP-A2, and SP-D. DNA sequencing and BLAST 
search results are presented in Appendix III. 
 
 
3.3.4  Raw Genotype Results 
  
Following completion of real-time PCR and SYBR® Green I 
melting curve analysis, case and control population genotyping 
results for each of the eleven SNPs in SP-A1, SP-A2 and SP-D 
were collated in a Microsoft Excel spreadsheet. A subset of this 
data is shown in Table 3.4. 
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Table 3.4. Raw genotype data for SP-A1, SP-A2, and SP-D alleles in case and 
control individuals. Homozygous (e.g. G G) and heterozygous (e.g. A G) 
genotypes are shown for each individual at each SNP loci. 
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The complete genotyping datasets for the case and control 
populations are presented in Appendix IV. 
 
 
3.4 Haploview 
 
The raw SNP genotype data for the case and control populations 
was converted into a tab-delimited text file for importation into 
the Haploview software. An excerpt of the Haploview import file 
is provided in Figure 3.18.  
 
 
1 1 0 0 2 2 4 2 3 3 1 1 
2 2 0 0 1 2 4 4 3 3  1 1 
3 3 0 0 1 2 4 2 2 2 1 3 
137 C1 0 0 2 1 4 2 2 3 1 3 
138 C2 0 0 2 1 4 2 2 3 1 1 
139 C3 0 0 1 1 4 4 3 3 0 0 
 
 
Figure 3.18. Excerpt of Haploview input file containing raw genotype data. 
Information on case samples 1 – 6 are shown (European-Caucasian), which 
includes: A) Overall sample number, B) Sample number within case/control 
population, C) Father’s ID number, D) Mother’s ID number, E) Gender (1= 
male, 2= female), F) Affectation status (1= control, 2=case), G) Genotypes 
for SP-A1 SNPs 19, 50, and 62 (1= A, 2= C, 3= G, 4= T). Unknown values 
are represented by a zero. 
   G     
 A       B         C        D        E         F         19       50       62     
 
Information on each individual in the case and control 
populations was given in the Haploview import file including: 
unique inter- and intra-population sample numbers; gender; and 
affectation status (case/control). In addition, Haploview is often 
used to analyze pedigree data and requires information on each 
individual’s Father and Mother. However, for non-pedigree data, 
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like that obtained in the present study, pedigree information was 
filled with a zero value.  
 
For each of the eleven SNPs screened the concluding genotypes 
were recorded in the import file. For example, Figure 3.18 shows 
that case sample 1 has the genotype ‘4 2’ for the SP-A1 SNP at 
amino acid 19. Haploview encodes nucleotides with 
corresponding numbers (1= A, 2= C, 3= G, 4= T), thus the 
genotype ‘4 2’ represents ‘T C’. This means that both alleles 
could be detected in that particular individual’s genome and is 
therefore heterozygous at the SNP locus. A summary of the 
Haploview analysis process is shown in Figure 3.19. 
 
 Raw genotype data 
(including sample 
numbers, gender, and 
affectation status)
 
 
 
 
 
Χ2-Analysis comparing 
allele and Haplotype 
frequencies in the 
Case and Control 
Populations 
Control Population 
-Genotyping Statistics 
-Hardy-Weinberg Statistics 
-Linkage Disequilibrium Info 
-Haplotype Construction 
Case Population (e.g. 
RAOM/OME individuals) 
-Genotyping Statistics 
-Hardy-Weinberg Statistics 
-Linkage Disequilibrium Info 
-Haplotype Construction 
SP-A1, SP-A2, and
SP-D Alleles and 
Haplotypes associated 
with RAOM/OME 
identified 
Figure 3.19. Flow diagram summarizing the process of Haploview Analysis.  
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3.4.1  European-Caucasian Population Statistics 
 
Table 3.5 presents the genotyping and Hardy-Weinberg 
equilibrium statistics generated by Haploview for the SP-A1, SP-
A2, SP-D SNPs within the European-Caucasian case population of 
RAOM/OME patients (N = 136). All of the individual SNPs were at 
least 97% successfully genotyped, except for SPA1-62A/G, which 
was 94.8% successfully genotyped across the case population. 
 
The sum of the major  and minor allele population frequencies 
(MjAF and MAF) for a particular SNP equals one (Equation 1.0), 
and if that SNP is in Hardy-Weinberg equilibrium (Equation 2.0) 
in the population, then the observed genotype frequencies 
should simply be a function of the relative allele frequencies. 
 
MjAF + MAF = 1         (Equation 1.0) 
 
MjAF2 + 2(MjAF x MAF) + MAF2 = 1     (Equation 2.0) 
 
Equation 2.0 states that the frequency of homozygous major 
allele individuals (MjAF2), heterozygous individuals (2(MjAF x 
MAF)), and homozygous minor allele individuals (MAF2) also adds 
up to one. 
 
Predicted proportions of heterozygosity for the SP-A1, SP-A2, 
and SP-D SNPs were then calculated using the observed minor 
allele frequency (MAF) and Equation 3.0 (derived from Equation 
2.0): 
 
Predicted SNP heterozygosity = 2(MjAF x MAF)     (Equation 3.0) 
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Observed proportions of SNP heterozygosity were then compared 
to their predicted values, and any significant deviations (P < 
0.0001) indicated that the alleles of that particular SNP were not 
in Hardy-Weinberg equilibrium. 
 
Within the European-Caucasian case population, minor allele 
frequencies for a particular SNP locus ranged between 0.160 
(SPA1-219C/T) and 0.485 (SPA1-50G/C). The mean minor allele 
frequency was 0.319 ± 0.086 standard deviation (SD). In 
addition, ten of the eleven SNPs were in Hardy-Weinberg 
equilibrium. However, the SP-A1 50G/C polymorphism had an 
observed heterozygosity frequency of 0.328, which was 
significantly lower than the expected value of 0.500 (P < 0.0001) 
and was thus not in Hardy-Weinberg equilibrium. 
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SNP ObsHET PredHET HWpval %Geno MAF M.A. 
SPA1-19 0.474 0.439 0.4997 100.0 0.326 C 
SPA1-50 0.328 0.500 1.00 x10-4 97.0 0.485 C 
SPA1-62 0.461 0.401 0.1451 94.8 0.277 G 
SPA1-133 0.427 0.436 0.9470 97.0 0.321 G 
SPA1-219 0.201 0.269 0.0133 99.3 0.160 T 
SPA2-9 0.407 0.478 0.1116 100.0 0.396 C 
SPA2-91 0.296 0.369 0.0386 100.0 0.244 C 
SPA2-140 0.385 0.439 0.2003 100.0 0.326 T 
SPA2-223 0.400 0.384 0.8436 100.0 0.259 A 
SPD-11 0.393 0.447 0.2067 100.0 0.337 C 
SPD-160 0.425 0.470 0.3402 99.3 0.377 A 
 
Table 3.5. Quality statistics for the SP-A1, SP-A2, and SP-D, SNP loci 
genotyped in the European-Caucasian case population. Observed (ObsHET) 
and predicted (PredHET) heterozygosity values were calculated for each SNP 
loci. Significant deviations from the predicted heterozygosity estimates were 
determined by the Hardy-Weinberg equilibrium p value (HWpval < 0.0001) 
and highlighted in bold font. The percentage of non-missing genotypes for 
each SNP loci was calculated (%Geno).  The minor allele (M.A.) for each SNP 
loci and their corresponding population frequencies (MAF) were also 
presented.  
 
Haploview analyzed the raw genotype data and determined the 
levels of linkage disequilibrium (LD) between each of the eleven 
SNP loci, as illustrated in Figure 3.20. Levels of LD were 
presented as: D’ (measure of LD between two SNP loci)/ LOD 
(logarithm of the odds for LD between the two SNP loci).  
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Figure 3.20. Linkage disequilibrium (LD) plot of the eleven SNPs in SP-A1, SP-
A2, and SP-D detected within the European-Caucasian case population. The 
values given in each square represent: D’ (measure of LD between two SNP 
loci)/ LOD (logarithm of the odds for LD between the two SNP loci). A value of 
D’/LOD = 100 indicates complete LD and suggests that the two SNPs have not 
been separated by recombination. Values of D’/LOD < 100 imply incomplete 
LD and indicate that the ancestral LD was disrupted during the population’s 
history.  Dark grey squares represent higher levels of LD, while light grey or 
white squares represent lower levels of LD. 
 
A value of D’/LOD = 100 indicated complete LD and suggested 
that the two SNPs had not been separated by recombination. 
Values of D’/LOD < 100 implied incomplete LD and indicated that 
the ancestral LD had been disrupted during the population’s 
history. The highest levels of LD were seen between SPA1-
50/SPA1-219 (D’/LOD = 88), SPA1-50/SPA2-9(D’/LOD = 87), 
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and SPD-11/SPD-160 (D’/LOD = 88). However, very low levels 
of LD were observed for both SPA1-19 and SPA1-133 when 
compared with each other and the remaining SNP loci. 
 
Following LD analysis, haplotype blocks were constructed for 
each of the genes SP-A1, SP-A2, and SP-D based on the 
genotyping data from individuals in the European-Caucasian case 
population (Figure 3.21).  
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SP-A1       f          SP-A2     f         SP-D   f 
                          D’                      D’ 
Figure 3.21. Constructed haplotypes for SP-A1, SP-A2, and SP-D alleles seen 
in the European-Caucasian case population. Columns 01 – 05 represent the 
nucleotide variants detected at the SP-A1 SNPs: 19T/C, 50G/C, 62A/G, 
133A/G, and 219C/T. Columns 06 – 09 represent the SP-A2 SNPs: 9A/C, 
91G/C, 140C/T, and 223C/A. Columns 10 – 11 correspond to SP-D: 11T/C 
and 160G/A. Haplotype population frequencies (f) are also presented. Thick 
black lines link SP-A1, SP-A2, and SP-D haplotypes that were observed 
together at a frequency of ≥ 0.1. Thin black lines link haplotypes that were 
observed together at a frequency of ≥ 0.01. A value of multiallelic D’ is 
shown, which represents the estimated level of recombination between the 
haplotypes. 
 
Using the nomenclature discussed in section 1.3, haplotypes 
found in the European-Caucasian case population were identified. 
The most common known SP-A1 haplotypes found were 6A2 
(TGAAC, 24.5%), 6A3 (TCAAC, 16.3%), and 6A4 (TCGAT, 7.1%). 
In addition, two unknown haplotypes were observed in 9.2% 
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(CGAAC) and 6.5% (TGAGC) of the European-Caucasian case 
population. All other SP-A1 haplotypes were found in 36.4% of 
the population. 
 
The most predominant SP-A2 haplotype, 1A0 (AGCC) was found 
in 42.8% of the European-Caucasian case population. The other 
commonly seen haplotypes included 1A5 (CCTC, 9.1%), 1A1 
(CGTA, 7.4%), 1A (CCCC, 7.1%), and 1A9 (AGTC, 6.0%). All 
remaining haplotypes combined to make up 27.6% of the SP-A2 
haplotypes. 
 
Of the four possible SP-D haplotypes, three were present in 
similar proportions: TA (36.1%), CG (32.2%), and TG (30.2%). 
In contrast, the remaining haplotype, CA, was found in only 
1.5% of the European-Caucasian case population. 
 
The SP-A1-SP-A2-SP-D haplotype 6A2-1A0-TA was observed in 
over 10% of the European-Caucasian case population, as 
illustrated by the thick black lines in Figure 3.21. Furthermore, 
many other SP-A1-SP-A2-SP-D haplotypes were found at 
population frequencies between 1 – 10%, shown by the thin 
black lines linking the haplotypes in Figure 3.21. 
 
 
3.4.2  Control Population Statistics 
 
Table 3.6 contains the SNP genotyping and Hardy-Weinberg 
equilibrium statistics for the control population (N = 160). The 
SNP SPA1-62A/G was 76.9% successfully genotyped across the 
whole control population. In comparison, at least 98.8% total 
genotyping was achieved with the remaining ten SNPs.  
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SNP ObsHET PredHET HWpval %Geno MAF M.A. 
SPA1-19 0.356 0.345 0.9132 100.0 0.222 C 
SPA1-50 0.396 0.480 0.0384 99.4 0.399 C 
SPA1-62 0.366 0.365 1.0000 76.9 0.240 G 
SPA1-133 0.278 0.308 0.3265 98.8 0.190 G 
SPA1-219 0.169 0.205 0.0780 100.0 0.116 T 
SPA2-9 0.381 0.484 0.0106 100.0 0.409 C 
SPA2-91 0.176 0.298 5.64 x10-6 99.4 0.182 C 
SPA2-140 0.377 0.383 0.9789 99.4 0.258 T 
SPA2-223 0.275 0.272 1.0000 100 0.162 A 
SPD-11 0.419 0.422 1.0000 100 0.303 C 
SPD-160 0.394 0.488 0.0203 100 0.422 A 
 
Table 3.6. Quality statistics for the SP-A1, SP-A2, and SP-D, SNP loci 
genotyped in the control population. Observed (ObsHET) and predicted 
(PredHET) heterozygosity values were calculated for each SNP loci. Significant 
deviations from the predicted heterozygosity estimates were determined by 
the Hardy-Weinberg equilibrium p value (HWpval < 0.0001) and highlighted 
in bold font. The percentage of non-missing genotypes for each SNP loci was 
calculated (%Geno).  The minor allele (M.A.) for each SNP loci and their 
corresponding population frequencies (MAF) were also presented.  
 
SNP minor allele frequencies ranged between 0.116 (SPA1-
219C/T) and 0.422 (SPD-160G/A). The mean minor allele 
frequency was 0.265 ± 0.107 SD. 
 
Similar to the European-Caucasian case population, ten of the 
SP-A1, SP-A2, and SP-D SNPs were in Hardy-Weinberg 
equilibrium. However, in this instance it was the SPA2-91G/C 
polymorphism which had an observed heterozygosity frequency 
of 0.176. This value was significantly lower than the expected 
heterozygosity frequency of 0.298 (P < 0.0001). 
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As with the European-Caucasian case population, LD analysis 
was performed by Haploview to determine the levels of LD 
between the eleven SNP loci in the control population (Figure 
3.22). 
 
Similar patterns of LD were observed in the control population in 
comparison to the European-Caucasian case population. The 
highest levels of LD were found between SPA1-50/SPA1-219 
(D’/LOD = 83), SPA1-62/SPA1-219 (D’/LOD = 84), SPA1-
219/SPD-160 (D’/LOD = 80), and SPD-11/SPD-160 (D’/LOD = 
88). Complete LD was observed in the analysis of SPA1-62 and 
SPA2-223 (D’/LOD = 100).  
 
In addition, the lowest levels of LD were again seen in the 
assessments of SPA1-19 and SPA1-133, with the remaining SNP 
loci in the control population. 
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Figure 3.22. Linkage disequilibrium plot of the eleven SNPs in SP-A1, SP-A2, 
and SP-D detected within the control population. The values given in each 
square represent: D’ (measure of LD between two SNP loci)/ LOD (logarithm 
of the odds for LD between the two SNP loci). A value of D’/LOD = 1 indicates 
complete LD and suggests that the two SNPs have not been separated by 
recombination. Values of D’/LOD < 1 imply incomplete LD and indicate that 
the ancestral LD was disrupted during the population’s history.  Dark grey 
squares represent higher levels of LD, while light grey or white squares 
represent lower levels of LD. D’/LOD values of 100 are not shown and are 
represented by a blank square. 
 
As shown in Figure 3.23, the most frequent SP-A1 haplotypes 
found in the control population included 6A2 (TGAAC, 39.9%), 
6A3 (TCAAC, 16.5%), CGAAC (7.9%), and 6A4 (TCGAT, 4.6%). 
However, the haplotype 6A (CCGGC) was also found in 3.9% of 
the population. All other SP-A1 haplotypes were found in 27.2% 
of the population. 
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SP-A1       f          SP-A2     f         SP-D   f 
                       D’                     D’ 
Figure 3.23. Constructed haplotypes for SP-A1, SP-A2, and SP-D alleles seen 
in the control population. Columns 01 – 05 represent the nucleotide variants 
detected at the SP-A1 SNPs: 19T/C, 50G/C, 62A/G, 133A/G, and 219C/T. 
Columns 06 – 09 represent the SP-A2 SNPs: 9A/C, 91G/C, 140C/T, and 
223C/A. Columns 10 – 11 correspond to SP-D: 11T/C and 160G/A. Haplotype 
population frequencies (f) are also presented. Thick black lines link SP-A1, SP-
A2, and SP-D haplotypes that were observed together at a frequency of ≥ 
0.1. Thin black lines link haplotypes that were observed together at a 
frequency of ≥ 0.01. A value of multiallelic D’ is shown, which represents the 
estimated level of recombination between the haplotypes. 
 
Approximately half of all the individuals in the control population 
exhibited the SP-A2 haplotype, 1A0 (AGCC, 49.9%). Other 
common haplotypes presented were 1A2 (CGCC, 10.7%), 1A1 
(CGTA, 8.8%), 1A5 (CCTC, 7.9%), and 1A (CCCC, 5.7%). All 
remaining haplotypes combined to make up 17% of the SP-A2 
haplotypes. 
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Similar to the European-Caucasian case population, the SP-D 
haplotype CA was found in only 1.6% of the control population. 
Haplotypes TA, CG, and TG were found to contribute 40.6%, 
30.0%, and 27.8%, respectively. 
 
The SP-A1-SP-A2-SP-D haplotype 6A2-1A0-TA was again 
observed in over 10% of the control population, as illustrated by 
the thick black lines in Figure 3.23. However, 6A2-1A0-TG and 
6A2-1A0-CG were also found in over 10% of the control 
individuals. 
 
 
3.5 Allele and Haplotype Associations with RAOM/OME 
 
 
3.5.1  Association of Single SNP Alleles with RAOM/OME 
 
Following determination of SP-A1, SP-A2, and SP-D 
genotype/haplotype frequencies in both the individuals with 
RAOM/OME and the control population, Haploview was further 
employed to investigate if there was any significant difference of 
these values between the two populations. If a significant 
difference in genotype/haplotype frequencies was seen between 
the two populations, it would indicate an association between 
that particular allele/haplotype with RAOM/OME. 
 
Initially, Haploview compared the major and minor allele 
frequencies for each SNP in the case and control populations. 
Using Chi square (χ2) analysis, significant differences were 
identified (P < 0.05) therefore suggesting an association 
between a particular allele and RAOM/OME (Table 3.7). 
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SNP Assoc Allele 
Case,Control 
Frequencies 
Chi 
square P value 
SPA1-19 C 0.326, 0.222 8.053 0.0045 
SPA1-50 C 0.485, 0.399 2.380 0.1229 
SPA1-62 A 0.280, 0.261 0.003 0.9542 
SPA1-133 G 0.319, 0.190 12.886 3.00 x10-4
SPA1-219 T 0.160, 0.116 2.493 0.1144 
SPA2-9 A 0.604, 0.591 0.104 0.747 
SPA2-91 C 0.244, 0.182 3.218 0.0728 
SPA2-140 T 0.326, 0.258 3.291 0.0696 
SPA2-223 A 0.259, 0.162 8.359 0.0038 
SPD-11 T 0.337, 0.316 0.007 0.9343 
SPD-160 G 0.623, 0.578 1.230 0.2675 
 
Table 3.7. Single SNP allele associations with RAOM/OME. For each SNP locus, 
the associated allele’s case/control population frequencies, χ2 test result, and 
P value are presented. Statistically significant differences in the case and 
control populations are highlighted in bold font. 
 
Minor alleles of the SNPs SPA1-19, SPA1-133, and SPA2-223 
were found to be associated with RAOM/OME. The presence of a 
cytosine at codon 19 of SP-A1 was found in 32.6% of the 
European-Caucasian case population, but only 22.2% of the 
control population. The calculated χ2 value for this allele was 
8.053 (P = 0.0045). 
 
Also in SP-A1, a guanine at codon 133 was detected in 31.9% 
and 19.0% of the European-Caucasian case and control 
population, respectively. This difference was found to be 
significantly different by χ2 analysis  
(χ2 = 12.886, P = 3.00 x10-4). 
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Finally, an adenine at codon 223 of SP-A2 was also found to be 
over-represented in the population containing individuals with 
RAOM/OME (χ2 = 8.359, P = 0.0038), present in 25.9% of 
European-Caucasian case individuals and only 16.2% of control 
individuals. 
 
 
3.5.2  Association of Haplotypes with RAOM/OME 
 
The χ2 analysis for statistical significance between European-
Caucasian case and control population frequencies was repeated 
for the SP-A1, SP-A2, and SP-D haplotypes previously 
constructed by the Haploview software. The associations of the 
SP-A1 haplotypes with RAOM/OME are presented in Table 3.8. 
 
SP-A1 haplotypes 6A2 and CGAGC were found to be associated 
with RAOM/OME. Haplotype 6A2 was found to be under-
represented in the European-Caucasian case population (24.9%) 
in comparison to the control population (38.9%). This population 
frequency difference was determined statistically significant (χ2 
= 12.813, P = 3.00 x10-4).  
 
The population frequency of the haplotype CGAGC was also 
significantly different, with 5% in the European-Caucasian case 
population and 3.6% in the control population (χ2 = 6.932, P = 
0.0085). All other haplotype population differences were not 
statistically significant i.e. P > 0.05). 
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Haplotype Total 
Freq 
Case, Control 
Frequencies 
Chi 
Square 
P Value 
TGAAC (6A2) 0.336 0.249, 0.389 12.813 3.00 x10-4
TCAAC (6A3) 0.157 0.161, 0.172 0.292 0.5891 
CGAAC 0.082 0.092, 0.083 0.330 0.5654 
TGAGC 0.064 0.066, 0.037 3.303 0.0692 
TCGAT (6A4) 0.048 0.049, 0.048 0.060 0.8059 
CGAGC 0.039 0.050, 0.036 6.932 0.0085 
CCGGC (6A) 0.038 0.047, 0.028 0.004 0.9516 
CCAAC (6A11) 0.035 0.022, 0.031 0.527 0.4679 
TCAGC (6A16) 0.031 0.021, 0.025 1.289 0.2562 
TCGGT (6A9) 0.025 0.038, 0.011 0.049 0.8249 
CCAGC (6A17) 0.022 0.024, 0.021 3.614 0.0573 
TCGAC (6A14) 0.019 0.020, 0.024 0.051 0.8212 
CCGAT (6A5) 0.016 0.024, 0.019 0.247 0.6190 
CCGAC (6A10) 0.011 0.029, 0.012 1.177 0.2780 
CCGGT 0.011 0.023, 0.014 3.736 0.0532 
TGGGC (6A6) 0.011 0.020, 0.013 0.587 0.4434 
TGGAC (6A13) 0.011 0.023, 0.007 0.569 0.4505 
TCAAT (6A8) 0.011 0.010, 0.014 0.345 0.5572 
 
Table 3.8. SP-A1 haplotypes in association with RAOM/OME. For each SP-A1 
haplotype, the associated allele’s case/control population frequencies, χ2 test 
result, and P value are presented. Statistically significant differences in the 
case and control population frequencies are highlighted in bold font. 
 
Table 3.9 presents the associations between the Haploview 
constructed SP-A2 haplotypes and RAOM/OME. 
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Haplotype Total 
Freq 
Case, Control 
Frequencies 
Chi 
Square
P Value 
AGCC (1A0) 0.443 0.425, 0.490 3.763 0.0524 
CCTC (1A5) 0.084 0.089, 0.079 0.092 0.7620 
CGTA (1A1) 0.084 0.080, 0.083 0.012 0.9113 
CGCC (1A2) 0.072 0.046, 0.111 6.135 0.0133 
CCCC (1A) 0.07 0.070, 0.056 0.043 0.8352 
ACCC (1A12) 0.046 0.046, 0.033 0.907 0.3408 
CGCA (1A8) 0.04 0.055, 0.024 0.692 0.4056 
AGTC (1A9) 0.037 0.040, 0.024 4.058 0.0440 
AGCA 0.031 0.018, 0.037 1.434 0.2310 
CGTC (1A6) 0.029 0.046, 0.013 1.868 0.1717 
AGTA (1A3) 0.025 0.030, 0.025 5.578 0.0182 
CCTA (1A10) 0.016 0.030, 0.007 4.258 0.0391 
ACTC  (1A7) 0.013 0.009, 0.015 0.250 0.6171 
 
Table 3.9. SP-A2 haplotypes in association with RAOM/OME. For each SP-A2 
haplotype, the associated allele’s case/control population frequencies, χ2 test 
result, and P value are presented. Statistically significant differences in the 
case and control populations are highlighted in bold font. 
  
Of the thirteen SP-A2 haplotypes identified, 1A9, 1A3, and 1A10, 
were found to be over-represented in the European-Caucasian 
case population containing individuals with RAOM/OME (P < 
0.05). In contrast, haplotype 1A2 was found in 4.6% of 
European-Caucasian individuals with RAOM/OME, and 11.1% of 
control individuals (χ2 = 6.135, P = 0.0133). 
 
Lastly, associations between SP-D haplotypes and RAOM/OME 
were investigated and the results are shown in Table 3.10. 
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Haplotype Freq. Case, Control Frequencies 
Chi 
Square P Value 
TA 0.392 0.362, 0.406 0.715 0.3979 
TG 0.307 0.322, 0.300 0.954 0.3287 
CG 0.292 0.301, 0.278 0.050 0.8235 
CA 0.015 0.015, 0.016 0.01 0.9203 
 
Table 3.10. SP-D haplotypes in association with RAOM/OME. For each SP-D 
haplotype, the associated allele’s case/control population frequencies, χ2 test 
result, and P value are presented.  
 
None of the SP-D haplotype frequencies were found to differ 
significantly between the European-Caucasian case and control 
populations (P > 0.05). 
 
 
3.6 New Zealand Maori and Pacific Island Population 
Statistics 
 
Twenty-two of the individuals diagnosed with RAOM/OME were of 
New Zealand Maori or Pacific Island descent. This subset of 
individuals were compared by Haploview to the control 
population in order to see if there are any additional 
allele/haplotype associations with RAOM/OME which may explain 
their higher population incidence of RAOM/OME (Paterson et al., 
2006).  
 
Table 3.11 outlines the observed and predicted SNP 
heterozygosity; percentage of SNP genotyping; and minor allele 
statistics. Nine of the eleven SNPs were completely genotyped 
for the New Zealand Maori and Pacific Island case population, 
while SP-A1 SNPs at codons 50 and 62 were 95.5% successfully 
genotyped.  
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The minor allele frequency for a particular SNP ranged between 
0.25 (SPA1-133 and SPD-160) and 0.477 (SPA2-9 and SPA2-
140). The mean minor allele frequency was 0.352 ± 0.084 SD. 
 
SNP ObsHET PredHET HWpval %Geno MAF M.A. 
SPA1-19 0.455 0.434 1.000 100.0 0.318 C 
SPA1-50 0.333 0.387 0.8187 95.5 0.262 G 
SPA1-62 0.714 0.459 0.0360 95.5 0.357 G 
SPA1-133 0.500 0.375 0.3768 100.0 0.250 G 
SPA1-219 0.273 0.434 0.1693 100.0 0.318 T 
SPA2-9 0.409 0.499 0.5954 100.0 0.477 A 
SPA2-91 0.409 0.474 0.7539 100.0 0.386 C 
SPA2-140 0.409 0.499 0.5954 100.0 0.477 C 
SPA2-223 0.500 0.449 1.0000 100.0 0.341 A 
SPD-11 0.409 0.491 0.6450 100.0 0.432 C 
SPD-160 0.500 0.375 0.3768 100.0 0.250 A 
 
Table 3.11. Quality statistics for the SP-A1, SP-A2, and SP-D, SNP loci 
genotyped in the New Zealand Maori and Pacific Island population with 
RAOM/OME. Observed (ObsHET) and predicted (PredHET) heterozygosity 
values were calculated for each SNP loci. Significant deviations from the 
predicted heterozygosity estimates were determined by the Hardy-Weinberg 
equilibrium p value (HWpval < 0.0001). The percentage of non-missing 
genotypes for each SNP loci was calculated (%Geno).  The minor allele (M.A.) 
for each SNP loci and their corresponding population frequencies (MAF) were 
also presented. 
 
The differences between the predicted and observed values of 
heterozygosity for each SNP were determined to be not 
statistically significant, therefore suggesting that all the SNPs 
were in Hardy-Weinberg equilibrium (P > 0.001). 
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Following evaluation of SNP genotyping and Hardy-Weinberg 
statistics, the levels of LD between each pair of SNPs were 
calculated. The results from the LD analysis are shown in Figure 
3.24.  
 
Complete LD (D’/LOD = 100) was observed between five pairs of 
SNPs: SPA1-50/SPA2-9, SPA1-62/SPA1-133, SPA1-50/SPA2-
223, SPA1-133/SPA2-223, and SPA2-223/SPD-160. As 
previously seen in both the European-Caucasian case and control 
populations, SPA1-19 exhibited very low levels of LD with the 
rest of the SNP loci. 
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Figure 3.24. Linkage disequilibrium plot of the eleven SNPs in SP-A1, SP-A2, 
and SP-D detected in New Zealand Maori and Pacific Island individuals with 
RAOM/OME. The values given in each square represent: D’ (measure of LD 
between two SNP loci)/ LOD (logarithm of the odds for LD between the two 
SNP loci). A value of D’/LOD = 1 indicates complete LD and suggests that the 
two SNPs have not been separated by recombination. Values of D’/LOD < 1 
imply incomplete LD and indicate that the ancestral LD was disrupted during 
the population’s history.  Dark grey squares represent higher levels of LD, 
while  light grey or white squares represent lower levels of LD. D’/LOD values 
of 100 are not shown and are represented by a blank square. 
 
The Haploview software was also employed to construct 
haplotypes from the alleles detected at the SP-A1, SP-A2 and 
SP-D SNP loci in the New Zealand Maori and Pacific Island case 
population. The constructed haplotypes and their population 
frequencies are presented in Figure 3.25. 
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SP-A1       f         SP-A2     f         SP-D   f 
                           D’                      D’
Figure 3.25. Constructed haplotypes for SP-A1, SP-A2, and SP-D alleles seen 
in the New Zealand Maori and Pacific Island case population. Columns 01 – 05 
represent the nucleotide variants detected at the SP-A1 SNPs: 19T/C, 50G/C, 
62A/G, 133A/G, and 219C/T. Columns 06 – 09 represent the SP-A2 SNPs: 
9A/C, 91G/C, 140C/T, and 223C/A. Columns 10 – 11 correspond to SP-D: 
11T/C and 160G/A. Haplotype population frequencies (f) are also presented. 
Thick black lines link SP-A1, SP-A2, and SP-D haplotypes that were observed 
together at a frequency of ≥0.1. Thin black lines link haplotypes that were 
observed together at a frequency of ≥0.01. A value of multiallelic D’ is shown, 
which represents the estimated level of recombination between the 
haplotypes. 
 
In common with both the European-Caucasian case and control 
populations, the most frequent SP-A1 haplotype (37.6%) found 
in the New Zealand Maori/Pacific Island case population was 6A2 
(TGAAC). This was followed by haplotypes 6A3 (TCAAC, 15.6%), 
CGAAC (6.6%), 6A11 (CCAAC, 6.4%), and 6A4 (TCGAT, 5.2%). 
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The remaining haplotypes identified contributed to 28.6% of the 
population. 
 
Again, the predominant SP-A2 haplotype previously seen in both 
the European-Caucasian case and control populations, 1A0 
(AGCC), was also the major haplotype in the New Zealand Maori 
and Pacific Island case population (45.6%). Haplotype 1A1 
(CGTA) was detected in 9.7% of the population. The next most 
common haplotypes 1A5 (CCTC), 1A2 (CGCC), and 1A (CCCC) 
were found in 8.7%, 8.5%, and 7.4% of the population, 
respectively. The remaining SP-A2 haplotypes identified made-up 
20.1% of the total number of haplotypes found. 
 
The three SP-D haplotypes TA, TG, and CG were found in 38.6%, 
30.6%, and 29.3% of the New Zealand Maori and Pacific Island 
case population. The remaining 1.5% of individuals displayed the 
haplotype CA. 
  
In addition, SP-A1-SP-A2-SP-D haplotypes 6A2-1A0-TA and 6A2-
1A0-TG were both shown to be present in over 10% of the 
individuals from the New Zealand Maori and Pacific Island case 
population. 
 
 
3.6.1  Association of Single SNP Alleles with RAOM/OME in 
the New Zealand Maori and Pacific Island Population 
 
Following analysis of genotype and haplotype frequencies in the 
New Zealand Maori and Pacific Island case population, Haploview 
compared these values with those determined from the control 
population and identified any statistically significant differences 
(P < 0.05). The results from the comparative analysis of allele 
frequencies are presented in Table 3.12. 
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SNP Assoc 
Allele 
Case, Control Frequencies Chi 
square 
P value 
SPA1-19 C 0.318, 0.222 2.004 0.1568 
SPA1-50 C 0.738, 0.399 17.285 3.22 x10-5
SPA1-62 G 0.372, 0.261 2.270 0.1319 
SPA1-133 G 0.250, 0.190 0.882 0.3477 
SPA1-219 T 0.318, 0.116 13.173 3.00 x10-4
SPA2-9 C 0.523, 0.409 2.036 0.1536 
SPA2-91 C 0.386, 0.182 9.790 0.0018 
SPA2-140 T 0.523, 0.258 13.168 3.00 x10-4
SPA2-223 A 0.341, 0.162 8.198 0.0042 
SPD-11 C 0.432, 0.316 2.363 0.1242 
SPD-160 G 0.750, 0.578 4.757 0.0292 
 
Table 3.12. Allele associations with RAOM/OME seen in New Zealand Maori 
and Pacific Island individuals. For each SNP, the associated allele’s 
case/control population frequencies, χ2 test result, and P value are presented. 
Statistically significant differences between the New Zealand Maori and Pacific 
Island case population and the control population are highlighted in bold font. 
 
In common with the European-Caucasian case population, an 
adenine at codon 223 of SP-A2 was also associated with 
increased risk of RAOM/OME in New Zealand Maori and Pacific 
Island individuals in comparison to the control population (χ2 = 
8.198, P = 0.0042). However, the association of a cytosine and a 
guanine at codons 19 and 133 of SP-A1, respectively, previously 
seen in the European-Caucasian case population was not found 
in the New Zealand Maori and Pacific Island case population. 
 
In addition to the allele 223A, two other SP-A2 alleles were more 
frequent in the New Zealand Maori and Pacific Island case 
population: 91C and 140T. A cytosine at codon 91 of SP-A2 was 
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present in 38.6% of the New Zealand Maori and Pacific Island 
individuals but only 18.2% of the control individuals (χ2 = 9.790, 
P = 0.0018). At SP-A2 codon 140, a thymidine was found in 
52.3% and 25.8% of the New Zealand Maori/Pacific Island and 
control individuals, respectively (χ2 = 13.168, P = 3.00 x10-4). 
 
SP-A1 alleles 50C and 219T were found to be over-represented 
in the New Zealand Maori/Pacific Island case population, 
compared to the control population. A cytosine at codon 50 was 
detected in 73.8% of the New Zealand Maori/Pacific Island 
individuals, but was much less frequent in the control population 
(39.9%: χ2 = 17.285, P = 3.22 x10-5). Within the New Zealand 
Maori/Pacific Island individuals, 31.8% were found to carry a 
thymidine at codon 219 of SP-A1, while only 11.6% of the 
control individuals had the same allele (χ2 = 13.173, P = 3.00 
x10-4). 
 
In the European-Caucasian case population, none of the SP-D 
alleles were found to be over- or under- represented and were 
therefore not associated with RAOM/OME. However, in the New 
Zealand Maori/Pacific Island case population a guanine at codon 
160 of SP-D was detected in 75% of the individuals. This minor 
allele was significantly less frequent in the control population, 
with 57.8% exhibiting a guanine at codon 160 (χ2 = 4.757, P = 
0.0292), indicating that this allele is associated with an increased 
risk of RAOM/OME in New Zealand Maori and Pacific Island 
individuals. 
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3.6.2 Association of Haplotypes with RAOM/OME in the 
New Zealand Maori and Pacific Island Population 
 
Table 3.13 shows the results from the Haploview investigation 
for any associations between the previously constructed SP-A1 
haplotypes in the New Zealand Maori and Pacific Island case 
population, and RAOM/OME. 
 
Haplotype Total 
Freq 
Case, Control 
Frequencies 
Chi 
Square
P Value 
TGAAC (6A2) 0.360 0.092, 0.397 15.560 8.00 x10-5
TCAAC (6A3) 0.177 0.241, 0.168 1.411 0.2349 
CGAAC  0.076 0.062, 0.078 0.140 0.7081 
TCGAT (6A4) 0.045 0.056, 0.043 0.132 0.7165 
CCGGC (6A) 0.036 0.024, 0.037 0.186 0.6660 
TGAGC  0.033 0.029, 0.033 0.023 0.8798 
CCAAC (6A11) 0.033 0.048, 0.031 0.353 0.5525 
TCAGC (6A16) 0.030 0.048, 0.028 0.522 0.4699 
TGGAC (6A13) 0.029 0.024, 0.029 0.044 0.8340 
TCGGT (6A9) 0.028 0.067, 0.022 2.806 0.0939 
TGGGC (6A6) 0.026 0.016, 0.027 0.184 0.6679 
CCGAT (6A5) 0.026 0.055, 0.022 1.724 0.1892 
CCGAC (6A10) 0.020 0.060, 0.014 4.169 0.0412 
CCGGT 0.017 0.045, 0.013 2.358 0.1247 
TCAAT (6A8) 0.013 0.072, 0.005 13.630 2.00 x10-4
TCGAC (6A14) 0.013 0.011, 0.013 0.009 0.9236 
 
Table 3.13. SP-A1 haplotypes in association with RAOM/OME in the New 
Zealand Maori and Pacific Island case population. For each SP-A1 haplotype, 
the associated allele’s case/control population frequencies, χ2 test result, and 
P value are presented. Statistically significant differences between the New 
Zealand Maori and Pacific Island case population and the control population 
are highlighted in bold font. 
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In common with the earlier haplotype analysis of the European-
Caucasian case population, under-representation of the SP-A1 
haplotype 6A2 was also seen in the New Zealand Maori/Pacific 
Island case population (9.2%), compared to the control 
population (39.7%). Thus suggesting that the particular 
haplotype is protective against RAOM/OME (χ2 = 15.560, P = 
8.00 x10-5). Two SP-A1 haplotypes, 6A8 and 6A10, were found to 
be significantly more frequent in the New Zealand Maori/Pacific 
Island case individuals in comparison to the control population (P 
< 0.05). 
 
Associations between SP-A2 haplotypes and RAOM/OME in the 
New Zealand Maori and Pacific Island case population are shown 
in Table 3.14. 
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Haplotype Total 
Freq 
Case, Control 
Frequencies 
Chi 
Square
P Value 
AGCC (1A0) 0.468 0.264, 0.496 8.361 0.0038 
CGCC (1A2) 0.098 0.010, 0.110 4.321 0.0377 
CGTA (1A1) 0.095 0.152, 0.087 1.883 0.1700 
CCTC (1A5) 0.085 0.135, 0.079 1.557 0.2121 
CCCC (1A) 0.063 0.113, 0.057 2.050 0.1523 
CGTC (1A6) 0.033 0.008, 0.037 1.026 0.3111 
CGCA (1A8) 0.032 0.028, 0.033 0.022 0.8811 
AGTC (1A9) 0.027 0.068, 0.021 3.253 0.0713 
ACCC (1A12) 0.026 0.048, 0.023 1.029 0.3104 
AGCA 0.022 0.013, 0.024 0.191 0.6622 
CCTA (1A10) 0.016 0.077, 0.008 11.510 7.00 x10-4
AGTA (1A3) 0.016 0.070, 0.009 8.896 0.0029 
ACTC (1A7) 0.015 0.013, 0.016 0.022 0.883 
 
Table 3.14. SP-A2 haplotypes in association with RAOM/OME in the New 
Zealand Maori and Pacific Island case population. For each SP-A2 haplotype, 
the associated allele’s case/control population frequencies, χ2 test result, and 
P value are presented. Statistically significant differences between the New 
Zealand Maori and Pacific Island case population and the control population 
are highlighted in bold font. 
 
In the European-Caucasian case population, the SP-A2 haplotype 
1A2 was the only haplotype found to be under-represented (P < 
0.05). However, both 1A2 and 1A0 were found to be significantly 
less common in the New Zealand Maori/Pacific Island case 
population than the control population. Haplotype 1A2 was found 
in only 1% of the New Zealand Maori/Pacific Island case 
individuals, but in 11% of the control individuals (χ2 = 4.321, P 
= 0.0377). Furthermore, haplotype 1A0 was present in 26.4% 
and 49.6% of the New Zealand Maori and Pacific Island case 
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population and control population, respectively (χ2 = 8.361, P = 
0.0038). 
 
On the other hand, SP-A2 haplotypes 1A3 and 1A10 were over-
represented in the European-Caucasian case population, and this 
finding was repeated in the New Zealand Maori and Pacific Island 
case population. Haplotype 1A3 was found in 7% of the New 
Zealand Maori/Pacific Island case individuals, but only 0.9% of 
the control individuals (χ2 = 8.896, P = 0.0038). Similarly, 
haplotype 1A10 was present in 7.7% of the New Zealand 
Maori/Pacific Island case individuals and 0.8% of the control 
individuals (χ2 = 11.51, P = 7.00 x10-4). 
 
None of the SP-D haplotypes were found to be significantly 
associated with RAOM/OME in the previous analysis of the 
European-Caucasian case population. However, in the New 
Zealand Maori and Pacific Island case population the haplotype 
TA was under-represented, indicating that it has a protective 
function against RAOM/OME (Table 3.15). Approximately 20% of 
New Zealand Maori/Pacific Island individuals diagnosed with 
RAOM/OME had a thymidine and an adenine at codons 11 and 
160, correspondingly. However, this quantity was significantly 
higher in the control population, with 40.6% of the individuals 
displaying the haplotype TA (χ2 = 5.480, P = 0.0192).  
 
 
 
 
 
 
 
 
Chapter Three: Results 95
 
Haplotype Total 
Freq 
Case, Control 
Frequencies 
Chi 
Square
P 
Value 
TA 0.384 0.223, 0.406 5.480 0.0192 
CG 0.312 0.405, 0.299 1.988 0.1586 
TG 0.287 0.345, 0.279 0.845 0.3580 
CA 0.017 0.027, 0.016 0.28 0.5967 
 
Table 3.15. SP-D haplotypes in association with RAOM/OME in the New 
Zealand Maori and Pacific Island case population. For each SP-D haplotype, 
the associated allele’s case/control population frequencies, χ2 test result, and 
P value are presented. Statistically significant differences between the New 
Zealand Maori and Pacific Island case population and the control population 
are highlighted in bold font. 
 
 
3.7 Association with Meningococcal Disease 
 
Three individuals diagnosed with meningococcal diseases were 
also genotyped for the eleven SP-A1, SP-A2, and SP-D 
polymorphisms, and the findings are presented in Table 3.16. 
 
Sample M1 was found to be heterozygous for both the major and 
minor alleles at three SP-A1 loci (codons 19, 50, and 62), two 
SP-A2 loci (codons 9 and 223), and the two SP-D loci (codons 11 
and 160). Only the major allele was detected at codon 219 of 
SP-A1, and codon 140 of SP-A2. However, sample M1 was 
homozygous for the minor allele at SPA1-133 and SPA2-91. 
 
At eight of the eleven SNP loci, sample M2 was determined to be 
homozygous for the major allele. In contrast, this individual was 
heterozygous for both alleles at SNPs SPA1-50, SPA1-133, and 
SPA2-9. 
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The last of the three meningococcal samples, M3, was 
homozygous for the major alleles at ten of the eleven SNP loci. 
The exception was seen at codon 19 of SP-A1, where both the 
major and minor alleles were detected. 
 
Genotypes Detected 
SNP Alleles 
M1 M2 M3 
SPA1-19T/C TC TT TC 
SPA1-50G/C GC GC GG 
SPA1-62A/G AG AA AA 
SPA1-133A/G GG  AG AA 
SPA1-219C/T CC CC CC 
SPA2-9A/C AC AC AA 
SPA2-91G/C CC GG GG 
SPA2-140C/T CC CC CC 
SPA2-223C/A CA CC CC 
SPD-11T/C TC TT TT 
SPD-160G/A GA GG GG 
 
Table 3.16. Genotypes of three individuals with meningococcal disease at the 
eleven SNP loci within SP-A1, SP-A2, and SP-D. The major/minor alleles for 
each SNP loci are provided e.g. SPA2-140C/T. The three possible genotypes 
for each SNP are: Homozygous for the major allele; homozygous for the 
minor allele; and heterozygous for both alleles. 
 
 
3.7.1 Association of Single SNP Alleles with Meningococcal 
Disease 
 
The allele and haplotype frequencies determined in the 
meningococcal individuals were compared to those of the control 
population using the Haploview software. Resulting associations 
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of single alleles with meningococcal disease are presented in 
Table 3.17. 
 
SNP Assoc 
Allele 
Case, Control Frequencies Chi Square P value 
SPA1-19 C 0.333, 0.222 0.421 0.5164 
SPA1-50 G 0.667, 0.601 0.107 0.7434 
SPA1-62 A 0.833, 0.739 0.271 0.6025 
SPA1-133 G 0.500, 0.190 3.599 0.0578 
SPA1-219 C 1.000, 0.884 0.783 0.3764 
SPA2-9 A 0.667, 0.591 0.141 0.7073 
SPA2-91 C 0.333, 0.182 0.889 0.3457 
SPA2-140 C 1.000, 0.742 2.071 0.1501 
SPA2-223 A 0.167, 0.162 0.001 0.9781 
SPD-11 T 0.833, 0.684 0.608 0.4356 
SPD-160 A 0.833, 0.422 4.069 0.0437 
 
Table 3.17. Association of specific SP-A1, SP-A2, and SP-D alleles with 
meningococcal disease. For each allele analyzed, their frequencies within the 
meningococcal and control individuals are given. χ2 analysis was performed 
and any significant results are highlighted in bold font (P < 0.05). 
 
Out of the eleven alleles analyzed by Haploview, only one was 
determined to differ significantly in frequency between the 
meningococcal and control individuals. An adenine at codon 160 
of SP-D was detected in 83.3% of the meningococcal individuals 
but was present in only 42.2% of the control population (χ2 = 
4.069, P = 0.0437). Such an over-representation may suggest 
increased host susceptibility to meningococcal infection. 
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3.7.2 Association of Haplotypes with Meningococcal 
Disease 
 
Following investigation of single allele associations, Haploview-
constructed haplotypes were also examined for association with 
meningococcal disease. The results of this analysis with SP-A1 
haplotypes are shown in Table 3.18. 
 
Haplotype Total 
Freq 
Case, Control 
Frequencies 
Chi 
Square
P Value 
TGAAC (6A2) 0.397 0.289, 0.399 0.297 0.5858 
TCAAC (6A3) 0.161 0.044, 0.164 0.622 0.4304 
CGAAC 0.081 0.167, 0.080 0.597 0.4397 
TCGAT (6A4) 0.046 0.000, 0.047 0.297 0.5860 
CCGGC (6A) 0.041 0.122, 0.039 1.034 0.3092 
TCAGC (6A16) 0.037 0.167, 0.035 2.859 0.0909 
TGAGC 0.033 0.166, 0.031 3.385 0.0658 
CCAAC (6A11) 0.032 0.000, 0.033 0.203 0.6521 
TGGAC (6A13) 0.028 0.000, 0.029 0.179 0.6726 
TGGGC (6A6) 0.026 0.000, 0.027 0.165 0.6850 
CCGAT (6A5) 0.021 0.000, 0.022 0.133 0.7157 
TCGGT (6A9) 0.018 0.000, 0.018 0.112 0.7374 
TCGAC (6A14) 0.015 0.000, 0.015 0.091 0.7635 
CCGGT 0.014 0.000, 0.015 0.089 0.7654 
CGGGC (6A19) 0.013 0.045, 0.013 0.465 0.4953 
CGAGC 0.011 0.000, 0.012 0.07 0.7916 
 
Table 3.18. SP-A1 haplotypes in association with meningococcal disease. For 
each SP-A1 haplotype, the associated allele’s case/control population 
frequencies, χ2 test result, and P value are presented.  
 
No significant association between any of the SP-A1 haplotypes 
and meningococcal disease was found (P > 0.05). 
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Table 3.19 presents the results from association testing the SP-
A2 haplotypes with meningococcal disease. Similar to the SP-A1 
haplotypes, no association between SP-A2 haplotypes and 
meningococcal disease was identified. 
  
Haplotype Total Freq 
Case, Control 
Frequencies 
Chi 
Square P Value 
AGCC (1A0) 0.498 0.500, 0.498 0 0.9939 
CGCC (1A2) 0.109 0.167, 0.107 0.214 0.6440 
CGTA (1A1) 0.089 0.000, 0.091 0.598 0.4392 
CCTC (1A5) 0.077 0.000, 0.078 0.509 0.4758 
CCCC (1A) 0.059 0.167, 0.057 1.26 0.2617 
CGTC (1A6) 0.038 0.000, 0.038 0.239 0.6251 
CGCA (1A8) 0.032 0.000, 0.032 0.201 0.6540 
AGCA 0.022 0.000, 0.022 0.135 0.7136 
ACCC (1A12) 0.021 0.000, 0.021 0.129 0.7196 
AGTC (1A9) 0.019 0.000, 0.020 0.121 0.7276 
ACTC (1A7) 0.017 0.000, 0.017 0.103 0.7483 
 
Table 3.19. SP-A2 haplotypes in association with meningococcal disease. For 
each SP-A2 haplotype, the associated allele’s case/control population 
frequencies, χ2 test result, and P value are presented.  
 
Finally, SP-D haplotypes were investigated for any significant 
association with meningococcal disease (Table 3.20). Haplotype 
TA in the Pacific Island sub-sample previously analyzed (section 
3.5.3) was found to be under-represented compared to the 
control population. However, in regards to meningococcal 
disease it is indicated that this haplotype was over-represented 
in comparison to the control population. Haplotype TA was 
detected in 82.8% of meningococcal individuals and 40.6% of 
control individuals, thus suggesting an association with increased 
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host susceptibility to meningococcal infection (χ2 = 4.312, P = 
0.0378). 
 
Haplotype Total 
Freq 
Case, Control 
Frequencies 
Chi 
Square
P Value 
TA 0.414 0.828, 0.406 4.312 0.0378 
CG 0.298 0.161, 0.300 0.544 0.4608 
TG 0.273 0.005, 0.278 2.204 0.1377 
 
Table 3.20. SP-D haplotypes in association with meningococcal disease. For 
each SP-D haplotype, the associated allele’s case/control population 
frequencies, χ2 test result, and P value are presented. Statistically significant 
differences between the meningococcal individuals and the control population 
are highlighted in bold font (P < 0.05). 
 
 
3.8 PolyPhen Results 
 
The amino acid sequence for SP-A1 (Homo sapiens) was 
obtained from the National Centre for Biotechnology Information 
(NCBI) and entered into the PolyPhen server in FASTA format 
(Figure 3.26).  
 
>gi|38888175|ref|NP_005402.3| surfactant, pulmonary-
associated protein A1 [Homo sapiens] 
MWLCPLALNLILMAASGAVCEVKDVCVGSPGIPGTPGSHGLPGRDGRDGLKGDP
GPPGPMGPPGEMPCPPGNDGLPGAPGIPGECGEKGEPGERGPPGLPAHLDEELQA
TLHDFRHQILQTRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEACARAGGRIAV
PRNPEENEAIASFVKKYNTYAYVGLTEGPSPGDFRYSDGTPVNYTNWYRGEPAGR
GKEQCVEMYTDGQWNDRNCLYSRLTICEF 
 
Figure 3.26. Amino acid sequence of human SP-A1 in FASTA format. Location 
of non-synonymous SNPs are in bold and underlined. Obtained from NCBI. 
 
For each of the three non-synonymous SNPs the location of the 
specific amino acid changed was entered, along with the major 
and minor amino acid variants. PolyPhen estimated position-
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specific independent counts (PSIC) scores (measure of structural 
and functional attributes) for both variants, calculated the 
difference between them, and predicted whether a significant 
change would occur. A prediction on the structural and functional 
implications each non-synonymous SNP could potentially have on 
the translated SP-A1 was then made, as documented in Table 
3.21. 
 
Amino 
Acid 
 
AA1 AA2 PSIC 
Score 1 
PSIC 
Score 2 
(Score 1-
Score 2) 
Prediction 
19 
 
Val Ala -0.496 -0.487 0.009 Benign 
50 
 Leu Val 0.136 1.153 1.017 Benign 
219 Arg Trp 1.391 -0.879 2.270 Probably 
Damaging 
 
Table 3.21. Polymorphism phenotyping results for SP-A1 as predicted by 
PolyPhen. 
 
PolyPhen predicted that the polymorphisms that would result at 
non-synonymous changes at amino acids 19 and 50 would have 
a benign effect. In other words, such changes would not have a 
significant deleterious effect on the translated SP-A1’s structure 
and function.  
 
In contrast, it was predicted that a tryptophan substituted for an 
arginine at amino acid position 219 would probably have a 
damaging effect on SP-A1’s structural and functional attributes. 
 
The FASTA amino acid sequence for SP-A2 (Homo sapiens) seen 
in Figure 3.27 was also subjected to Polyphen analysis.  
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>gi|13346506|ref|NP_008857.1| surfactant, pulmonary-
associated protein A2 [Homo sapiens] 
MWLCPLALNLILMAASGAACEVKDVCVGSPGIPGTPGSHGLPGRDGRDGVKGDPG
PPGPMGPPGETPCPPGNNGLPGAPGVPGERGEKGEAGERGPPGLPAHLDEELQAT
LHDFRHQILQTRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEACARAGGRIAVP
RNPEENEAIASFVKKYNTYAYVGLTEGPSPGDFRYSDGTPVNYTNWYRGEPAGRG
KEQCVEMYTDGQWNDRNCLYSRLTICDF 
 
Figure 3.27. Amino acid sequence of human SP-A2 in FASTA format. Location 
of non-synonymous SNPs are in bold and underlined. Obtained from NCBI. 
 
Table 3.22 provides the results for the three non-synonymous 
SNPs after PolyPhen analysis. A lysine at amino acid position 223 
in SP-A2 was estimated to have no detrimental effect on the 
protein’s structure and function. PolyPhen could not produce 
predictions for non-synonymous changes at amino acids 9 and 
91. 
 
Amino 
Acid 
 
AA1 AA2 PSIC Score 1 
PSIC 
Score 2 
(Score 1-
Score 2) Prediction 
9 
 Asn Thr N/A N/A N/A Unknown 
91 
 
Ala Pro N/A N/A N/A Unknown 
223 
 Gln Lys 1.387 1.352 0.035 Benign 
 
Table 3.22. Polymorphism phenotyping results for SP-A2 as predicted by 
PolyPhen. 
 
Finally, the primary structure of SP-D (Figure 3.28) was analyzed 
with PolyPhen to predict the possible effects the two non-
synonymous SNPs could have on the protein’s structure and 
function.  
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>gi|61699226|ref|NP_003010.4| pulmonary surfactant-   
associated protein D precursor [Homo sapiens] 
LFLLSALVLLTQPLGYLEAEMKTYSHRTMPSACTLVMCSSVESGLPGRDGRDGRE
GPRGEKGDPGLPGAAGQAGMPGQAGPVGPKGDNGSVGEPGPKGDTGPSGPPGPPG
VPGPAGREGPLGKQGNIGPQGKPGPKGEAGPKGEVGAPGMQGSAGARGLAGPKGE
RGVPGERGVPGNTGAAGSAGAMGPQGSPGARGPPGLKGDKGIPGDKGAKGESGLP
DVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEA
QLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDSKTEGKFTYPTGESL
VYSNWAPGEPNDDGGSEDCVEIFTNGKWNDRACGEKRLVVCEF 
 
Figure 3.28. Amino acid sequence of human SP-D in FASTA format. Location 
of non-synonymous SNPs are in bold and underlined. Obtained from NCBI. 
 
The resulting predictions, recorded in Table 3.23, determined 
that such changes in SP-D would have a benign effect on the 
protein’s structure and function. 
 
Amino 
Acid 
 
AA1 AA2 PSIC Score 
1 
PSIC Score 
2 
(Score 1-
Score 2) 
Prediction 
11 
 
Thr Met 1.125 -0.225 1.350 Benign 
160 
 Ala Thr 0.214 0.203 0.011 Benign 
 
Table 3.23. Polymorphism phenotyping results for SP-D as predicted by 
PolyPhen. 
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CHAPTER FOUR 
 
DISCUSSION 
 
 
4.1 Background 
 
The prevalence of recurrent acute otitis media (RAOM) and otitis 
media with effusion (OME) in the general population is assumed 
to exhibit an underlying normal distribution (Kvestad et al., 
2003a). Some individuals are more susceptible to such infections 
and are placed at the far right tail of the bell-shaped curve, while 
others are more resistant and are placed at the far left tail of the 
bell-shaped curve. Despite the extreme phenotypes at either 
end, the majority of the population sits in the middle of the bell-
shaped curve near the population mean number of episodes of 
AOM/OME per person per year. Though a variety of 
environmental and socio-economic factors contribute to the 
pathogenesis of otitis media (age, bacterial and viral exposure, 
innate and adaptive immunity status, Eustachian tube structure 
and function), substantial evidence indicates that susceptibility to 
otitis media can also be inherited (Casselbrandt et al., 1999; 
Kvestad et al., 2003b). Casselbrandt and co-workers conducted 
a twin and triplet cohort study to determine the genetic 
component of time with and episodes of middle ear effusion and 
AOM during the first two years of life. They estimated of 
heritability of time with middle ear effusion was 0.73 (P < 0.001) 
during this time period. 
 
Previous studies have implicated polymorphisms in the two 
genes for the surfactant-related protein SP-A with susceptibility 
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or resistance to otitis media (Pettigrew et al., 2006; Rämet et 
al., 2001). SP-A and it’s closely related collectin-family member 
SP-D are host defense proteins which are expressed in the lungs, 
middle ear, and a range of other mucosae (Bourbon and 
Chailley-Heu, 2001; Dutton et al., 1999). They contribute to host 
immunity by binding and aggregating Gram-negative and Gram-
positive bacteria or viruses, and enhancing their destruction by 
phagocytes (Crouch et al., 1998, 2000, 2001; Crouch and 
Wright, 2001; Ding et al., 2004; Shepherd, 2002). SP-A and SP-
D also interact with and/or stimulate members of the adaptive 
immune system to further combat pathogen infection e.g. 
RAOM/OME in the middle ear (Bohlson et al., 2007; Murakami et 
al., 2002; Nadesalingam et al., 2005; Ohya et al., 2006).  
 
Biallelic single nucleotide polymorphisms in SP-A1, SP-A2, and 
SP-D have been identified which result in either synonymous or 
non-synonymous amino acid substitutions in the translated 
protein. Additionally, all three genes are in linkage disequilibrium 
and thus haplotypes can be constructed from the alleles found at 
each of the SNP loci (Floros et al., 1996; Hoover and Floros, 
1998). As recombination occurs less often than expected in 
regions in linkage disequilibrium, haplotypes can be inherited as 
units. Certain SP-A1 and SP-A2 alleles and haplotypes have been 
correlated with increased or decreased host susceptibility to otitis 
media (Pettigrew et al., 2006; Rämet et al., 2001). No previous 
research has linked SP-D alleles or haplotypes with otitis media. 
 
In a Finnish population, Rämet and colleagues (2001) analyzed 
DNA from forty-seven children diagnosed with acute otitis media 
(AOM) and 147 children with RAOM for SP-A haplotypes. Using a 
previously described PCR-restriction fragment length 
polymorphism-based method they compared the SP-A1 and SP-
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A2 haplotype frequencies from the case groups with 228 
individuals from the general population. The haplotypes found 
were composites of alleles from single nucleotide polymorphisms 
at codons 19, 50, 62, 133, and 219 of SP-A1 and at codons 9, 
91, 140, and 223 of SP-A2. SP-A1 haplotypes are denoted with 
6Am and SP-A2 haplotypes with 1An. As SP-A1, SP-A2, and SP-D 
are in linkage disequilibrium, such haplotypes can be combined 
e.g. 6Am-1An.  
 
Rämet et al. identified statistically significant differences in 
haplotype frequencies between the case and control populations 
with χ2 analysis.  The haplotype 6A4-1A5 (TCGAT-CCTC) was 
found to be over-represented in both the AOM (P = 0.02) and 
RAOM (P = 0.003) groups. Additionally, the AOM group exhibited 
an under-representation of the 6A2-1A0 (TGAAC-AGCC) 
haplotype (P = 0.03). 
 
In an American study, 355 infants at risk for developing asthma 
were genotyped to evaluate the association between the same 
SP-A1 and SP-A2 loci as described above, and risk of otitis media 
during the first year of life (Pettigrew et al., 2006). They 
demonstrated that the major allele, an alanine at codon 19 of 
SP-A1 corresponded with a significantly greater chance of otitis 
media within the first year of life (χ2, P = 0.01). They further 
determined that Caucasian infants with an alanine at SP-A1 
codon 19 were >3.8 times more likely to have otitis media in the 
first year of life, in comparison to those with a valine at that 
position. Alleles at codons 19, 62, and 133 in SP-A1, and 223 in 
SP-A2 were found to be differentially distributed across 
Caucasian, Hispanic, and African-American infants.  
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In decreasing order of frequency, the most common SP-A1 
haplotypes found by Pettigrew et al. in the Caucasian infants 
were 6A2, 6A3, 6A4, and 6A. Again in decreasing order, 
haplotypes 1A0, 1A1, 1A2, 1A, 1A5, 1A6, and 1A3 were the most 
frequent SP-A2 haplotypes detected. In complete contrast to the 
findings of Rämet et al. Caucasian infants with haplotype 6A4-1A5 
were associated with a 76% decreased risk of otitis media during 
their first year of life (OR = 0.23, 95% CI = 0.07 – 0.73). 
 
In this study, eleven single nucleotide polymorphisms in the 
coding regions of SP-A1, SP-A2, and SP-D were genotyped in 
160 unaffected individuals (control population) and in 136 
individuals diagnosed with recurrent acute otitis media (RAOM) 
or otitis media with effusion (OME), in order to identify any 
associated alleles/haplotypes.  The SNP loci investigated were 
situated at codons 19, 50, 62, 133, and 219 of SP-A1, and 
codons 9, 91, 140, and 223 of SP-A2. Lastly, SNPs at SP-D 
codons 11 and 160 were examined. Out of the eleven loci 
investigated, single nucleotide changes at all but three resulted 
in non-synonymous amino acid changes. Substitutions at SPA1-
62, SPA1-133, and SPA2-140 resulted in synonymous amino acid 
changes. It was hypothesized that specific alleles and haplotypes 
of SP-A1, SP-A2 and SP-D would be more or less frequent in the 
RAOM/OME individuals, confirming the findings of previous 
studies (Pettigrew et al., 2006; Rämet et al., 2001).  
 
The most common SP-A1 haplotypes found in descending order 
in this study’s European-Caucasian RAOM/OME population were 
6A2 (TGAAC), 6A3 (TCAAC), CGAAC, 6A4 (TCGAT), and TGAGC. 
Appropriate nomenclature for haplotypes CGAAC and TGAGC was 
unknown. Most frequent SP-A2 haplotypes in this population 
were 1A0 (AGCC), 1A5 (CCTC), 1A1 (CGTA), 1A (CCCC), and 1A9 
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(AGTC) in descending order of frequency. In the control 
population the most common SP-A1 haplotypes, in decreasing 
order, were 6A2 (TGAAC), 6A3 (TCAAC), CGAAC, 6A4 (TCGAT), 
and 6A (CCGGC). The most common SP-A2 haplotypes in the 
same population were 1A0 (AGCC), 1A2 (CGCC), 1A1 (CGTA), 1A5 
(CCTC), and 1A (CCCC). In both the case and control 
populations, SP-D haplotypes TA, CG, and TG were most 
frequently seen while haplotype CA was present in less than 2% 
of each population. 
 
Specific SP-A1, SP-A2, and SP-D alleles and haplotypes found to 
be associated with host susceptibility or resistance to RAOM/OME 
are presented in the following sections. 
 
 
4.2 SP-A1, SP-A2, and SP-D Alleles and Haplotypes 
associated with increased host susceptibility to 
RAOM/OME 
 
 
4.2.1  SP-A1, SP-A2, and SP-D Alleles 
 
Three specific alleles were found to be over-represented in the 
European-Caucasian population of individuals diagnosed with 
RAOM/OME: SPA1-19C, SPA1-133G, and SPA2-223A.  
 
In SP-A1, an alanine (major allele) at codon 19 was associated 
with increased risk of RAOM/OME (P = 0.0045). Codon 19 is 
located in the N-terminal of SP-A1, the region responsible for 
interacting with other SP-A1 and SP-A2 molecules to form 
trimeric subunits and higher order multimers. An amino acid 
substitution at codon 19 from an alanine (major allele) to a 
valine (minor allele) may affect how successfully SP-A1 forms 
trimeric subunits and octadecamers; however, no evidence has 
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been published to support this hypothesis. Leth-Larsen and 
colleagues (2005) separated purified human SP-D by gel 
filtration chromatograghy and identified the components using 
atomic force microscopy. They found that multimers, 
dodecamers, and monomers of subunits displayed a higher level 
of binding to intact influenza A virus, Gram-positive bacteria, and 
Gram-negative bacteria than did SP-D monomers. However, 
monomers of SP-D preferentially bound isolated LPS. The 
researchers postulated that differences in the proportions of 
trimeric subunits and higher order multimers of SP-D in 
individuals were associated with differential activation of anti- 
and pro-inflammatory signalling pathways and consequently 
affected the efficiency of inflammatory response and subsequent 
clearance of microbes. However, they conducted no further 
research to test this hypothesis. 
 
Such SP-D findings could also potentially apply to SP-A1 in the 
context of the middle ear. For example, the non-synonymous 
amino acid change in the N-terminal of SP-A1 may have a 
deleterious effect on the protein’s ability to form trimers and 
multimers, which could subsequently reduce their ability to clear 
the bacteria/viruses involved in RAOM/OME pathogenesis. 
Unfortunately, these ideas are purely speculative as no research 
has investigated the effects of an alanine at SP-A1 codon 19 on 
the protein’s structural and functional characteristics. Polyphen 
analysis (http://www.bork.embl-heidelberg.de/PolyPhen) 
employed in this study predicted that such a change would have 
a benign effect on SP-A1’s structure and function. Using 3D 
protein structures, multiple alignments of homologous 
sequences, and amino acid contact information from a variety of 
protein structure databases, the differences between the two 
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protein variants were investigated by PolyPhen and deemed non-
significant (Ramensky et al., 2002). 
 
The major allele of SPA1-133, situated in the collagenous region 
of SP-A1, was also determined to be associated with increased 
risk of RAOM/OME (P = 3.00 x10-4). However, this result was 
unexpected considering that a synonymous amino acid 
substitution occurs and has no functional effect on the gene 
product; the nucleotides guanine and adenine at this locus both 
encode a threonine. The substitution was predicted by PolyPhen 
to not have a significant effect on SP-A1’s structure and function. 
Perhaps the presence of the nucleotide guanine (major allele) 
rather than an adenine (minor allele) at the SNP locus allows for 
additional CpG methylation, a trait of heterochromatin and 
repressed gene expression. A reduction in gene expression would 
therefore result in reduced SP-A1 in the middle ear and 
Eustachian tube which may subsequently lead to increased host 
susceptibility to infection by the common respiratory bacteria 
and viruses known to cause RAOM/OME. Research investigating 
the levels of CpG methylation in the SP-A1 region and 
subsequent gene expression is currently nonexistent, therefore 
further investigation is needed to assess whether changes to 
SPA1-133 have any influence on SP-A1 expression. 
 
Finally, the presence of a lysine (minor allele) at amino acid 
position 223 of SP-A2 was found in significantly more RAOM/OME 
individuals compared to the control population (P = 0.0038). 
This over-representation in the case population indicated an 
association with an increased risk for RAOM/OME. Similar results 
were seen in the research conducted by Lofgren and co-workers 
(2002) that compared the frequencies of SP-A1 and SP-A2 alleles 
in a population of children with severe respiratory syncytial virus 
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(RSV) bronchiolitis and a control population. Among patients with 
severe RSV infection, a lysine at codon 223 of SP-A2 was also 
significantly over-represented (0.28 vs. 0.18; OR = 1.78; 95% 
CI = 1.1 - 2.9; P = 0.023).  
 
Lofgren et al. (2002) postulated that because amino acid 223 is 
in the carbohydrate recognition domain (CRD) of SP-A2, perhaps 
the substitution of the neutral amino acid glutamine (with an 
amidic side chain), for a cationic lysine (with a basic side chain), 
may alter the protein’s affinity for microbial carbohydrate 
moieties. This explanation could also apply to the association of 
a lysine at SP-A2 codon 223 with increased risk of RAOM/OME. It 
is possible that having a lysine at this particular position in the 
CRD may reduce the protein’s ability to bind to or interact with 
the cell wall components (e.g. LPS, LTA, and PepG) of gram-
negative and gram-positive bacteria known to contribute to 
RAOM/OME pathogenesis, and facilitate their clearance from the 
middle ear and Eustachian tube. On the other hand, changes to 
the CRD may affect how SP-A can interact with 
polymorphonuclear neutrophils, macrophages, monocytes, and 
immunoglobulins. Despite these possible explanations, no 
conclusive evidence is available that implicates a lysine at SP-A2 
codon 223 with reduced pathogen binding and/or immune-
signalling. Again, PolyPhen predicted no significant structural or 
functional effect on SP-A2. 
 
 
4.2.2  SP-A1, SP-A2, and SP-D Haplotypes 
 
The previously uncategorized SP-A1 haplotype CGAGC was over-
represented in the RAOM/OME case population (P = 0.0085). 
This haplotype contains an alanine (major allele) at SP-A1 codon 
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19, and a guanine (major allele) at codon 133, both of which 
were earlier shown to be associated with increased risk for 
RAOM/OME. It is possible that the presence of these two alleles 
and their hypothetical effect on SP-A1’s pathogen binding and 
clearance capabilities leads to increased host susceptibility to 
RAOM/OME; however, no experimental work is available to 
confirm this theory. 
SP-A2 haplotypes 1A3 (AGTA), 1A9 (AGTC), and 1A10 (CCTA) 
were all over-represented in the RAOM/OME population in 
comparison with the control population (1A3, P = 0.0182; 1A9, P 
= 0.044; 1A10, P = 0.0391).  
 
Haplotype 1A3 contains an asparagine (major allele), alanine 
(minor allele), serine (minor allele), and lysine (minor allele) at 
codons 9, 91, 140, and 223 of SP-A2. Interestingly, Lofgren and 
associates (2002) observed that haplotype 1A3 was significantly 
over-represented amongst infants with severe RSV infection in 
comparison with a control group (0.05 vs. 0.005; OR = 10.44; 
95% CI = 1.3 – 83.2; P = 0.006). This haplotype was also 
implicated as being associated with increased susceptibility to 
infection with the intracellular pathogen Mycobacterium 
tuberculosis, by Floros and colleagues (2000). However, the 
functional and structural influences of haplotype 1A3 on SP-A2 
are currently unknown. 
 
The rare haplotype 1A9 encodes an asparagine (major allele) at 
codon 9, alanine (minor allele) at codon 91, serine (minor allele) 
at codon 140, and a glutamine (major allele) at codon 223. The 
reason why this particular haplotype is associated with an 
increased risk of RAOM/OME is unclear since no association with 
the individual alleles was previously seen. Despite the fact that 
none of the individual alleles were associated with RAOM/OME, 
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perhaps, when present together, they have a synergistic effect 
on SP-A2’s structure and function, consequently leading to 
increased host susceptibility to the development of RAOM/OME. 
Seifart et al. (2005) found that haplotype 1A9 was associated 
with increased risk for non-small cell lung carcinoma and 
adenocarcinoma. The researchers also conducted a methylation 
assay and found that the human SP-A promoter was 
hypomethylated in lung cancer, indicating that SP-A1 and SP-A2 
expression is enhanced in lung cancer.  
 
It is possible that in the middle ear of an individual with SP-A2 
haplotype 1A9, hypomethylation of the SP-A promoter also 
occurs and leads to excess expression of SP-A1 and SP-A2. 
However, no current research can provide evidence of this. 
Overproduction of SP-A1 and SP-A2 could possibly lead to a 
heightened inflammatory state in the middle ear, as SP-A 
activates pro- and anti-inflammatory cytokine expression by 
macrophages and interacts with other immune related cells in an 
attempt to combat bacterial/viral infection. However, if a 
prolonged state of inflammation was established in the middle 
ear it potentially could maintain RAOM/OME for a period of time 
exceeding the presence of contributing pathogens, leading to 
inflammatory-related cellular damage e.g. free radical damage. 
Further research is needed to determine the influence of 
haplotype 1A9 on SP-A2 expression and the functionality of the 
gene product.  
 
The amino acids encoded at the four SP-A2 loci for haplotype 
1A10 were: threonine (minor allele), proline (major allele), serine 
(minor allele), and lysine (minor allele). A lysine at SP-A2 codon 
223 was determined earlier to be associated with increased risk 
of RAOM/OME. Therefore, the presence of this amino acid in 
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haplotype 1A10 may be responsible for the association between 
the haplotype and RAOM/OME. On the other hand, a proline 
often facilitates the conformation of random coils and β-turns in 
a polypeptide chain. The carbon ring in proline’s R group is 
bound to the amino group in the polypeptide backbone and 
therefore cannot participate in hydrogen bonding, which is vital 
for formation of some secondary structures. 
Perhaps in SP-A2 the presence of a proline at codon 91 prevents 
maintenance of a different secondary structure, which might 
have a detrimental effect on the protein’s ability to bind and 
clear pathogens or interact with other immune-related 
cells/molecules. However, PolyPhen analysis undertaken for this 
study did not predict any significant detrimental affect of a 
proline at SP-A2 codon 91. Further protein structure 
experimentation needs to be conducted to demonstrate what 
functional changes occur as a result of SP-A2 haplotype 1A10. 
 
Finally, in addition to the four SP-A2 haplotypes found to be 
associated with increased risk of RAOM/OME, the power of the 
significance of haplotype 1A0 (AGCC, P = 0.0524) was on the 
threshold borderline of 0.05. If deemed to be significant, 
haplotype 1A0 would have been under-represented in the 
RAOM/OME population. However, in the RAOM/OME case 
population, SP-A1 haplotype 6A2 was detected in combination 
with SP-A2 haplotype 1A0 in over 10% of the population. Since 
haplotype 6A2 was determined to be protective against 
RAOM/OME, it is possible that haplotype 1A0 would also have a 
protective effect. Rämet and colleagues (2000, 2001) found that 
the 6A2/1A0 haplotypes were under-represented in infants with 
their first episode of AOM before six months of age (χ2, P = 
0.03) but over-represented in infants with respiratory distress 
syndrome (OR = 1.66; 95% CI = 1.09 – 2.54; P = 0.018). It is 
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possible that if larger populations were genotyped for haplotype 
1A0 then the frequency difference between the case and control 
populations would be determined to be statistically significant (P 
< 0.05). Alternatively, the discrepancy seen may be due to the 
absence of genotyping replicates.  
 
Rämet et al. (2001) also uncovered an over-representation of 
the 6A4-1A5 haplotype in the AOM infants (χ2, P = 0.02) and in 
RAOM infants (χ2, P = 0.003). These findings were in contrast to 
those of Pettigrew et al. (2006) who determined that the 6A4-1A5 
haplotype was actually under-represented, and hence associated 
with a decreased risk of otitis media during the first year of life 
(OR = 0.23; 95% CI = 0.07 - 0.73). However, no significant 
difference in the 6A4-1A5 haplotype frequency was found in this 
current study’s case population in comparison with the control 
population; therefore confirmation of either Rämet et al. or 
Pettigrew et al.’s findings was not possible. 
 
No association between any of the four SP-D haplotypes and 
increased risk of RAOM/OME was found in the case population 
studied. 
 
 
4.3 SP-A1, SP-A2, and SP-D Alleles and Haplotypes 
associated with host resistance to RAOM/OME 
 
 
4.3.1  SP-A1, SP-A2, and SP-D Alleles  
 
No single SP-A1, SP-A2, or SP-D alleles were individually found 
to be under-represented and thus associated with host 
resistance to RAOM/OME in the mainly European-Caucasian 
population. 
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4.3.2  SP-A1, SP-A2, and SP-D Haplotypes  
 
The SP-A1 haplotype 6A2 (TGAAC) was under-represented in the 
population consisting of patients with RAOM/OME in comparison 
to the control population (P = 3.00 x10-4), thus suggesting a 
protective effect against RAOM/OME. Haplotype 6A2 encodes a 
valine (minor allele), valine (minor allele), proline (minor allele), 
threonine (minor allele) and an arginine (major allele) at codons 
19, 50, 62, 133, and 219 of SP-A1. Identical results were 
obtained by Rämet et al. (2001) who found that infants with 
their first episode of AOM diagnosed before six months of age 
showed an under-representation of the 6A2 haplotype alone (χ2, 
P < 0.05), and in conjunction with the SP-A2 haplotype 1A0  (χ2, 
P = 0.03). On the other hand, Lofgren et al. (2002) found that 
the haplotype 6A2 was associated with increased risk of severe 
RSV infection when linked with the SP-A2 haplotype 1A3 (5.2 vs. 
0.5, OR = 10.4; 95% CI = 1.3 - 83.2; P = 0.006), but not when 
analyzed alone. 
 
The apparent protective effect of haplotype 6A2 may potentially 
originate from the absence of an alanine at amino acid position 
19 of SP-A1. This allele was previously found to be associated 
with an increased risk of RAOM/OME, possibly due to changes in 
the ability of SP-A1’s N-terminal to form trimeric subunits and 
multimers with other SP-A1 and SP-A2 molecules. The presence 
of a valine instead of an alanine at this SNP locus may allow for 
effective binding of the N-terminal of SP-A1 to other SP-A1 and 
SP-A2 N-terminals in order to form the subunits and multimers 
necessary for efficient binding and clearance of bacteria/viruses 
in the middle ear and Eustachian tube. More efficient destruction 
and clearance of such pathogens would therefore decrease the 
host’s susceptibility for developing RAOM/OME. In addition, the 
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haplotype 6A2 presented the nucleotide adenine (minor allele) 
instead of a guanine (major allele) at SP-A1 codon 133. Even 
though a SNP at this locus results in a synonymous amino acid 
change (threonine to threonine), the presence of a guanine was 
shown to be associated with increased risk of RAOM/OME in this 
study. However, none of these speculations are confirmed by 
appropriate research and the effect of haplotype 6A2 on the 
functionality of SP-A1 remains unknown. 
 
Haplotype 1A2 (CGCC) was found to be under-represented in the 
RAOM/OME population of mainly European-Caucasian individuals 
(P = 0.0133). This finding is suggestive of a protective effect 
against ROAM/OME in individuals with the haplotype 1A2. At 
amino acid position 223, haplotype 1A2 contains a glutamine 
(major allele) instead of a lysine (minor allele) which was found 
earlier to be over-represented in this study’s RAOM/OME 
population and, therefore, associated with an increased risk of 
RAOM/OME. Nonetheless, no scientific evidence is available 
regarding the influence of haplotype 1A2 on SP-A2’s ability to 
bind to pathogens and facilitate their destruction/clearance.  
 
Furthermore, no association between any of the four SP-D 
haplotypes and decreased risk of RAOM/OME was found in the 
case population studied. 
 
 
4.4 New Zealand Maori and Pacific Island RAOM/OME 
Population 
 
In concordance with their significantly greater prevalence of 
RAOM/OME and subsequent hearing loss (National Audiology 
Centre, 2003; Paterson et al., 2006), it was expected that a 
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population of New Zealand Maori and Pacific Island individuals 
would exhibit more RAOM/OME associated alleles and haplotypes 
than the mainly European-Caucasian population. A subset of New 
Zealand Maori and Pacific Island individuals diagnosed with 
RAOM/OME were analyzed for significant differences in SP-A1, 
SP-A2, and/or SP-D alleles and haplotypes in comparison to the 
control population.  
 
The most common SP-A1 haplotypes in the New Zealand Maori 
and Pacific Island individuals with RAOM/OME were 6A2, 6A3, 
CGAAC, 6A11, and 6A4. Most frequent SP-A2 haplotypes were 
1A0, 1A1, 1A5, 1A2, and 1A in decreasing order. As with the 
European-Caucasian RAOM/OME population and the control 
population, SP-D haplotypes TA, TG, and CG made up 
approximately 98% of the SP-D haplotypes detected in the New 
Zealand Maori and Pacific Island RAOM/OME population. 
 
 
4.4.1 SP-A1, SP-A2, and SP-D Alleles associated with 
increased host susceptibility to RAOM/OME in New 
Zealand Maori and Pacific Island individuals 
 
Haploview comparison of SP-A1, SP-A2, and SP-D allele 
frequencies in the New Zealand Maori and Pacific Island 
population of individuals diagnosed with RAOM/OME determined 
that there were six alleles associated with increased risk of the 
diseases (P < 0.05). 
 
A leucine (major allele) and tryptophan (minor allele) at codons 
50 and 219 of SP-A1, respectively, were individually found to be 
associated with an increased risk of RAOM/OME (SPA1-50C, P = 
3.22 x10-5; SPA1-219T, P = 3.00 x10-4). Both of these alleles 
were previously associated by Selman and colleagues (2003) 
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with increased predisposition to idiopathic pulmonary fibrosis, a 
progressive lung disorder, characterized by sequential acute lung 
epithelial injuries and fibrosis (SPA1-50C: 94.4 vs 74.8, OR = 
6.68, 95% CI = 1.87 – 23.86, P = <0.01; SPA1-219T: 7.8 vs. 
22.2, OR = 3.13, 95% CI = 1.18 – 8.32, P = 0.02).  
 
The presence of a tryptophan at SP-A1 codon 219 was predicted 
by PolyPhen to be ‘damaging’ to SP-A1’s structure and function. 
No other allele in SP-A1, SP-A2, or SP-D was predicted to have a 
deleterious effect on the corresponding protein’s structural and 
functional attributes. Selman et al. (2003) demonstrated that 
SP-A1 with a tryptophan at codon 219 was more susceptible to 
oxidation than its arginine-containing counterparts, and self-
aggregated to a higher level as a consequence. In the context of 
RAOM/OME, it is possible that the increased levels of reactive 
oxygen species (i.e. nitric oxide) produced by phagocytes in 
response to pathogen infection may lead to increased oxidation 
of SP-A and SP-D in the middle ear, ultimately resulting in a 
reduction in their ability to bind to and clear bacteria and/or 
viruses. Furthermore, particular amino acid substitutions may 
render the proteins either more or less susceptible to free radical 
damage. On the other hand, despite these hypothetical 
explanations, no substantiating experimental evidence is 
available that addresses the functional effect of the presence of a 
tryptophan at SP-A1 codon 219. 
 
The presence of a proline (major allele), serine (minor allele), 
and lysine (minor allele) at SP-A2 codons 91, 140, and 223, 
respectively, were also individually associated with an increased 
risk of RAOM/OME (SPA2-91C, P = 0.0018; SPA2-140T, P = 3.00 
x10-4; SPA2-223A, P = 0.0042). Currently, there have been no 
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other association studies that have identified a proline and a 
serine at SP-A2 codons 91 and 140 as disease markers.   
 
As previously discussed, a proline at SP-A2 codon 91 may 
prevent formation of some secondary structures essential for SP-
A2 to form oligomers, bind to pathogens, and interact with other 
immune-related cells/molecules. However, no research has been 
conducted to assess the structural and functional consequences 
of this substitution. 
 
The SNP at SP-A2 codon 140 results in a synonymous amino acid 
change which does not affect the gene product, therefore it was 
not predicted that this locus would be associated with 
RAOM/OME. Having a thymidine (minor allele) at this SNP locus 
instead of a cytosine (major allele), may result in reduced CpG 
methylation and ensuing enhanced gene expression. If this was 
the case, it would be expected that increased transcription and 
translation of SP-A2 would, in fact, improve host susceptibility to 
RAOM/OME as enhanced bacterial/viral clearance would be 
possible. However, it is possible that over-production of SP-A2 
occurs as a result of hypomethylation, leading to prolonged 
inflammation and related damage in the middle ear and 
Eustachian tube. Further work in this area is needed to assess 
the consequences (if any), a thymidine at SP-A2 codon 140 will 
cause the protein. 
 
Pettigrew et al. (2006) could not obtain reproducible results for 
the C/T polymorphism at SPA2-140, using the allele-specific 
primers previously published (Pantelidis et al., 2003). The 
identical allele-specific primers for SPA2-140 were employed in 
the present study but no such difficulty was encountered. 
Perhaps the additional genotyping success achieved was due to 
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the touchdown thermocycling protocol utilized. There was no 
evidence given to suggest that Pettigrew et al. (2006) 
investigated the appropriate annealing temperature needed for 
the SPA2-140 primers, however in the present study, the optimal 
annealing temperatures for the real-time PCR were determined 
by gradient PCR in order to increase specificity for amplification 
and subsequently reduce mispriming. 
 
Lastly, in the New Zealand Maori and Pacific Island population, 
an increased risk of RAOM/OME was associated with the 
presence of an alanine (minor allele) at amino acid position 160 
of SP-D (P = 0.0292). Amino acid position 160 is located within 
the collagenous domain of SP-D, a region essential for binding to 
collectin receptors and for complement activation via the lectin 
pathway (Eda et al., 1996; Erdei and Reid, 1989; Ikeda et al., 
1987). Perhaps the presence of an alanine at this position in the 
collagenous domain results in impaired binding to collectin 
receptors, reduced complement activation, and decreased 
clearance of pathogens causing RAOM/OME. Changes in the 
collagenous domain of mannose binding lectin have been shown 
to contribute to immunodeficiencies in affected individuals 
(Summerfield et al., 1995), but similar research has not been 
conducted with SP-D. 
 
 
4.4.2 SP-A1, SP-A2, and SP-D Alleles associated with 
increased host susceptibility to RAOM/OME in New 
Zealand Maori and Pacific Island individuals 
 
Haplotypes 6A8 (TCAAT) and 6A10 (CCGAC) were found to be 
associated with increased risk of RAOM/OME (6A8, P = 2.00 x10-
4; 6A10, P = 0.0412). Haplotype 6A8 encodes a valine (minor 
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allele), leucine (major allele), proline (minor allele), threonine 
(minor allele) and a tryptophan (minor allele) at SP-A1 codons 
19, 50, 62, 133, and 219. Haplotype 6A10 encodes an alanine 
(major allele), leucine (major allele), proline (major allele), 
threonine (minor allele), and an arginine at the five SP-A1 
codons. Both haplotypes 6A8 and 6A10 encode a leucine at SP-A1 
codon 50, which was already determined to be associated with 
increased risk of RAOM/OME in the New Zealand Maori and 
Pacific Island population. In addition, haplotype 6A8 also encodes 
a tryptophan at SP-A1 codon 219, another allele linked with 
increased RAOM/OME susceptibility in this study’s New Zealand 
Maori and Pacific Island population. 
 
In the European-Caucasian RAOM/OME population, haplotypes 
1A3 (AGTA) and 1A10 (CCTA) were linked to increased risk of 
RAOM/OME. Haplotype 1A3 contains an asparagine (major 
allele), alanine (minor allele), serine (minor allele), and a lysine 
(minor allele) at SP-A2 codons 9, 91, 140, and 223. Haplotype 
1A10 encodes a threonine (minor allele), proline (major allele), 
serine (minor allele), and a lysine (minor allele), at the four SP-
A2 loci. Haplotypes 1A3 and 1A10 were also found to have the 
same associations in the New Zealand Maori and Pacific Island 
population, indicating that they also are protective against 
RAOM/OME regardless of an individual’s ethnicity (1A3, P = 
0.0029; 1A10, P = 7.00 x10-4). Haplotype 1A3 encodes a serine 
and a lysine at codons 140 and 223, two alleles which were 
individually shown to be associated with increased risk of 
RAOM/OME in the New Zealand Maori and Pacific Island 
individuals. Haplotype 1A10 also contains a serine and lysine at 
codons 140 and 223, as well as a proline at codon 91. A proline 
at this amino acid position was also found earlier to be 
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associated with increased susceptibility to RAOM/OME in New 
Zealand Maori and Pacific Island individuals. 
 
4.4.3 SP-A1, SP-A2, and SP-D Alleles associated with 
increased host resistance to RAOM/OME in New 
Zealand Maori and Pacific Island individuals 
 
No individual SP-A1, SP-A2, or SP-D alleles were found to be 
associated with host resistance to RAOM/OME. 
 
 
4.4.4 SP-A1, SP-A2, and SP-D Haplotypes associated with 
increased host resistance to RAOM/OME in New 
Zealand Maori and Pacific Island individuals 
 
Haplotype 6A2 was identified as a protective haplotype against 
RAOM/OME (P = 8.00 x10-5), similar to the European-Caucasian 
case population, the findings of Rämet et al. (2001), and 
Pettigrew et al. (2006). SP-A2 haplotypes 1A0 and 1A2 were both 
found to be protective against susceptibility to RAOM/OME in 
New Zealand Maori and Pacific Island individuals (1A0, P = 
0.0038; 1A2, P = 0.0377). Similar results were found in the 
European-Caucasian case population, except the population 
frequency difference of haplotype 1A0 in the total case population 
compared to the control population exhibited borderline 
significance. Without further experimentation in order to 
replicate the results, it cannot be determined whether 1A0 is, in 
fact, a protective haplotype in European-Caucasian individuals as 
well as in New Zealand Maori and Pacific Island individuals. In 
light of previous research, which documented that haplotype 1A0 
was protective in other Caucasian populations (Pettigrew et al., 
2006; Rämet et al., 2001), it is likely that the same applies for 
the total case population in the present study. Additional studies 
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with larger population sizes need to be undertaken in order to 
confirm or challenge these results. 
 
SP-D haplotype TA was observed to be protective against host 
susceptibility to RAOM/OME in the New Zealand Maori and Pacific 
Island individuals (P = 0.0192). It is possible that the association 
of this haplotype is due to the presence of an alanine at SP-D 
codon 160, which was previously shown to be over-represented 
in the New Zealand Maori and Pacific Island population in 
comparison to the control population. 
 
The population containing New Zealand Maori and Pacific Island 
individuals diagnosed with RAOM/OME exhibited an under-
representation of the SPA1/SPA2/SPD haplotype 6A2-1A0-TA. 
These three haplotypes were found to be protective against 
susceptibility to RAOM/OME individually and were concurrent 
with each other in over 10% of the individuals. The finding that a 
New Zealand Maori and Pacific Island population displays a 
significant reduction in the RAOM/OME protecting haplotype 6A2-
1A0-TA suggests that such individuals are genetically more 
susceptible to RAOM/OME than their European-Caucasian 
counterparts. 
 
 
4.5 Association of SP-A1, SP-A2, and SP-D Alleles and 
Haplotypes with Meningococcal Disease 
 
Previous research by Jack and colleagues (2006) linked 
meningococcal disease with the presence of an adenine at codon 
223 of SP-A2, leading to an amino acid substitution from a 
glutamine (major allele) to a lysine (minor allele). In an attempt 
to replicate their findings, three patients diagnosed with 
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meningococcal disease were genotyped for the eleven SNP loci in 
SP-A1, SP-A2, and SP-D and allele/haplotype frequencies were 
compared to the control population to identify any significant 
differences. 
 
Haploview analysis uncovered an association between an alanine 
at codon 160 of SP-D and meningococcal disease. The presence 
of an adenine instead of a guanine at SPD-160 was found to be 
over-represented in the meningococcal population (P = 0.0437). 
No association between a lysine at SP-A2 codon 223 and 
meningococcal disease was found.  
 
As previously discussed, the non-synonymous substitution of a 
threonine for an alanine at codon 160 of SP-D may alter SP-D 
collagenous domain’s ability to participate in immune-related 
pathways, which in turn could result in increased host 
susceptibility to infection by Neisseria meningitidis. However, to 
date no research has investigated this suggestion.  Only three 
individuals diagnosed with meningococcal disease were 
genotyped for the eleven SNPs in SP-A1, SP-A2, and SP-D in this 
study; thus, it is possible that findings from such a small 
population may not be valid. Further research with a larger 
sample size would either validate or challenge the results from 
this study and that of Jack et al. (2006). 
 
 
4.6 Copy Number Variants of SP-A1 and SP-A2 
 
In addition to the genomic variation seen between individuals 
due to SNPs, it has recently been ascertained that the human 
genome is adundant in copy number variations (CNVs) of DNA 
segments often ranging from kilobases to megabases in length 
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(Redon et al., 2006). Redon and colleagues (2006) defined a 
CNV as a genomic region equal or greater than 1 kb in length 
and present in variable copy numbers, compared to a reference 
genome. They conducted a global genome-wide scan for CNVs in 
270 individuals representing four populations with different 
ancestry. Nearly 1,500 CNVs were identified across the 270 
samples covering approximately 12% of the human genome, 
with the mean total CNV length per genome estimated at more 
than 20 Mbp. These figures suggested that the average amount 
of genomic variation between any two randomly selected 
individuals was 5 – 10 times greater than previously estimated 
by SNP studies (Shianna and Willard, 2006). 
 
If these CNVs occur within a gene or its regulatory region, 
duplications or deletions could alter the levels of mRNA produced 
for that gene, which would consequently result in increased or 
reduced levels of protein translated. In the context of SP-A1, SP-
A2, and SP-D any CNVs within these genes could influence gene 
expression, phenotypic variation, and/or gene dosage and could 
increase/decrease host susceptibility to related diseases e.g. 
RAOM and/or OME. 
 
Gonzalez and co-workers (2005) investigated inter-individual 
and inter-population variations in the copy number of a 
segmental duplication containing the gene CCL3L1, which 
encodes for a human immunodeficiency virus-1 (HIV-1)-
suppressive chemokine and ligand for the HIV co-receptor CCR5. 
They found that individuals with a CCL3L1 copy number lower 
than the population average exhibited a significantly higher 
susceptibility to HIV and/or acquired immunodeficiency 
syndrome (AIDS). The researchers concluded that variations in 
the quantity of immune-related genes like that seen in CCL3L1, 
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may contribute to a genetic susceptibility or resistance to 
particular infectious diseases. 
 
In the latest human genome reference sequence (Ensemble 
human, release 40), two identical copies of both SP-A1 and SP-
A2 were evident, approximately 300 kb apart, while only one 
copy of SP-D was apparent. Duplication of SP-A1 and SP-A2 
indicates that CNV is present in the genes’ region. If this was the 
case it would suggest that differences in the copy numbers of 
SP-A1 and SP-A2 would result in gene dosage variations. Lower 
(or higher) amounts of the proteins in the middle ear may result 
in reduced (or enhanced) bacterial/viral clearance; thus any 
individual could have a genetically determined level of 
susceptibility to RAOM and/or OME. However, there is no 
evidence to support this hypothesis. 
 
Joanna Floros, Professor of Cellular and Molecular Physiology at 
the Pennsylvania State University, USA, examined the duplicated 
sequences of SP-A1 and SP-A2 and also found them to be 
identical (personal communication, 2006). For example, there 
was only one nucleotide difference between the two SP-A1 
sequences of approximately 3.2 kb. However, Floros considered 
that it was unlikely that each SP-A1 and SP-A2 was duplicated, 
and given that the sequence of the two SP-A genes is so similar, 
any computer matching analysis could potentially produce flawed 
results. 
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4.7 Study Limitations 
 
 
4.7.1  Confounding Factors 
 
It has been frequently noted that very few published findings of 
significant associations between alleles and disease can be 
replicated indisputably (Colhoun et al., 2003). Statistical 
evidence that indicates an association between an allele and a 
particular disease phenotype could arise from three situations 
(Cordon and Palmer, 2003): 
 
1. Stochastic variation in allele frequencies present in the 
populations. 
2. Associated allele may be in linkage disequilibrium with a 
causative allele located nearby. 
3. Associated allele may have a functional and direct effect on 
the corresponding gene product. 
 
Linkage disequilibrium in an individual’s genome depends heavily 
on the population’s history and the genetic characteristics of the 
population’s founding individuals (Hirschorn et al., 2002). For 
example, in a population with a relatively recent common 
ancestor such as New Zealand Maori and Pacific Islanders, fewer 
recombination events would have occurred to separate the SP-
A1, SP-A2, and SP-D alleles. Therefore, certain haplotypes will 
often be inherited together throughout the population. On the 
other hand, a European-Caucasian population with a relatively 
older common ancestor would have been subjected to more 
recombination events, possibly resulting in disrupted linkage 
disequilibrium and reduced haplotype inheritance. Thus, if a 
specific allele is in linkage disequilibrium with a nearby 
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RAOM/OME-associated allele in one population (e.g. Maori and 
Pacific Island) but not another (e.g. European-Caucasian), then a 
false positive association between that allele and RAOM/OME 
could possibly have occurred. It is possible that higher linkage 
disequilibrium in the New Zealand Maori and Pacific Island 
population may have resulted in the incidence of more SP-A1, 
SP-A2, and SP-D alleles and haplotypes appearing to be 
implicated with RAOM/OME in this study. 
Another confounding factor that has been noted to affect the 
validity of genetic association studies is population stratification. 
Population stratification occurs when the case and control groups 
of a genetic association study are drawn from two or more ethnic 
groups, and one of these groups has higher disease prevalence 
than the others (Hirschorn et al., 2002). Stratification occurs due 
to the fact that the high-prevalence group will be over-
represented in the case group, and under-represented in the 
control group. Therefore, an allele that is found by chance to be 
more frequent in the high-prevalence group will falsely appear to 
be associated with the disease in question.  
 
In this study, allele and haplotype frequencies in a population 
containing twenty-two New Zealand Maori or Pacific Island 
individuals diagnosed with RAOM/OME was compared to a control 
population consisting of mainly European-Caucasian individuals. 
It is possible that due to the higher prevalence of RAOM/OME in 
New Zealand Maori and Pacific Island children, their subsequent 
over-representation in the case group and under-representation 
in the control group, that population stratification was present. If 
this is true then it is also possible that some of the 
alleles/haplotypes found in the New Zealand Maori and Pacific 
Island population to be implicated with RAOM/OME are in fact 
indicative of stochastic variation in the population. 
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4.7.2  Hardy-Weinberg Equilibrium 
 
If a particular SNP is in Hardy-Weinberg equilibrium in a 
population then the observed genotype frequencies should 
simply be a function of the relative allele frequencies, assuming 
that migration, mutation, natural selection, and assortative 
mating are absent (Wigginton et al., 2005). All eleven SP-A1, 
SP-A2, and SP-D SNPs were found to be in Hardy-Weinberg 
equilibrium in the case, control, and Pacific Island populations, 
except for the following two exceptions: 
 
The SNP at SP-A1 codon 50 exhibited a level of heterozygosity 
significantly lower in the total case population than expected by 
the Haploview program based on the raw major and minor allele 
frequencies (P = 1.00 x10-4). Such a discrepancy indicated that 
the SNP was not in Hardy-Weinberg equilibrium. In contrast, 
SPA1-50 was in Hardy-Weinberg equilibrium in the control 
population and the New Zealand Maori and Pacific Island 
population. 
 
A similar scenario was seen at SP-A2 codon 91 in the control 
population. The predicted proportion of heterozygotes was 
significantly higher than that observed (P = 5.64 x10-6), thus the 
SNP was also not in Hardy-Weinberg equilibrium within that 
population. However, no significant deviations from Hardy-
Weinberg equilibrium were seen at SPA2-91 in the case 
population or the New Zealand Maori and Pacific Island 
population. 
 
Wigginton and associates (2005) suggested that any departures 
from Hardy-Weinberg equilibrium at a particular SNP locus could 
be due to problems with population structure or genotyping. 
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Furthermore, if the SNP in question is in the context of a 
population consisting of affected individuals (i.e. diagnosed with 
RAOM/OME) then it may suggest an association between the SNP 
locus and that particular disease. However, no association 
between SPA1-50 and RAOM/OME was apparent (P > 0.05) in 
the total case population, even though the locus was not in 
Hardy-Weinberg equilibrium.  
 
 
4.8 Conclusions  
 
In a population of primarily European-Caucasians, two SP-A1 
alleles and one SP-A2 allele were found to be associated with 
increased susceptibility to RAOM/OME. SP-A1 haplotype 6A2 and 
SP-A2 haplotype 1A2 were both found to be protective against 
RAOM/OME. However, a previously unclassified SP-A1 haplotype 
CGAGC, and three SP-A2 haplotypes (1A3, 1A9, and 1A10) were 
shown to be associated with increased risk of RAOM/OME. 
 
Significantly different results were observed in a population of 
New Zealand Maori and Pacific Island individuals diagnosed with 
RAOM/OME. Twice as many alleles (two SP-A1 alleles, three SP-
A2 alleles, and one SP-D allele) were found to be over-
represented in the affected individuals and therefore associated 
with increased risk of RAOM/OME. One SP-A1 haplotype (6A2), 
two SP-A2 haplotypes (1A0 and 1A2), and one SP-D haplotype 
(TA) were all found to have a protective effect against 
RAOM/OME. On the other hand, two SP-A1 haplotypes (6A8 and 
6A10) and two SP-A2 haplotypes (1A3 and 1A10) were associated 
with increased susceptibility to RAOM/OME. The SPA1/SPA2/SPD 
haplotype 6A2-1A0-TA was under-represented in the New 
Zealand Maori and Pacific Island individuals with RAOM/OME.  
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The observation of additional alleles and haplotypes that were 
associated with increased risk of RAOM/OME, and the reduced 
frequency of the protective haplotypes suggests that New 
Zealand Maori and Pacific Island individuals maybe more 
susceptible to RAOM/OME than European-Caucasian individuals. 
However, very little is known about the functional consequences 
of the various SP-A1, SP-A2, and SP-D alleles and haplotypes 
and whether they really do affect the corresponding protein’s 
host defense abilities, thus, it would be naïve to conclude that 
the findings of this study accurately describe valid explanations 
for host susceptibility or resistance to RAOM/OME. 
 
A single SP-D allele and haplotype (TA) were found to be 
associated with increased susceptibility to meningococcal 
disease. However, this finding does not confirm the results of a 
much larger association study (Jack et al., 2006) and the small 
sample size employed in the present study may mean that the 
data are not significant. 
 
Despite the apparent significant results of this study there are a 
number of potential confounding variables that could challenge 
their validity. It is vital that more research is done to further 
confirm or deny the relationship of SP-A and SP-D variants with 
susceptibility/resistance to RAOM/OME. 
 
 
4.9 Future Research 
 
The findings of this present study are the first to suggest a 
possible genetic predisposition of New Zealand Maori and Pacific 
Island individuals to RAOM/OME. In order to confirm or challenge 
these findings, it would be valuable to replicate the current 
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methodology using two larger separate populations of New 
Zealand Maori and Pacific Island individuals. This would allow 
researchers to see if there is any significant difference in the SP-
A1, SP-A2, and SP-D alleles and haplotypes between the two 
populations.  
 
A large amount of time and effort is needed to research the 
structural and functional consequences of the SP-A1, SP-A2, and 
SP-D allele and haplotypes on the actual proteins themselves, 
and whether these affect the proteins’ ability to combat bacterial 
and/or viral infection in the middle ear and Eustachian tube. For 
example, purified SP-A and SP-D could be isolated from 
individuals with specific genetic variants, and assayed for 
bacterial and viral binding efficiency. 
 
Novel research investigating the possibility of SP-A1 and SP-A2 
copy number variations would also be beneficial to researchers 
studying SP-A and SP-D influences on a variety of pulmonary 
pathologies as well as RAOM/OME in the middle ear. It would be 
interesting to determine whether individuals particularly resistant 
to RAOM/OME displayed higher copy numbers of SP-A1 and SP-
A2, compared to susceptible individuals. Furthermore, copy 
number variations across a range of ethnicities (i.e. European-
Caucasian, New Zealand Maori, Pacific Island, and others) would 
identify any ethnicity-related variations.  
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APPENDIX I 
 
ETHICS INFORMATION 
 
 
 
 
Information sheets and consent forms were given to and signed 
by parents of individuals (under 18 years old) undergoing 
RAOM/OME-related surgery, and blood donors comprising the 
control population. These documents were approved by the 
Northern Y Regional Ethics Committee, administered by the New 
Zealand Ministry of Health, and are presented in the following 
pages. 
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Department of Biological 
Sciences 
School of Science &  
Engineering 
Te Pūtaiao me te 
Mātauranga Pūkaha 
The University of Waikato 
Private Bag 3105 
Hamilton 
New Zealand 
Phone +64 7 838 4148 
www.bio.waikato.ac.nz 
  
 
Information Sheet for Parents 
 
Project Title 
 
Influence of genetic factors on individual susceptibility for middle ear diseases. 
 
Principle Investigator 
 
Catherine Barnett (Master of Science student) 
Molecular Genetics Laboratory (C.2.03) 
Department of Biological Sciences 
The University of Waikato 
Day Ph: (07) 838 4466 ext 8482 Evening Ph: (021) 1022687 
Supervisor: Dr Ray T. M. Cursons, Senior Lecturer, the University of Waikato. 
 
Introduction 
 
You are invited to participate in a study that will investigate the influence of 
genetic factors on susceptibility of middle ear diseases. 
 
Participation and Confidentiality 
 
• Your child’s participation is entirely voluntary. 
• If you agree to your child’s participation, you are free to withdraw him/her 
from the study at any time, without having to give a reason and this will in 
no way affect your child’s future health care. 
• There will be neither cost nor payment towards the participation. 
• No material which could personally identify your child will be used in any 
reports on this study. 
• Results will be kept confidential throughout the duration of the study and 
stored in a secure location after the completion of the study. 
• If you would like to know the results of the study, the research student or 
the supervisor will give you a copy of the final report once the report is 
finished or published, or discuss the results with you in person. 
 
Project Purpose 
 
Middle ear diseases are among the most common diseases found in infants and 
children. The genetic influence on an individual’s susceptibility of these diseases 
is currently unknown. Particular proteins found in the lungs, associated with 
preventing and combating infection, have also been found in the middle ear. 
These proteins are called Surfactant Proteins. These proteins have been found to 
bind to many different pathogens often found in middle ear diseases and promote 
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their destruction. A mutation in these proteins may cause them to be less active 
or not at all. This study wants to find out if individuals with these mutations are 
more prone to middle ear diseases. 
 
 
Project Method 
 
A small blood sample will be taken by the surgeon during your child’s scheduled 
surgery at Waikato Hospital. This will not result in an increased time in theatre. 
The sample will be transported to the Molecular Genetics Lab at the University of 
Waikato, and stored at 4°C until required. Then the DNA from the blood cells will 
be isolated and analyzed using specialized techniques that will identify the 
mutations in question. 
 
Approximately 100 participants will be involved in this project. All participants will 
be patients admitted to Waikato Hospital for surgery due to middle ear disease. 
 
After analysis, all blood samples and DNA will be kept until safely disposed 
of in July 2007. 
 
Benefits and Risks 
 
The results of this proposed study will potentially improve understanding of the 
causal factors of middle ear diseases in an attempt to contribute to the improved 
management of these diseases in the future. 
No side effects or risks are anticipated in this study. 
 
Definition of Scientific Terms 
 
Mutation – a change in the DNA sequence 
Pathogen – disease causing micro organism 
DNA – genetic ‘blueprint’ of an organism e.g. human 
 
Declaration 
 
In the unlikely event of a physical injury as a result of your child’s participation in 
this study, they may be covered by ACC under the Injury Prevention, 
Rehabilitation and Compensation Act 2001. ACC cover is not automatic and your 
case will need to be assessed by ACC according to the provisions of the 2002 
Injury Prevention compensation. ACC usually provides only partial 
reimbursement of costs and expenses and there may be no lump sum 
compensation payable. There is no cover for mental injury unless it is a result of 
physical injury. If you have ACC cover, generally this will affect your right to sue 
the investigators. If you have any questions about ACC, contact your nearest 
ACC office or the investigator. 
 
Statement of Ethical Approval 
 
This project has received ethical approval from the Northern Y Regional Ethics 
Committee and the University of Waikato’s School of Science and Engineering 
Ethics Committee. If you have any questions or concerns regarding your child’s 
rights as a participant in this study you may wish to contact a Health and 
Disability Advocate of Mid and Lower North Island on  
0800 42 36 38. 
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Consent Form
 
Project: Influence of genetic factors on individual susceptibility for middle 
ear diseases. 
 
Research Student: Catherine Barnett 
Supervisor: Dr Ray T. M. Cursons 
Location: Molecular Genetics Lab (C.2.03), the University of Waikato. 
Ph: (07) 838 4466 ext 8482 
 
Request for Interpreter 
 
English I wish to have an interpreter Yes No 
Maori Ehiahia ana ahau ki tetahi kaiwhakamaori/kaiwhaka 
pakeha korero 
Ae Kao 
Samoan Out e mana’o ia I ai se fa’amatala upu Ioe Leai 
Tongan Oku ou fiema’u ha fakatonulea Io Ikai 
Cook 
Island 
Ka inangaro au I tetai tangata uri reo Ae Kare 
Niuean Fia manako au ke fakaaonga e taha tagata 
fakahokohoko kupu 
E Nakai 
 
Fijian Au gadreva me dua e vakadewa vei au Io Sega 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana Peletania 
kin a gagana o na motu o te Pahefika 
Ioe Leai 
 
• I have read and I understand the information sheet for my child taking part 
in the study designed to identify mutations in the genes coding for some 
proteins involved in host defence in the middle ear. I have had the 
opportunity to discuss this study. I am satisfied with the answers I have 
been given. 
Yes/No 
 
• I understand that my child’s participation in this study is completely 
voluntary and that I may withdraw him/her from the study at any time and 
this will in no way affect my child’s future health care. 
Yes/No 
 
• I understand that my child’s participation in the study is confidential and 
that no material which could identify them will be used in any reports on 
this study. 
Yes/No 
 
• I have had time to consider whether to allow my child to take part. I know 
whom to contact if my child has any side effects to the study. 
Yes/No 
 
• I understand the ACC compensation provisions for this study. 
Yes/No 
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• I wish to receive a copy of the results or to discuss the outcomes of the 
study with the researcher. 
Yes/No 
 
• I agree to my GP or other current provider being informed of my 
participation in this study and/or the results of my participation in this 
study. 
Yes/No 
 
 
I………………………………………………………………………..hereby consent to 
taking part in this study. 
 
 
Date:……………………………………………………………………………………….. 
 
 
Signature:………………………………………………………………………………….
.. 
 
 
Project explained 
by:……………………………………………………………………….. 
 
 
Project 
role:………………………………………………………………………………… 
 
 
Signature:………………………………………………………………………………….
.. 
 
 
Date:………………………………………………………………………………………..
. 
 
Contact details (please feel free to contact the researchers if you have any 
questions about this study): 
 
Catherine Barnett 
Location: Molecular Genetics Lab (C.2.03), the University of Waikato. 
Day Ph: (07) 838 4466 ext 8482 Evening Ph: (021) 1022687 
Email: cmem1@waikato.ac.nz
 
Dr Ray T. M. Cursons, the University of Waikato, Ph: (07) 858 5120  
  
Email: r.cursons@waikato.ac.nz
 
Mr Tony Cecire, Anglesea Clinic, Cnr Anglesea and Thackeray Sts, Hamilton, Ph: 
(07) 839 2152 
Email: cecire@xtra.co.nz
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Department of Biological 
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School of Science &  
Engineering 
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The University of Waikato 
Private Bag 3105 
Hamilton 
New Zealand 
Phone +64 7 838 4148 
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Information Sheet for Control Participants 
 
Project Title 
 
Influence of genetic factors on individual susceptibility for middle ear diseases. 
 
Principle Investigator 
 
Catherine Barnett (Master of Science student) 
Molecular Genetics Laboratory (C.2.03) 
Department of Biological Sciences 
The University of Waikato 
Day Ph: (07) 838 4466 ext 8482 Evening Ph: (021) 1022687 
Supervisor: Dr Ray T. M. Cursons, Senior Lecturer, the University of Waikato. 
 
Introduction 
 
You are invited to participate in a study that will investigate the influence of 
genetic factors on susceptibility of middle ear diseases. 
 
Participation and Confidentiality 
 
• Your participation is entirely voluntary. 
• If you do agree to take part you are free to withdraw from the study at any 
time, without having to give a reason and this will in no way affect your 
future health care. 
• There will be neither cost nor payment towards the participation. 
• No material which could personally identify you will be used in any reports 
on this study. 
• Results will be kept confidential throughout the duration of the study and 
stored in a secure location after the completion of the study. 
• If you would like to know the results of the study, the research student or 
the supervisor will give you a copy of the final report once the report is 
finished or published, or discuss the results with you in person. 
 
Project Purpose 
 
Middle ear diseases are among the most common diseases found in infants and 
children. The genetic influence on an individual’s susceptibility of these diseases 
is currently unknown. Particular proteins found in the lungs, associated with 
preventing and combating infection, have also been found in the middle ear. 
These proteins are called Surfactant Proteins. These proteins have been found to 
bind to many different pathogens often found in middle ear diseases and promote 
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their destruction. A mutation in these proteins may cause them to be less active 
or not at all. This study wants to find out if individuals with these mutations are 
more prone to middle ear diseases. 
 
Project Method 
 
A small blood sample will be taken by the nurse during your scheduled blood 
donation at the New Zealand Blood Service (Hamilton Branch). The sample will 
be transported to the Molecular Genetics Lab at the University of Waikato, and 
stored at 4°C until required. Then the DNA from the blood cells will be isolated 
and analyzed using specialized techniques that will identify the mutations in 
question. 
 
The blood sample given will be part of a group which will be used as a control for 
the study. A group of patients with middle ear disease will then be compared to 
the control group to assess any differences from the normal population. 
Approximately 100 control participants will be involved in this project. Participants 
with middle ear disease will consist of patients admitted to Waikato Hospital for 
surgery due to middle ear disease. 
 
After analysis, all blood samples and DNA will be kept until safely disposed 
of in July 2007. 
 
Benefits and Risks 
 
The results of this proposed study will potentially improve understanding of the 
causal factors of middle ear diseases in an attempt to contribute to the improved 
management of these diseases in the future. 
No side effects or risks are anticipated in this study. 
 
Definition of Scientific Terms 
 
Mutation – a change in the DNA sequence 
Pathogen – disease causing micro organism 
DNA – genetic ‘blueprint’ of an organism e.g. human 
 
Declaration 
 
In the unlikely event of a physical injury as a result of your participation in this 
study, you may be covered by ACC under the Injury Prevention, Rehabilitation 
and Compensation Act 2001. ACC cover is not automatic and your case will need 
to be assessed by ACC according to the provisions of the 2002 Injury Prevention 
compensation. This depends on a number of factors such as whether you are an 
earner or non-earner. ACC usually provides only partial reimbursement of costs 
and expenses and there may be no lump sum compensation payable. There is 
no cover for mental injury unless it is a result of physical injury. If you have ACC 
cover, generally this will affect your right to sue the investigators. If you have any 
questions about ACC, contact your nearest ACC office or the investigator. 
 
Statement of Ethical Approval 
 
This project has received ethical approval from the Northern Y Regional Ethics 
Committee and the University of Waikato’s School of Science and Engineering 
Ethics Committee. If you have any questions or concerns regarding your rights as 
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a participant in this study you may wish to contact a Health and Disability 
Advocate of Mid and Lower North Island on 0800 42 36 38. 
 
Consent Form
 
Project: Influence of genetic factors on individual susceptibility for middle 
ear diseases. 
 
Research Student: Catherine Barnett 
Supervisor: Dr Ray T. M. Cursons 
Location: Molecular Genetics Lab (C.2.03), the University of Waikato. 
Ph: (07) 838 4466 ext 8482 
 
Request for Interpreter 
 
English I wish to have an interpreter Yes No 
Maori Ehiahia ana ahau ki tetahi kaiwhakamaori/kaiwhaka 
pakeha korero 
Ae Kao 
Samoan Out e mana’o ia I ai se fa’amatala upu Ioe Leai 
Tongan Oku ou fiema’u ha fakatonulea Io Ikai 
Cook 
Island 
Ka inangaro au I tetai tangata uri reo Ae Kare 
Niuean Fia manako au ke fakaaonga e taha tagata 
fakahokohoko kupu 
E Nakai 
 
Fijian Au gadreva me dua e vakadewa vei au Io Sega 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana Peletania 
kin a gagana o na motu o te Pahefika 
Ioe Leai 
 
• I have read and I understand the information sheet for volunteers taking 
part in the study designed to identify mutations in the genes coding for 
some proteins involved in host defence in the middle ear. I have had the 
opportunity to discuss this study. I am satisfied with the answers I have 
been given. 
Yes/No 
 
• I understand that taking part in this study is completely voluntary and that 
I may withdraw from the study at any time and this will in no way affect my 
future health care. 
Yes/No 
 
• I understand that my participation in the study is confidential and that no 
material which could identify me will be used in any reports on this study. 
Yes/No 
 
• I have had time to consider whether to take part. I know whom to contact 
if I have any side effects to the study. 
Yes/No 
 
 
 
Appendix I: Ethics Information 
142
• I understand the ACC compensation provisions for this study. 
Yes/No 
 
• I wish to receive a copy of the results or to discuss the outcomes of the 
study with the researcher. 
Yes/No 
 
• I agree to my GP or other current provider being informed of my 
participation in this study and/or the results of my participation in this 
study. 
Yes/No 
 
 
I………………………………………………………………………..hereby consent to 
taking part in this study. 
 
 
Date:……………………………………………………………………………………….. 
 
 
Signature:………………………………………………………………………………….
.. 
 
 
Project explained 
by:……………………………………………………………………….. 
 
 
Project 
role:………………………………………………………………………………… 
 
 
Signature:………………………………………………………………………………….
.. 
 
 
Date:………………………………………………………………………………………..
. 
 
Contact details (please feel free to contact the researchers if you have any 
questions about this study): 
 
Catherine Barnett 
Location: Molecular Genetics Lab (C.2.03), the University of Waikato. 
Day Ph: (07) 838 4466 ext 8482 Evening Ph: (021) 1022687 
Email: cmem1@waikato.ac.nz
 
Dr Ray T. M. Cursons, the University of Waikato, Ph: (07) 858 5120  
  
Email: r.cursons@waikato.ac.nz
 
Mr Tony Cecire, Anglesea Clinic, Cnr Anglesea and Thackeray Sts, Hamilton, Ph: 
(07) 839 2152 
Email: cecire@xtra.co.nz
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                                            APPENDIX II 
 
SEQUENCING RESULTS 
 
 
 
 
For each of the eleven SP-A1, SP-A2, and SP-D SNPs 
investigated in this study, the major and minor allele-specific 
primers amplified the same genomic region during real-time 
PCR. The following sections describe the sequence of the single 
amplified region, for each of these SNPs, and their subsequent 
National Centre of Biotechnology Information (NCBI) BLAST 
searches. 
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AII.1 SPA1-19  
 
 
 
 CATCTGNNGNTATGGACAGGCCAGGCTTTCTGCAGAGCACGGAATGATTC 
 ATGCTGAACGCTCAGAGACGGTGAACGCCATGTTTCCCAGGTTAACATAG 
 TGAGCGCACTGAAAGAAAGTGAGACTGCACTGGAGCCCAGGTCCCCGGGC 
 TCCTCCTAGAGCTCCTTACTCTTCCTCCGTACCTCAGGCAGCCTTGAGAC 
 CCCACAACCTCCAGGCCGGAGGCNCTAGAAGCATGACGTGCCATGCCACG 
 GTGCCATGGTGATGCTGGGAATTTTCCCGGGAGCTTCGGGTCTTCCCAGT 
 CACTCTGGTCTCGCCCGCCCTGCCTCTCGGGCTCTGCCCAGCTTCCTGAG 
 TCCTGACAGAGCACAGTGGGGGAGATAGTTGGCAGAGGTGGCAGATGGGC 
 TCACGGTCATCCCTCCTGCAGGATCAGTCGACTGGACCCAGAGCCATGTG 
 GCTGTGCCCTCTGGCCCTCATCCTCATCTTGATCGCTGCCTCTGGTGCTG 
 CGTGCGNACAGTGNAGGNCCGTTAGTCGGTC 
 
 
Figure AII.1. Sequence of PCR product amplified for SPA1-19. The PCR 
product length was expected to be 515 bp but sequencing reported 531 bp. 
 
 
 
 
  BLASTN 2.2.15 [Oct-15-2006]  
  Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. SchÃ¤ffer,  
  Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
  (1997), "Gapped BLAST and PSI-BLAST: a new generation of   
  protein database search programs", Nucleic Acids Res. 25:3389-3402. 
  RID: 1168983901-20321-158253073062.BLASTQ1 
 
 
  Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
  GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
  4,758,117 sequences; 18,951,497,157 total letters 
  Query=   
  Length=531 
 
 
Figure AII.2. Parameters from BLAST search with SPA1-19 sequence.  
 
 
 
                                                                   Score     E 
                                                                                             (Bits)  Value 
 
 gb|AC068139.6|  Homo sapiens chromosome 10 clone RP11-506M13, com  525   1e-146 
 emb|BX248123.5|  Human DNA sequence from clone RP11-589B3 on c...  525   1e-146 
 gb|AY198391.1|  Homo sapiens surfactant, pulmonary-associated ...  525   1e-146 
 ref|XM_934590.2|  PREDICTED: Homo sapiens similar to surfactan...  515   1e-143 
 ref|XM_001133039.1|  PREDICTED: Homo sapiens similar to Pulmon...  494   4e-137 
 gb|AY206682.1|  Homo sapiens surfactant, pulmonary-associated ...  494   4e-137 
 gb|M30838.1|HUMPSAP  Human pulmonary surfactant apoprotein (PSAP)  488   3e-135 
 gb|S69679.1|  SP-A2=surfactant protein {5' region} [human, Genomi  442   1e-121 
 gb|M68519.1|HUMSFTP1A  Human pulmonary surfactant-associated p...  442   1e-121 
 ref|XM_001133054.1|  PREDICTED: Homo sapiens similar to Pulmon...  131   7e-28  
 
 
Figure AII.3. First ten sequences producing significant alignments with SPA1-
19. 
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  Length=24037 
 
  Score =  525 bits (265),  Expect = 1e-146 
  Identities = 455/493 (92%), Gaps = 24/493 (4%) 
  Strand=Plus/Plus 
 
 Query  14     GGACAGGCCAGGCTTTCTGCAGAGCACGGAATGATTCATGCTGAACGCTCAGAGACGGTG 73 
               ||||||| |||| |||||||||||||||||| |||||| ||||||   ||||||| |||| 
 Sbjct 10795   GGACAGGGCAGGTTTTCTGCAGAGCACGGAA-GATTCA-GCTGAAG--TCAGAGA-GGTG 10849 
 
 Query  74     AACGCCATGTTTCCCAGGTTAACATAGTGAGCGCACTGAAAGAAAGTGAGACTGCACTGG 133 
               || |||| |||||||||| |||||||||||| |||||||||||||| ||||||||||||| 
 Sbjct  10850  AA-GCCA-GTTTCCCAGGGTAACATAGTGAG-GCACTGAAAGAAAG-GAGACTGCACTGG 10905 
 
 Query  134    AGCCCAGGTCCCCGGGCTCCTCCTAGAGCTCCTTACTCTTCCTCCGTACCTCAGGCAGCC 193 
               |||||||||||||||||||| |  |||||||||||||||||||||   |||||| ||||| 
 Sbjct  10906  AGCCCAGGTCCCCGGGCTCCCC--AGAGCTCCTTACTCTTCCTCCT--CCTCAG-CAGCC 10960 
 
 Query  194    TTGAGACCCCACAACCTCCAGGCCGGAGGCNCTAGAAGCATGACGTGCCATGCCACGGTG 253 
               | ||||||||||||||||||| |||||||| || ||||||||| |  |||||||| |||| 
 Sbjct  10961  TGGAGACCCCACAACCTCCAG-CCGGAGGC-CT-GAAGCATGAGG--CCATGCCA-GGTG 11014 
 
 Query  254    CCATGGTGATGCTGGGAATTTTCCCGGGAGCTTCGGGTCTTCCCAGTCACTCTGGTCTCG 313 
               ||| |||||||||||||||||||||||||||||||||||||||||| ||||||||||||| 
 Sbjct  11015  CCA-GGTGATGCTGGGAATTTTCCCGGGAGCTTCGGGTCTTCCCAG-CACTCTGGTCTCG 11072 
 
 Query  314    CCCGCCCTGCCTCTCGGGCTCTGCCCAGCTTCCTGAGTCCTGACAGAGCACAGTGGGGGA 373 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11073  CCCGCCCTGCCTCTCGGGCTCTGCCCAGCTTCCTGAGTCCTGACAGAGCACAGTGGGGGA 11132 
 
 Query  374    GATAGTTGGCAGAGGTGGCAGATGGGCTCACGGTCATCCCTCCTGCAGGATCAGTCGACT 433 
               ||| ||||||||||||||||||||||||||||| |||||||||||||||| ||| ||||| 
 Sbjct  11133  GAT-GTTGGCAGAGGTGGCAGATGGGCTCACGGCCATCCCTCCTGCAGGAGCAG-CGACT 11190 
 
 Query  434    GGACCCAGAGCCATGTGGCTGTGCCCTCTGGCCCTCATCCTCATCTTGATCGCTGCCTCT 493 
               ||||||||||||||||||||||||||||||||||||| |||||||||||| || |||||| 
 Sbjct  11191  GGACCCAGAGCCATGTGGCTGTGCCCTCTGGCCCTCAACCTCATCTTGATGGCAGCCTCT 11250 
 
 Query  494    GGTGCTGCGTGCG  506 
               ||||||| ||||| 
 Sbjct  11251  GGTGCTGTGTGCG  11263 
 
 
 
Figure AII.4. Alignment of Query sequence with: gb|AY198391.1| Homo 
sapiens surfactant, pulmonary-associated protein A1 (SFTPA1) gene, 
complete cds. 
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AII.2 SPA1-50  
 
 
  
 ANCTGGGAGGGANAGGCAGGTTTTCTTGCAGAGCACGGAAGATTCAGCTG 
 AAGTCAGAGAGGTGAAGCCAGTTTCCCAGGGTAACATAGTGAGGCACTGA 
 AAGAAAGGGAGACTGCACTGGAGCCCAGGTCCCCGGGCTCCCCAGAGCTC 
 CTTACTCTTCCTCCTCCTCAGCAGCCTGGAGACCCCACAACCTCCAGCCG 
 GAGGCCTGAAGCATGAGGCCATGCCAGGTGCCAGGTGATGCTGGGAATTT 
 TCCCGGGAGCTTCGGGTCTTCCCAGCACTCTGGTCTCGCCCGCCCTGCCT 
 CTCGGGCTCTGCCCAGCTTCCTGAGTCCTGACAGAGCACAGTGGGGGAGA 
 TGTTGGCAGAGGTGGCAGATGGGCTCACGGCCATCCCTCCTGCAGGAGCA 
 GCGACTGGACCCAGAGCCATGTGGCTGTGCCCTCTGGCCCTCAACCTCAT 
 CTTGATGGCAGCCTCTGGTGCTGTGTGCGAAGTGAAGGACGTTTGTGTTG 
 GAAGCCCTGGTATCCCCGGCACTCCTGGATCCCACGGCCTGCCAGGCAGG 
 GACGGGAGAGATGGTGTCAAAGGAGACTTNNGGGAAGGGGG 
 
Figure AII.5. Sequence of PCR product amplified for SPA1-50. The PCR 
product length was expected to be 605 bp but sequencing reported 591 bp. 
 
 
 
 BLASTN 2.2.15 [Oct-15-2006]  
 
 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer,  
 Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
 (1997), "Gapped BLAST and PSI-BLAST: a new generation of  
 protein database search programs", Nucleic Acids Res. 25:3389-3402. 
 
 RID: 1168984875-28908-125734700402.BLASTQ4 
 
 
 Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
 GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
 4,758,117 sequences; 18,951,497,157 total letters 
 Query=   
 Length=591 
 
Figure AII.6. Parameters from BLAST search with SPA1-50 sequence.  
 
 
 
                                                                   Score     E 
                                                                   (Bits)  Value 
 
 gb|AY198391.1|  Homo sapiens surfactant, pulmonary-associated ...  1088   0.0   
 gb|AC068139.6|  Homo sapiens chromosome 10 clone RP11-506M13, com  1080   0.0   
 emb|BX248123.5|  Human DNA sequence from clone RP11-589B3 on c...  1080   0.0   
 gb|M30838.1|HUMPSAP  Human pulmonary surfactant apoprotein (PSAP)  1031   0.0   
 gb|AY206682.1|  Homo sapiens surfactant, pulmonary-associated ...  1017   0.0   
 ref|XM_001133039.1|  PREDICTED: Homo sapiens similar to Pulmon...  1009   0.0   
 ref|XM_934590.2|  PREDICTED: Homo sapiens similar to surfactan...   989   0.0   
 gb|M68519.1|HUMSFTP1A  Human pulmonary surfactant-associated p...   965   0.0   
 gb|S69679.1|  SP-A2=surfactant protein {5' region} [human, Genomi   779   0.0   
 ref|XM_934600.2|  PREDICTED: Homo sapiens similar to surfactan...   359   2e-96 
 
 
Figure AII.7. First ten sequences producing significant alignments with SPA1-
50. 
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 Length=24037 
 
  Score = 1088 bits (549),  Expect = 0.0 
  Identities = 572/576 (99%), Gaps = 3/576 (0%) 
  Strand=Plus/Plus 
 
 Query  3      CTGGGAGGGANAGG-CAGGTTTTCTTGCAGAGCACGGAAGATTCAGCTGAAGTCAGAGAG 61 
               |||||||||| ||| |||||||||| |||||||||||||||||||||||||||||||||| 
 Sbjct  10788  CTGGGAGGGACAGGGCAGGTTTTCT-GCAGAGCACGGAAGATTCAGCTGAAGTCAGAGAG 10846 
 
 Query  62     GTGAAGCCAGTTTCCCAGGGTAACATAGTGAGGCACTGAAAGAAAGGGAGACTGCACTGG 121 
               ||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||| 
 Sbjct  10847  GTGAAGCCAGTTTCCCAGGGTAACATAGTGAGGCACTGAAAGAAAGG-AGACTGCACTGG 10905 
 
 Query  122    AGCCCAGGTCCCCGGGCTCCCCAGAGCTCCTTACTCTTCCTCCTCCTCAGCAGCCTGGAG 181 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  10906  AGCCCAGGTCCCCGGGCTCCCCAGAGCTCCTTACTCTTCCTCCTCCTCAGCAGCCTGGAG 10965 
 
 Query  182    ACCCCACAACCTCCAGCCGGAGGCCTGAAGCATGAGGCCATGCCAGGTGCCAGGTGATGC 241 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  10966  ACCCCACAACCTCCAGCCGGAGGCCTGAAGCATGAGGCCATGCCAGGTGCCAGGTGATGC 11025 
 
 Query  242    TGGGAATTTTCCCGGGAGCTTCGGGTCTTCCCAGCACTCTGGTCTCGCCCGCCCTGCCTC 301 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11026  TGGGAATTTTCCCGGGAGCTTCGGGTCTTCCCAGCACTCTGGTCTCGCCCGCCCTGCCTC 11085 
 
 Query  302    TCGGGCTCTGCCCAGCTTCCTGAGTCCTGACAGAGCACAGTGGGGGAGATGTTGGCAGAG 361 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11086  TCGGGCTCTGCCCAGCTTCCTGAGTCCTGACAGAGCACAGTGGGGGAGATGTTGGCAGAG 11145 
 
 Query  362    GTGGCAGATGGGCTCACGGCCATCCCTCCTGCAGGAGCAGCGACTGGACCCAGAGCCATG 421 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11146  GTGGCAGATGGGCTCACGGCCATCCCTCCTGCAGGAGCAGCGACTGGACCCAGAGCCATG 11205 
 
 Query  422    TGGCTGTGCCCTCTGGCCCTCAACCTCATCTTGATGGCAGCCTCTGGTGCTGTGTGCGAA 481 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11206  TGGCTGTGCCCTCTGGCCCTCAACCTCATCTTGATGGCAGCCTCTGGTGCTGTGTGCGAA 11265 
 
 Query  482    GTGAAGGACGTTTGTGTTGGAAGCCCTGGTATCCCCGGCACTCCTGGATCCCACGGCCTG 541 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11266  GTGAAGGACGTTTGTGTTGGAAGCCCTGGTATCCCCGGCACTCCTGGATCCCACGGCCTG 11325 
 
 Query  542    CCAGGCAGGGACGGGAGAGATGGTGTCAAAGGAGAC  577 
               |||||||||||||||||||||||||||||||||||| 
 Sbjct  11326  CCAGGCAGGGACGGGAGAGATGGTGTCAAAGGAGAC  11361 
 
 
Figure AII.8. Alignment of Query sequence with: gb|AY198391.1| Homo 
sapiens surfactant, pulmonary-associated protein A1 (SFTPA1) gene, 
complete cds. 
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AII.3 SPA1-62 
 
 
 
 CTGGGAGGGACAGGCAGGTTTCTGCAGAGCACGGAAGATTCAGCTGAAGT 
 CAGAGAGGTGAAGCCAGTTTCCCAGTGTAACATAGTGAGGCACTGAAAGA 
 AAGGGAGACTGCACTGGAGCCCAGGTCCCCGGGCTCCCCAGAGCTCCTTA 
 CTCTTCCTCCTCCTCAGCAGCCTGGAGACCCCACAACCTCCAGCCGGAGG 
 CCTGAAGCATGAGGCCATGCCAGGTGCCAGGTGATGCTGGGAATTTTCCC 
 GGGAGCTTCGGGTCTTCCCAGCACTCTGGTCTCGCCCGCCCTGCCTCTCG 
 GGCTCTGCCCAGCTTCCTGAGTCCTGACAGAGCACAGTGGGGGAGATGTT 
 GGCAGAGGTGGCAGATGGGCTCACGGCCATCCCTCCTGCAGGAGCAGCGA 
 CTGGACCCAGAGCCATGTGGCTGTGCCCTCTGGCCCTCAACCTCATCTTG 
 ATGGCAGCCTCTGGTGCTGTGTGCGAAGTGAAGGACGTTTGTGTTGGAAG 
 CCCTGGTATCCCCGGCACTCCTGGATCCCACGGCCTGCCAGGCAGGGACG 
 GGAGAGATGGTGTCAAAGGAGACCCTGGCCCTCCAGGTACTGTGCTGCAG 
 ACCCCACCCTCAGCTGAGGGACACAGACCCCTTTTCAGGAGGCCCATCTG 
 TCCAGGCCCCTAGGCTGTGGGCCATAGTGAGCTGGGGGCTATAGTAAGCT 
 GGGTGGGACTTCAGTCTGCAGGGCTGGTGGGTTCCTGGGGCCCCTTATGA 
 TGGGCGCATTCCTGGGAGAGTCTTGTCCTCATAGTGCCCCACGGACGTGA 
 TACGAGTGATTAGCTGAGCCAGCCTGGTGATTACTGGGCATCGGAAGTCT 
 CACTAGGCTCCAACCAGTTNTGGGTGACAGATCTTACCATCCCTGTTCTC 
 TTTCTCCTGCAGGCCCNTGGGTCCCTGAGANGCCA 
 
Figure AII.9. Sequence of PCR product amplified for SPA1-62. The PCR 
product length was expected to be 959 bp but sequencing reported 936 bp. 
 
 
 
 BLASTN 2.2.15 [Oct-15-2006]  
 Reference: 
 Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer,  
 Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
 (1997), "Gapped BLAST and PSI-BLAST: a new generation of  
 protein database search programs", Nucleic Acids Res. 25:3389-3402. 
 
 RID: 1168985320-28281-93807524397.BLASTQ4 
 
 Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
 GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
 4,758,117 sequences; 18,951,497,157 total letters 
 
 Query= 
 Length=936   
 
Figure AII.10. Parameters from BLAST search with SPA1-62 sequence.  
 
 
 
                                                                   Score    E                       
                                                                   (Bits) Value 
 gb|AY198391.1|  Homo sapiens surfactant, pulmonary-associated ...  1481   0.0    
 gb|AC068139.6|  Homo sapiens chromosome 10 clone RP11-506M13, com  1473   0.0    
 emb|BX248123.5|  Human DNA sequence from clone RP11-589B3 on c...  1473   0.0    
 gb|M30838.1|HUMPSAP  Human pulmonary surfactant apoprotein (PSAP)  1392   0.0    
 gb|AY206682.1|  Homo sapiens surfactant, pulmonary-associated ...  1362   0.0    
 gb|M68519.1|HUMSFTP1A  Human pulmonary surfactant-associated p...  1310   0.0    
 ref|XM_001133039.1|  PREDICTED: Homo sapiens similar to Pulmon...  1033   0.0    
 ref|XM_934590.2|  PREDICTED: Homo sapiens similar to surfactan...  1009   0.0    
 gb|S69679.1|  SP-A2=surfactant protein {5' region} [human, Genomi   775   0.0    
 ref|XM_934600.2|  PREDICTED: Homo sapiens similar to surfactan...   387   1e-104 
 
 
Figure AII.11. First ten sequences producing significant alignments with SPA1-
62. 
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 Length=24037, Score = 1481 bits (747),  Expect = 0.0 
 Identities = 896/921 (97%), Gaps = 20/921 (2%), Strand=Plus/Plus 
 
 Query  1      CTGGGAGGGACAGG-CAGGTTT-CTGCAGAGCACGGAAGATTCAGCTGAAGTCAGAGAGG 58 
               |||||||||||||| ||||||| ||||||||||||||||||||||||||||||||||||| 
 Sbjct  10788  CTGGGAGGGACAGGGCAGGTTTTCTGCAGAGCACGGAAGATTCAGCTGAAGTCAGAGAGG 10847 
 
 Query  59     TGAAGCCAGTTTCCCAGTGTAACATAGTGAGGCACTGAAAGAAAGGGAGACTGCACTGGA 118 
               ||||||||||||||||| |||||||||||||||||||||||||||| ||||||||||||| 
 Sbjct  10848  TGAAGCCAGTTTCCCAGGGTAACATAGTGAGGCACTGAAAGAAAGG-AGACTGCACTGGA 10906 
 
 Query  119    GCCCAGGTCCCCGGGCTCCCCAGAGCTCCTTACTCTTCCTCCTCCTCAGCAGCCTGGAGA 178 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  10907  GCCCAGGTCCCCGGGCTCCCCAGAGCTCCTTACTCTTCCTCCTCCTCAGCAGCCTGGAGA 10966 
 
 Query  179    CCCCACAACCTCCAGCCGGAGGCCTGAAGCATGAGGCCATGCCAGGTGCCAGGTGATGCT 238 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  10967  CCCCACAACCTCCAGCCGGAGGCCTGAAGCATGAGGCCATGCCAGGTGCCAGGTGATGCT 11026 
 
 Query  239    GGGAATTTTCCCGGGAGCTTCGGGTCTTCCCAGCACTCTGGTCTCGCCCGCCCTGCCTCT 298 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11027  GGGAATTTTCCCGGGAGCTTCGGGTCTTCCCAGCACTCTGGTCTCGCCCGCCCTGCCTCT 11086 
 
 Query  299    CGGGCTCTGCCCAGCTTCCTGAGTCCTGACAGAGCACAGTGGGGGAGATGTTGGCAGAGG 358 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11087  CGGGCTCTGCCCAGCTTCCTGAGTCCTGACAGAGCACAGTGGGGGAGATGTTGGCAGAGG 11146 
 
 Query  359    TGGCAGATGGGCTCACGGCCATCCCTCCTGCAGGAGCAGCGACTGGACCCAGAGCCATGT 418 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11147  TGGCAGATGGGCTCACGGCCATCCCTCCTGCAGGAGCAGCGACTGGACCCAGAGCCATGT 11206 
 
 Query  419    GGCTGTGCCCTCTGGCCCTCAACCTCATCTTGATGGCAGCCTCTGGTGCTGTGTGCGAAG 478 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11207  GGCTGTGCCCTCTGGCCCTCAACCTCATCTTGATGGCAGCCTCTGGTGCTGTGTGCGAAG 11266 
 
 Query  479    TGAAGGACGTTTGTGTTGGAAGCCCTGGTATCCCCGGCACTCCTGGATCCCACGGCCTGC 538 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11267  TGAAGGACGTTTGTGTTGGAAGCCCTGGTATCCCCGGCACTCCTGGATCCCACGGCCTGC 11326 
 
 Query  539    CAGGCAGGGACGGGAGAGATGGTGTCAAAGGAGACCCTGGCCCTCCAGGTACTGTGCTGC 598 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11327  CAGGCAGGGACGGGAGAGATGGTGTCAAAGGAGACCCTGGCCCTCCAGGTACTGTGCTGC 11386 
 
 Query  599    AGACCCCACCCTCAGCTGAGGGACACAGACCCCTTTTCAGGAGGCCCATCTGTCCAGGCC 658 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11387  AGACCCCACCCTCAGCTGAGGGACACAGACCCCTTTTCAGGAGGCCCATCTGTCCAGGCC 11446 
 
 Query  659    CCTAGGCTGTGGGCCATAGTGAGCTGGGGGCTATAGTAAGCTGGGTGGGACTTCAGTCTG 718 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  11447  CCTAGGCTGTGGGCCATAGTGAGCTGGGGGCTATAGTAAGCTGGGTGGGACTTCAGTCTG 11506 
 
 Query  719    CAGGGCTGGTGGGTTCCTGGGGCCCCTTATGATGGGCGCATTCCTGGGAGAGTCTTGTCC 778 
               |||||||||||||||||||||| |||||||||| |||||| |||| |||||||| ||||| 
 Sbjct  11507  CAGGGCTGGTGGGTTCCTGGGG-CCCTTATGAT-GGCGCA-TCCT-GGAGAGTC-TGTCC 11561 
 
 Query  779    TCATAGTGCCCCACGGACGTGATACGAGTGATTAGCTGAGCCAG-CCTGGTGATTACTGG 837 
               |||||||| |||||||| |||||| |||||| |||||||||||| |||||||| || ||| 
 Sbjct  11562  TCATAGTG-CCCACGGA-GTGATA-GAGTGA-TAGCTGAGCCAGCCCTGGTGA-TAATGG 11616 
 
 Query  838    GCATCGGAAGTCTCACTAGGCTCCAACCAGTTNTGGGTGACAGATCTTAC-CATCCCTGT 896 
               ||||||  |||||||||| ||||||||||||| ||||||||||||| ||| ||||| ||  
 Sbjct  11617  GCATCG--AGTCTCACTA-GCTCCAACCAGTTGTGGGTGACAGATCCTACACATCCATG- 11672 
 
 Query  897    TCTCTTTTCTCCTGCAGGCCC  917 
               |||||||||| |||||||||| 
 Sbjct  11673  TCTCTTTTCT-CTGCAGGCCC  11692 
 
 
Figure AII.12. Alignment of Query sequence with: gb|AY198391.1| Homo 
sapiens surfactant, pulmonary-associated protein A1 (SFTPA1) gene, 
complete cds. 
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AII.4 SPA1-133 
 
 
 
 GGNAGAGAAAGGNNTTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCC 
 ATTCAGGAGGCATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAA 
 TCCAGAGGGAAAATGAGGCCATTGCAAGCTTCGTGAAGAAGTACAACACA 
 TATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGGAGACTTCCGCTA 
 CTCAGACGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCCG 
 CAGGTCGGGGAAAAGAGCAGTGTGTGGAGATGTACACAGATGGGCAGTGG 
 AATGACAGGAACTGCCTGTACTCCCGACTGACCATCTGTGAGTTCTGAGA 
 GGCATTTAGGCCATGGGACAGGGAGGACGCTCTCTGGCCTTCGGCCTCCA 
 TCCTGAGGCTCCACTTGGTCTGTGAGATGCTAGAACTCCCTTTCAACAGA 
 ATTCACTTGTGGCTATTGGGACTGGAGGCACCCTTAGCCACTTCATTCCT 
 CTGATGGGCCCTGACTCTTCCCCATAATCACTGACCAGCCTTGACACTCC 
 CCTTGCAAACTCTCCCAGCACTGCACCCCAGGCAGCCACTCTTAGCCTTG 
 GCCTTCGACATGAGATGGAGCCCTCCTTATTCCCCATCTGGTCCAGTTCC 
 TTCACTTACAGATGGCAGCAGTGAGGTCTTGGGGTAGAAGGACCCTCCAA 
 AGTCACACAAAGTGCCTGCTCCTGGTCCCTCAGCTCTGCCTCTGCAGCCC 
 AACTGCCTTGNCCCAGTGCCATCAGGATTGAGGCAGGTCCCGGGGCCCAA 
 GGCATAATTGGACCGAAGAAGAAGGCAGACCTTCGGGGGAAAGGCCCAGA 
 CTGTGCAGAGCTAAAGGACACCAGTGGANAATTCTCTGGGCACTCTGAGG 
 TCNCTCTGTGGCAGGCCTGGTC 
  
 
Figure AII.13. Sequence of PCR product amplified for SPA1-133. The PCR 
product length was expected to be 937 bp but sequencing reported 922 bp. 
 
 
 
 BLASTN 2.2.15 [Oct-15-2006] 
 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. SchÃ¤ffer,  
 Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
 (1997), "Gapped BLAST and PSI-BLAST: a new generation of  
 protein database search programs", Nucleic Acids Res. 25:3389-3402. 
 
 RID: 1168986954-30312-83801407081.BLASTQ1 
 
 Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
 GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
           4,758,117 sequences; 18,951,497,157 total letters 
 Query=   
 Length=922 
 
 Figure AII.14. Parameters from BLAST search with SPA1-133 sequence.  
  
 
                                                                   Score     E 
                                                                  (Bits)  Value 
 
 gb|AY198391.1|  Homo sapiens surfactant, pulmonary-associated ...  1427    0.0    
 ref|XM_001133073.1|  PREDICTED: Homo sapiens similar to surfac...  1394    0.0    
 ref|XM_934596.2|  PREDICTED: Homo sapiens similar to surfactan...  1394    0.0    
 ref|XM_934598.2|  PREDICTED: Homo sapiens similar to surfactan...  1394    0.0    
 ref|XM_934590.2|  PREDICTED: Homo sapiens similar to surfactan...  1394    0.0    
 ref|XM_934600.2|  PREDICTED: Homo sapiens similar to surfactan...  1394    0.0    
 gb|AC068139.6|  Homo sapiens chromosome 10 clone RP11-506M13, com  1394    0.0    
 emb|BX248123.5|  Human DNA sequence from clone RP11-589B3 on c...  1394    0.0    
 gb|M30838.1|HUMPSAP  Human pulmonary surfactant apoprotein (PSAP)  1308    0.0    
 ref|XM_001133054.1|  PREDICTED: Homo sapiens similar to Pulmon...  1237    0.0    
 
 
Figure AII.15. First ten sequences producing significant alignments with SPA1-
133. 
 
 
 
Appendix II: Sequencing Results  151
  
 
 Length=24037, Score = 1427 bits (720),  Expect = 0.0 
 Identities = 759/766 (99%), Gaps = 6/766 (0%), Strand=Plus/Plus 
 
 Query  15    TTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCATTCAGGAGGCATGTGCCAGAGCA 74 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13158 TTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCATTCAGGAGGCATGTGCCAGAGCA 13217 
 
 Query  75    GGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGGGAAAATGAGGCCATTGCAAGCTTCGT 134 
              |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||| 
 Sbjct  13218 GGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGG-AAAATGAGGCCATTGCAAGCTTCGT 13276 
 
 Query  135   GAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGGAGACTT 194 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13277 GAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGGAGACTT 13336 
 
 Query  195   CCGCTACTCAGACGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCCGCAGG 254 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13337 CCGCTACTCAGACGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCCGCAGG 13396 
 
 Query  255   TCGGGGAAAAGAGCAGTGTGTGGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTG 314 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13397 TCGGGGAAAAGAGCAGTGTGTGGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTG 13456 
 
 Query  315   CCTGTACTCCCGACTGACCATCTGTGAGTTCTGAGAGGCATTTAGGCCATGGGACAGGGA 374 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13457 CCTGTACTCCCGACTGACCATCTGTGAGTTCTGAGAGGCATTTAGGCCATGGGACAGGGA 13516 
 
 Query  375   GGACGCTCTCTGGCCTTCGGCCTCCATCCTGAGGCTCCACTTGGTCTGTGAGATGCTAGA 434 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13517 GGACGCTCTCTGGCCTTCGGCCTCCATCCTGAGGCTCCACTTGGTCTGTGAGATGCTAGA 13576 
 
 Query  435   ACTCCCTTTCAACAGAATTCACTTGTGGCTATTGGGACTGGAGGCACCCTTAGCCACTTC 494 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13577 ACTCCCTTTCAACAGAATTCACTTGTGGCTATTGGGACTGGAGGCACCCTTAGCCACTTC 13636 
 
 Query  495   ATTCCTCTGATGGGCCCTGACTCTTCCCCATAATCACTGACCAGCCTTGACACTCCCCTT 554 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13637 ATTCCTCTGATGGGCCCTGACTCTTCCCCATAATCACTGACCAGCCTTGACACTCCCCTT 13696 
 
 Query  555   GCAAACTCTCCCAGCACTGCACCCCAGGCAGCCACTCTTAGCCTTGGCCTTCGACATGAG 614 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13697 GCAAACTCTCCCAGCACTGCACCCCAGGCAGCCACTCTTAGCCTTGGCCTTCGACATGAG 13756 
 
 Query  615   ATGGAGCCCTCCTTATTCCCCATCTGGTCCAGTTCCTTCACTTACAGATGGCAGCAGTGA 674 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13757 ATGGAGCCCTCCTTATTCCCCATCTGGTCCAGTTCCTTCACTTACAGATGGCAGCAGTGA 13816 
 
 Query  675   GGTCTTGGGGTAGAAGGACCCTCCAAAGTCACACAAAGTGCCTG-CTCCTGGT-CCCTCA 732 
              |||||||||||||||||||||||||||||||||||||||||||| |||||||| |||||| 
 Sbjct  13817 GGTCTTGGGGTAGAAGGACCCTCCAAAGTCACACAAAGTGCCTGCCTCCTGGTCCCCTCA 13876 
 
 Query  733   GCTCTGCCTCTGCAGCCCAACTGCCTTGNCCCAGTGCCATCAGGAT  778 
              |||||||||||||||||| |||||||   ||||||||||||||||| 
 Sbjct  13877 GCTCTGCCTCTGCAGCCC-ACTGCCT--GCCCAGTGCCATCAGGAT  13919 
 
 
 Score = 58.0 bits (29),  Expect = 1e-05, Identities = 71/79 (89%), Gaps = 6/79 
(7%),   Strand=Plus/Plus 
 
 Query  844    GCCCAGACTGTGCAGAGCTAAAGGACACCAGTGGANAATTCTCTGGGCACTCTGAGGTCN  903 
               |||| |||||||||||||||| |||||| |||||| | |||||||| ||||||||||||  
 Sbjct  13969  GCCCTGACTGTGCAGAGCTAA-GGACAC-AGTGGAGA-TTCTCTGG-CACTCTGAGGTC-  14023 
 
 Query  904    CTCTGTGGCAGGCCTGGTC  922 
                |||||||||||||||||| 
 Sbjct  14024  -TCTGTGGCAGGCCTGGTC  14041 
 
Figure AII.16. Alignment of Query sequence with: gb|AY198391.1| Homo 
sapiens surfactant, pulmonary-associated protein A1 (SFTPA1) gene, 
complete cds. 
 
 
Appendix II: Sequencing Results  152
AII.5 SPA1-219 
 
 
 TGCTTGCTTTCACTGAATCAGGCAATTGCATCATTTCTGGCAATAGTAAT 
 TGTTACTTAGGTGAATGAATAAATGGAGGAGAGTCTAAAAGTGAATTTAG 
 AAAACTGCAATTGGAAGAGGAAGAGAAGACACAGAGAGAGGCAGAGATGG 
 AGAGACTGGGGAGAATCTGGTAGCAGAGACCCCAGGTGAGGGAGGTGGCT 
 TAGAGACAAAGTGGTCAGTGGCCTGACCCGGACTCCTCTGCTCTCAGCCC 
 TCAGTCTGCAGGGCTCCATAATGACAGTAGGAGAGAAGGTCTTCTCCAGC 
 AATGGGCAGTCCATCACTTTTGATGCCATTCAGGAGGCATGTGCCAGAGC 
 AGGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGGAAAATGAGGCCATTG 
 CAAGCTTCGTGAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAG 
 GGTCCCAGCCCTGGAGACTTCCGCTACTCAGACGGGACCCCTGTAAACTA 
 CACCAACTGGTACCGAGGGGAGCCCGCAGGTTG 
 
Figure AII.17. Sequence of PCR product amplified for SPA1-219. The PCR 
product length was expected to be 577 bp but sequencing reported 533 bp. 
 
 
 
 BLASTN 2.2.15 [Oct-15-2006] 
 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. SchÃ¤ffer,  
 Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
 (1997), "Gapped BLAST and PSI-BLAST: a new generation of  
 protein database search programs", Nucleic Acids Res. 25:3389-3402. 
 
 RID: 1168987122-9890-159767403929.BLASTQ1 
 
 Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
 GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
 4,758,117 sequences; 18,951,497,157 total letters 
 Query=   
 Length=533 
 
Figure AII.18. Parameters from BLAST search with SPA1-219 sequence.  
 
 
 
                                                                   Score     E 
                                                                   (Bits)  Value 
 
 gb|AC068139.6|  Homo sapiens chromosome 10 clone RP11-506M13, com   987    0.0    
 emb|BX248123.5|  Human DNA sequence from clone RP11-589B3 on c...   987    0.0    
 gb|AY198391.1|  Homo sapiens surfactant, pulmonary-associated ...   987    0.0    
 gb|M30838.1|HUMPSAP  Human pulmonary surfactant apoprotein (PSAP)   979    0.0    
 gb|AY206682.1|  Homo sapiens surfactant, pulmonary-associated ...   948    0.0    
 gb|M68519.1|HUMSFTP1A  Human pulmonary surfactant-associated p...   940    0.0    
 ref|XM_934592.2|  PREDICTED: Homo sapiens similar to surfactan...   567    3e-159 
 ref|XM_001133073.1|  PREDICTED: Homo sapiens similar to surfac...   567    3e-159 
 ref|XM_934596.2|  PREDICTED: Homo sapiens similar to surfactan...   567    3e-159 
 ref|XM_934598.2|  PREDICTED: Homo sapiens similar to surfactan...   567    3e-159 
 
 
Figure AII.19. First ten sequences producing significant alignments with SPA1-
219. 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II: Sequencing Results  153
 
 Length=24037 
 Score =  987 bits (498),  Expect = 0.0 
 Identities = 511/514 (99%), Gaps = 1/514 (0%) 
 Strand=Plus/Plus 
 
 Query  19     CAGGCAATTGCATCATTTCTGGCAATA-GTAATTGTTACTTAGGTGAATGAATAAATGGA 77 
               |||| ||||||| |||||||||||||| |||||||||||||||||||||||||||||||| 
 Sbjct  12884  CAGGAAATTGCACCATTTCTGGCAATAAGTAATTGTTACTTAGGTGAATGAATAAATGGA 12943 
 
 Query  78     GGAGAGTCTAAAAGTGAATTTAGAAAACTGCAATTGGAAGAGGAAGAGAAGACACAGAGA 137 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  12944  GGAGAGTCTAAAAGTGAATTTAGAAAACTGCAATTGGAAGAGGAAGAGAAGACACAGAGA 13003 
 
 Query  138    GAGGCAGAGATGGAGAGACTGGGGAGAATCTGGTAGCAGAGACCCCAGGTGAGGGAGGTG 197 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13004  GAGGCAGAGATGGAGAGACTGGGGAGAATCTGGTAGCAGAGACCCCAGGTGAGGGAGGTG 13063 
 
 Query  198    GCTTAGAGACAAAGTGGTCAGTGGCCTGACCCGGACTCCTCTGCTCTCAGCCCTCAGTCT 257 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13064  GCTTAGAGACAAAGTGGTCAGTGGCCTGACCCGGACTCCTCTGCTCTCAGCCCTCAGTCT 13123 
 
 Query  258    GCAGGGCTCCATAATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCAC 317 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13124  GCAGGGCTCCATAATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCAC 13183 
 
 Query  318    TTTTGATGCCATTCAGGAGGCATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAA 377 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13184  TTTTGATGCCATTCAGGAGGCATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAA 13243 
 
 Query  378    TCCAGAGGAAAATGAGGCCATTGCAAGCTTCGTGAAGAAGTACAACACATATGCCTATGT 437 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13244  TCCAGAGGAAAATGAGGCCATTGCAAGCTTCGTGAAGAAGTACAACACATATGCCTATGT 13303 
 
 Query  438    AGGCCTGACTGAGGGTCCCAGCCCTGGAGACTTCCGCTACTCAGACGGGACCCCTGTAAA 497 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13304  AGGCCTGACTGAGGGTCCCAGCCCTGGAGACTTCCGCTACTCAGACGGGACCCCTGTAAA 13363 
 
 Query  498    CTACACCAACTGGTACCGAGGGGAGCCCGCAGGT  531 
               |||||||||||||||||||||||||||||||||| 
 Sbjct  13364  CTACACCAACTGGTACCGAGGGGAGCCCGCAGGT  13397 
 
 
Figure AII.20. Alignment of Query sequence with: gb|AY198391.1| Homo 
sapiens surfactant, pulmonary-associated protein A1 (SFTPA1) gene, 
complete cds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II: Sequencing Results  154
AII.6 SPA2-9 
 
 
 CCGGGGCTGCTTCGGGTCTTCCAGCACTCTGGTCTCGCCCGCCCTGCCTC 
 TCGCGGCTCTGCCCTAGCTTCCTGACGTCCTGACAGAGCACAGTGGGGGA 
 GATGTTGGCGAGGTGGCAGATGGGCTCACGGCCATCCCTCCAGCAGGAGC 
 AGCGACTGGACCCAGAGCCATGTGGCTGTGCCCTCTGGCCCTCAACCTCA 
 TCTTGATGGCAGCCAA 
 
Figure AII.21. Sequence of PCR product amplified for SPA2-9. The PCR 
product length was expected to be 235 bp but sequencing reported 216 bp. 
 
 
 
 BLASTN 2.2.15 [Oct-15-2006] 
 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. SchÃ¤ffer,  
 Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
 (1997), "Gapped BLAST and PSI-BLAST: a new generation of  
 protein database search programs", Nucleic Acids Res. 25:3389-3402. 
 
 RID: 1168988625-12829-211014462206.BLASTQ4 
 
 Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
 GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
           4,758,117 sequences; 18,951,497,157 total letters 
 Query=   
 Length=216 
 
Figure AII.22. Parameters from BLAST search with SPA2-9 sequence.  
  
 
 
                                                                   Score     E 
                                                                   (Bits)  Value 
 
 gb|S69679.1|  SP-A2=surfactant protein {5' region} [human, Genomi   335    9e-90 
 gb|AY206682.1|  Homo sapiens surfactant, pulmonary-associated ...   335    9e-90 
 ref|XM_934590.2|  PREDICTED: Homo sapiens similar to surfactan...   325    8e-87 
 gb|AC068139.6|  Homo sapiens chromosome 10 clone RP11-506M13, com   325    8e-87 
 emb|BX248123.5|  Human DNA sequence from clone RP11-589B3 on c...   325    8e-87 
 gb|AY198391.1|  Homo sapiens surfactant, pulmonary-associated ...   325    8e-87 
 ref|XM_001133039.1|  PREDICTED: Homo sapiens similar to Pulmon...   319    5e-85 
 gb|M68519.1|HUMSFTP1A  Human pulmonary surfactant-associated p...   309    5e-82 
 gb|M30838.1|HUMPSAP  Human pulmonary surfactant apoprotein (PSAP)   297    2e-78 
 gb|S69681.1|  SP-A2=SP-2A beta {5' region, alternatively splic...   145    2e-32 
 
 
Figure AII.23. First ten sequences producing significant alignments with SPA2-
9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II: Sequencing Results  155
 
 Length=18039 
 Score =  335 bits (169),  Expect = 9e-90 
 Identities = 204/209 (97%), Gaps = 5/209 (2%) 
 Strand=Plus/Plus 
 
 Query  8      TGCTTCGGGTCTTCC-AGCACTCTGGTCTCGCCCGCCCTGCCTCTCGCGGCTCTGCCCTA 66 
               ||||||||||||||| ||||||||||||||||||||||||||||||| |||||||||| | 
 Sbjct  12856  TGCTTCGGGTCTTCCCAGCACTCTGGTCTCGCCCGCCCTGCCTCTCG-GGCTCTGCCC-A 12913 
 
 Query  67     GCTTCCTGACGTCCTGACAGAGCACAGTGGGGGAGATGTTGGC-GAGGTGGCAGATGGGC 125 
               ||||||||| ||||||||||||||||||||||||||||||||| |||||||||||||||| 
 Sbjct  12914  GCTTCCTGA-GTCCTGACAGAGCACAGTGGGGGAGATGTTGGCAGAGGTGGCAGATGGGC 12972 
 
 Query  126    TCACGGCCATCCCTCCAGCAGGAGCAGCGACTGGACCCAGAGCCATGTGGCTGTGCCCTC 185 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  12973  TCACGGCCATCCCTCCAGCAGGAGCAGCGACTGGACCCAGAGCCATGTGGCTGTGCCCTC 13032 
 
 Query  186    TGGCCCTCAACCTCATCTTGATGGCAGCC  214 
               ||||||||||||||||||||||||||||| 
 Sbjct  13033  TGGCCCTCAACCTCATCTTGATGGCAGCC  13061 
 
 
Figure AII.24. Alignment of Query sequence with: gb|AY206682.1| Homo 
sapiens surfactant, pulmonary-associated protein A2 (SFTPA2) gene, 
complete cds. 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II: Sequencing Results  156
AII.7 SPA2-91 
 
 
 
 GGGCTCGTCTGCTCACCTTCAGACTGCCCCCNGGGGCCTCCATCCCAGGA 
 CATGCCTCCCCTGCCTCCCAGTGCTGTCCCTCGTCCCACACCTGACTCAG 
 TGTGTTCCCCATCAGCGGTCATGAGGCACGGAGGACTTCCCACACCTGCC 
 CTTCTCTGAATTGTGACCACACTCCCCAGACACCTCGGCTTTCTCCCTCA 
 AATTCATATTCTCTTACTTAGGTTGAGCCAAATGCCCTTGGGGTACCTGC 
 AGGGTTTGTCTGATCCCCATCACCCCTGTGTAACTGACTTCAGGTCGCTG 
 TGCCCATGTTTCCACTGCCTACCTGCCCCGCCCTGCTCACCTGGAGGGCC 
 TCTCTCGCCAGGCTCCCCCTTCTCTTCCAA 
 
 
Figure AII.25. Sequence of PCR product amplified for SPA2-91. The PCR 
product length was expected to be 400 bp but sequencing reported 380 bp. 
 
 
 
 
 BLASTN 2.2.15 [Oct-15-2006]  
 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. SchÃ¤ffer,  
 Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
 (1997), "Gapped BLAST and PSI-BLAST: a new generation of  
 protein database search programs", Nucleic Acids Res. 25:3389-3402. 
 
 RID: 1168988950-1227-49382262643.BLASTQ1 
 
 Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
 GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
           4,758,117 sequences; 18,951,497,157 total letters 
 Query=   
 Length=380 
 
Figure AII.26. Parameters from BLAST search with SPA2-91 sequence.  
 
 
 
                                                                   Score    E 
                                                                  (Bits)  Value 
 
 gb|AC068139.6|  Homo sapiens chromosome 10 clone RP11-506M13, com   644   0.0    
 emb|BX248123.5|  Human DNA sequence from clone RP11-589B3 on c...   644   0.0    
 gb|AY206682.1|  Homo sapiens surfactant, pulmonary-associated ...   638   0.0    
 gb|M68519.1|HUMSFTP1A  Human pulmonary surfactant-associated p...   622   5e-176 
 gb|AY198391.1|  Homo sapiens surfactant, pulmonary-associated ...   511   1e-142 
 gb|M30838.1|HUMPSAP  Human pulmonary surfactant apoprotein (PSAP)   498   2e-138 
 dbj|AK225599.1|  Homo sapiens mRNA for Pulmonary surfactant-as...  71.9   4e-10  
 gb|K03475.1|HUMPSPB  Human pulmonary surfactant-associated pro...  71.9   4e-10  
 ref|XM_934592.2|  PREDICTED: Homo sapiens similar to surfactan...  63.9   9e-08  
 ref|XM_001133073.1|  PREDICTED: Homo sapiens similar to surfac...  63.9   9e-08  
 
 
Figure AII.27. First ten sequences producing significant alignments with SPA2-
91. 
 
 
 
 
  
 
 
 
 
 
 
Appendix II: Sequencing Results  157
 
 Length=18039 
 Score =  638 bits (322),  Expect = 0.0 
 Identities = 354/361 (98%), Gaps = 3/361 (0%) 
 Strand=Plus/Minus 
 
 Query  16     CCTTCAGACTGCCCCCNGGGGCCTCCATCCCAGGACATGCCTCCCCTGCCTCCCAGTGCT 75 
               |||||||||||||||| ||| ||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13938  CCTTCAGACTGCCCCCAGGG-CCTCCATCCCAGGACATGCCTCCCCTGCCTCCCAGTGCT 13880 
 
 Query  76     GTCCCTCGTCCCACACCTGACTCAGTGTGTTCCCCATCAGCGGTCATGAGGCACGGAGGA 135 
               |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
 Sbjct  13879  GTCCCTCGTCCCACACCTGACTCAGTGTGT-CCCCATCAGCGGTCATGAGGCACGGAGGA 13821 
 
 Query  136    CTTCCCACACCTGCCCTTCTCTGAATTGTGACCACACTCCCCAGACACCTCGGCTTTCTC 195 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13820  CTTCCCACACCTGCCCTTCTCTGAATTGTGACCACACTCCCCAGACACCTCGGCTTTCTC 13761 
 
 Query  196    CCTCAAATTCATATTCTCTTACTTAGGTTGAGCCAAATGCCCTTGGGGTACCTGCAGGGT 255 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  13760  CCTCAAATTCATATTCTCTTACTTAGGTTGAGCCAAATGCCCTTGGGGTACCTGCAGGGT 13701 
 
 Query  256    TTGTCTGATCCCCATCACCCCTGTGTAACTGACTTCA-GGTCGCTGTGCCCATGTTTCCA 314 
               |||||||| |||||||||||||||||||||||||||| |||||||||||||||||||||| 
 Sbjct  13700  TTGTCTGACCCCCATCACCCCTGTGTAACTGACTTCAGGGTCGCTGTGCCCATGTTTCCA 13641 
 
 Query  315    CTGCCTACCTGCCCCGCCCTGCTCACCTGGAGGGCCTCTCTCGCCAGGCTCCCCCTTCTC 374 
               ||||| ||||||||||||||||||||||||||||||||||||||||| |||||||||||| 
 Sbjct  13640  CTGCCCACCTGCCCCGCCCTGCTCACCTGGAGGGCCTCTCTCGCCAGCCTCCCCCTTCTC 13581 
 
 Query  375    T  375 
               | 
 Sbjct  13580  T  13580 
 
Figure AII.28. Alignment of Query sequence with: gb|AY206682.1| Homo 
sapiens surfactant, pulmonary-associated protein A2 (SFTPA2) gene, 
complete cds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II: Sequencing Results  158
AII.8 SPA2-140 
 
 
 
 CTCCTGTCATGGCTAATGCTCTCAAACTNCACAGATGGTCAGTCGGGAGT 
 ACAGGCAGTTCCTGTCATTCCACTGCCCATCTGTGTACATCTCCACACAC 
 TGGCTCTTTTCCCCGACCTGCAGGCTCCCCTCGGTACCAGTTGGTGTAGT 
 TTACAGGTGTCCCATCTGAGTAGCGGAAGTCTCCAGGGCTGGGACCCTCA 
 GTCAGGCCTACATAGGCATATGTGTTGTACTTCTTCACGAAGCTTGCAAT 
 GGCCTCATTTTCCTCTGGATTCCTTGGGACAGCAATGCGGCCGCCTGCTC 
 TGGCACATGCCTCCTGAATGGCATCAAAAGTGATGGACTGCCC 
 
Figure AII.29. Sequence of PCR product amplified for SPA2-140. The PCR 
product length was expected to be 395 bp but sequencing reported 343 bp. 
 
 
 
 BLASTN 2.2.15 [Oct-15-2006]  
 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. SchÃ¤ffer,  
 Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
 (1997), "Gapped BLAST and PSI-BLAST: a new generation of  
 protein database search programs", Nucleic Acids Res. 25:3389-3402. 
 
 RID: 1168989274-21576-192109586657.BLASTQ1 
 
 Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
 GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
           4,758,117 sequences; 18,951,497,157 total letters 
 Query=   
 Length=343 
 
Figure AII.30. Parameters from BLAST search with SPA2-140 sequence.  
 
 
 
                                                                   Score     E 
                                                                   (Bits)  Value 
 
 ref|XM_001133054.1|  PREDICTED: Homo sapiens similar to Pulmon...   599   6e-169 
 ref|XM_001133049.1|  PREDICTED: Homo sapiens similar to Pulmon...   599   6e-169 
 ref|XM_001133043.1|  PREDICTED: Homo sapiens similar to Pulmon...   599   6e-169 
 ref|XM_001133039.1|  PREDICTED: Homo sapiens similar to Pulmon...   599   6e-169 
 ref|XM_001133037.1|  PREDICTED: Homo sapiens similar to Pulmon...   599   6e-169 
 ref|XM_001133034.1|  PREDICTED: Homo sapiens similar to Pulmon...   599   6e-169 
 ref|XM_001133031.1|  PREDICTED: Homo sapiens similar to Pulmon...   599   6e-169 
 dbj|AK225599.1|  Homo sapiens mRNA for Pulmonary surfactant-as...   599   6e-169 
 gb|AC068139.6|  Homo sapiens chromosome 10 clone RP11-506M13, com   599   6e-169 
 emb|BX248123.5|  Human DNA sequence from clone RP11-589B3 on c...   599   6e-169 
 gb|AY206682.1|  Homo sapiens surfactant, pulmonary-associated ...   599   6e-169 
 
 
Figure AII.31. First ten sequences producing significant alignments with SPA2-
140. 
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 Length=18039 
 Score =  599 bits (302),  Expect = 6e-169 
 Identities = 312/314 (99%), Gaps = 1/314 (0%) 
 Strand=Plus/Minus 
 
 Query  30     CACAGATGGTCAGTCGGGAGTACAGGCAGTTCCTGTCATTCCACTGCCCATCTGTGTACA 89 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  15284  CACAGATGGTCAGTCGGGAGTACAGGCAGTTCCTGTCATTCCACTGCCCATCTGTGTACA 15225 
 
 Query  90     TCTCCACACACTGGCTCTTTTCCCCGACCTGCAGGCTCCCCTCGGTACCAGTTGGTGTAG 149 
               ||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  15224  TCTCCACACACTG-CTCTTTTCCCCGACCTGCAGGCTCCCCTCGGTACCAGTTGGTGTAG 15166 
 
 Query  150    TTTACAGGTGTCCCATCTGAGTAGCGGAAGTCTCCAGGGCTGGGACCCTCAGTCAGGCCT 209 
               |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  15165  TTTACAGGGGTCCCATCTGAGTAGCGGAAGTCTCCAGGGCTGGGACCCTCAGTCAGGCCT 15106 
 
 Query  210    ACATAGGCATATGTGTTGTACTTCTTCACGAAGCTTGCAATGGCCTCATTTTCCTCTGGA 269 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  15105  ACATAGGCATATGTGTTGTACTTCTTCACGAAGCTTGCAATGGCCTCATTTTCCTCTGGA 15046 
 
 Query  270    TTCCTTGGGACAGCAATGCGGCCGCCTGCTCTGGCACATGCCTCCTGAATGGCATCAAAA 329 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  15045  TTCCTTGGGACAGCAATGCGGCCGCCTGCTCTGGCACATGCCTCCTGAATGGCATCAAAA 14986 
 
 Query  330    GTGATGGACTGCCC  343 
               |||||||||||||| 
 Sbjct  14985  GTGATGGACTGCCC  14972 
 
Figure AII.32. Alignment of Query sequence with: gb|AY206682.1| Homo 
sapiens surfactant, pulmonary-associated protein A2 (SFTPA2) gene, 
complete cds. 
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AII.9 SPA2-223 
 
 
 
 CTCTTGCTTTCACTGAATCCTAGTGGACCTTGCACCNTTTCTGGCAACTA 
 AGTAATTAGTTCACTTAGCATAATGAATAAATGGAGGATGAGTCTAAACA 
 GTGAAGTNTAGAACAATCTGCNACTTGGCACACGAGGAATGAGAATGACA  
 CATGCAGAAGAGGCACGAGAATGGTTGTAGCACTGGTGAGAAGAATCTGG 
 TAGCAGAGTACCCTAGGCTGAGGGAGGTGGCTTAGAGACAACAGTGGTCA 
 GTGGCCTGACCTGGACTCCTCTGCTCTCAGCCCTCAGTCTGCAGGGCTCC 
 ATAATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCAC 
 TTTTGATGCCATTCAGGAGGCATGTGCCAGAGCAGGCGGCCGCATTGCTG 
 TCCCAATGGAATCCAGAGGAAAATGAGGCCATTGCAAGCTTCGTGAAGAA 
 GTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGGAG 
 ACTTCCGCTACTCAGATGGGACCCCTGTAAACTACACCAACTGGTACCGA 
 GGGGAGCCTGCAGGTCGGGGAAAAGAGCAGTGTGTGGAGATGTTAAGGGG 
 
Figure AII.33. Sequence of PCR product amplified for SPA2-223. The PCR 
product length was expected to be 588 bp but sequencing reported 600 bp. 
 
 
 
 BLASTN 2.2.15 [Oct-15-2006] 
 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. SchÃ¤ffer,  
 Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
 (1997), "Gapped BLAST and PSI-BLAST: a new generation of  
 protein database search programs", Nucleic Acids Res. 25:3389-3402. 
 
 RID: 1168989483-26420-86004695366.BLASTQ4 
 
 Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
 GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
           4,758,117 sequences; 18,951,497,157 total letters 
 Query=   
 Length=600 
  
Figure AII.34. Parameters from BLAST search with SPA2-223 sequence.  
 
 
 
                                                                   Score     E 
                                                                  (Bits)  Value 
 
 gb|AC068139.6|  Homo sapiens chromosome 10 clone RP11-506M13, com   733   0.0    
 emb|BX248123.5|  Human DNA sequence from clone RP11-589B3 on c...   733   0.0    
 gb|AY206682.1|  Homo sapiens surfactant, pulmonary-associated ...   733   0.0    
 gb|M68519.1|HUMSFTP1A  Human pulmonary surfactant-associated p...   728   0.0    
 gb|AY198391.1|  Homo sapiens surfactant, pulmonary-associated ...   702   0.0    
 gb|M30838.1|HUMPSAP  Human pulmonary surfactant apoprotein (PSAP)   694   0.0    
 ref|XM_001133054.1|  PREDICTED: Homo sapiens similar to Pulmon...   609   1e-171 
 ref|XM_001133049.1|  PREDICTED: Homo sapiens similar to Pulmon...   609   1e-171 
 ref|XM_001133043.1|  PREDICTED: Homo sapiens similar to Pulmon...   609   1e-171 
 ref|XM_001133039.1|  PREDICTED: Homo sapiens similar to Pulmon...   609   1e-171 
 
Figure AII.35. First ten sequences producing significant alignments with SPA2-
223. 
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 Length=18039 
 Score =  733 bits (370),  Expect = 0.0 
 Identities = 398/402 (99%), Gaps = 4/402 (0%) 
 Strand=Plus/Plus 
 
Query  192    AGAATCTGGTAGCAGAGTACCCTAGGCTGAGGGAGGTGGCTTAGAGACAACAGTGGTCAG  251 
              ||||||||||||||||| |||||||| ||||||||||||||||||||||| ||||||||| 
Sbjct  14830  AGAATCTGGTAGCAGAG-ACCCTAGG-TGAGGGAGGTGGCTTAGAGACAA-AGTGGTCAG  14886 
 
Query  252    TGGCCTGACCTGGACTCCTCTGCTCTCAGCCCTCAGTCTGCAGGGCTCCATAATGACAGT  311 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  14887  TGGCCTGACCTGGACTCCTCTGCTCTCAGCCCTCAGTCTGCAGGGCTCCATAATGACAGT  14946 
 
Query  312    AGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCATTCAGGAGGC  371 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  14947  AGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCATTCAGGAGGC  15006 
 
Query  372    ATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAATGGAATCCAGAGGAAAATGAGGCCA  431 
              ||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  15007  ATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAA-GGAATCCAGAGGAAAATGAGGCCA  15065 
 
Query  432    TTGCAAGCTTCGTGAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCA  491 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  15066  TTGCAAGCTTCGTGAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCA  15125 
 
Query  492    GCCCTGGAGACTTCCGCTACTCAGATGGGACCCCTGTAAACTACACCAACTGGTACCGAG  551 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  15126  GCCCTGGAGACTTCCGCTACTCAGATGGGACCCCTGTAAACTACACCAACTGGTACCGAG  15185 
 
Query  552    GGGAGCCTGCAGGTCGGGGAAAAGAGCAGTGTGTGGAGATGT  593 
              |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  15186  GGGAGCCTGCAGGTCGGGGAAAAGAGCAGTGTGTGGAGATGT  15227 
 
 
 Score = 48.1 bits (24),  Expect = 0.009 
 Identities = 85/98 (86%), Gaps = 7/98 (7%) 
 Strand=Plus/Plus 
 
Query  2      TCTTGCTTTC-ACTGAATCCTAGTGGACCTTGCACCNTTTCTGGCAACTAAGTAATTAGT  60 
              |||||||||| ||||||||||||  ||  ||||||| |||||||||| ||||||||| || 
Sbjct  14666  TCTTGCTTTCCACTGAATCCTAG--GAAATTGCACCATTTCTGGCAA-TAAGTAATT-GT  14721 
 
Query  61     TCACTTAGCATAATGAATAAATGGAGGATGAGTCTAAA  98 
              | ||||||   ||||||||||||||||| ||||||||| 
Sbjct  14722  T-ACTTAGATGAATGAATAAATGGAGGA-GAGTCTAAA  14757 
 
Figure AII.36. Alignment of Query sequence with: gb|AY206682.1| Homo 
sapiens surfactant, pulmonary-associated protein A2 (SFTPA2) gene, 
complete cds. 
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AII.10 SPD-11 
 
 
 
 GATCATTGACATTCTCCCCAGCAGGATAGCCTNTGCCCCACCCTACTGGG 
 TCCCCCTTCTCGCCCCGAGGGCCCTCTCTCCCATCCCGTCCATCGCGACC 
 AGGGCAGGCCACTCTCCACTGAGCTACACATGACCAGGGTGCAAGCACTG 
 GGCGTTGTTCTGTGGGAGTAGGTA 
 
Figure AII.37. Sequence of PCR product amplified for SPD-11. The PCR 
product length was expected to be 200 bp but sequencing reported 174 bp. 
 
 
 
 BLASTN 2.2.15 [Oct-15-2006] 
 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. SchÃ¤ffer,  
 Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
 (1997), "Gapped BLAST and PSI-BLAST: a new generation of  
 protein database search programs", Nucleic Acids Res. 25:3389-3402. 
 
 RID: 1168989590-468-26017252380.BLASTQ4 
 
 Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
 GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
           4,758,117 sequences; 18,951,497,157 total letters 
 Query=   
 Length=174 
 
 
Figure AII.38. Parameters from BLAST search with SPD-11 sequence.  
 
 
 
                                                                   Score     E 
                                                                   (Bits)  Value 
 
 emb|X65018.1|HSMRNAPD  H.sapiens mRNA for lung surfactant protein   238   1e-60 
 emb|AL512662.8|  Human DNA sequence from clone RP11-479O17 on ...   238   1e-60 
 gb|AY216721.1|  Homo sapiens surfactant, pulmonary-associated ...   238   1e-60 
 emb|CR541948.1|  Homo sapiens full open reading frame cDNA clo...   238   1e-60 
 gb|L05483.1|HUMSPD01  Human surfactant protein D (SP-D) gene, exo   238   1e-60 
 ref|NM_003019.4|  Homo sapiens surfactant, pulmonary-associate...   230   3e-58 
 gb|BC022318.1|  Homo sapiens surfactant, pulmonary-associated ...   230   3e-58 
 gb|AC090885.1|AC090885  Homo sapiens chromosome 3 clone RP11-2...  40.1   0.57  
 gb|AC006541.1|AC006541  Homo sapiens chromosome 19, cosmid R29621  40.1   0.57  
 gb|AC069246.6|  Homo sapiens chromosome 3 clone RP11-221A8 map...  40.1   0.57  
 
 
Figure AII.39. First ten sequences producing significant alignments with SPD-
11. 
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 Length=23538 
 Score =  238 bits (120),  Expect = 1e-60 
 Identities = 137/140 (97%), Gaps = 2/140 (1%) 
 Strand=Plus/Minus 
  
 Query  35    GCCCCACCCTAC-TGGGTCCCCCTTCTCGCCCCGAGGGCCCTCTCTCCCATCCCGTCCAT 93 
              |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  5094  GCCCCACCCTACCTGGGTCCCCCTTCTCGCCCCGAGGGCCCTCTCTCCCATCCCGTCCAT 5035 
 
 Query  94    CGCGACCAGGGCAGGCCACTCTCCACTGAGCTACACATGACCAGGGTGCAAGCACTGGGC 153 
              |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
 Sbjct  5034  CGCGACCAGG-CAGGCCACTCTCCACTGAGCTACACATGACCAGGGTGCAAGCACTGGGC 4976 
 
 Query  154   GTTGTTCTGTGGGAGTAGGT  173 
               ||||||||||||||||||| 
 Sbjct  4975  ATTGTTCTGTGGGAGTAGGT  4956 
 
Figure AII.40. Alignment of Query sequence with: gb|AY216721.1| Homo 
sapiens surfactant, pulmonary-associated protein D (SFTPD) gene, complete 
cds. 
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AII.11 SPD-160 
 
 
 
 CGTATCGTTTGTCCCTTCATCCCGGGGGTCCCCTGGCACCTGGACTTCCC 
 TGGGGACCCATGGCTCCAGCAGACCCTGGGGTAAAAGAAGAACTGGGTGA 
 GCTATGTACTCATTTTATTTTTTTTGTTTTTAGCATTTTTACCTTCCCAT 
 ACATGGACTAACTATCCTTATTGCCCAGAAATAGACAGATGGTCCCCAGT 
 ACCCAGCCATGCAGCTCCCTGTACACTGACTGTCCCTGTCACCCAGCAAT 
 CAACCCCGCTGTGGAAAACTGCCCCGCCACCCAACAACTAACCTTCCCTG 
 TATACAGACTTCTCCATTGCTTGCGCCTCACTCTCCCTAGATAGGAACAG 
 TCCCCAGAGCCCCCTCATGCACCCTTCTTGGATACAGATTCTCTCCATGT 
 TCCAGCGATACCACCTCTGCCTTTGTGGGTGGTGGAGGGGGTGTAGGCAT 
 TGACAGCTCCAAGCAGGCACAGGAGAACTGGACCCAGCCCAGCCCAGCTC 
 TTTCCACTGCTCACCTGCTGCCCCTGTGTTTCCAGGGAACTCCACGA 
 
 
Figure AII.41. Sequence of PCR product amplified for SPD-160. The PCR 
product length was expected to be 577 bp but sequencing reported 547 bp. 
 
 
BLASTN 2.2.15 [Oct-15-2006] 
Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. 
SchÃ¤ffer,  
Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman  
(1997), "Gapped BLAST and PSI-BLAST: a new generation of  
protein database search programs", Nucleic Acids Res. 25:3389-
3402. 
 
RID: 1169867613-22139-94224196694.BLASTQ1 
 
 
Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
GSS,environmental samples or phase 0, 1 or 2 HTGS sequences) 
4,911,723 sequences; 19,641,233,228 total letters 
Query=   
Length=547 
 
Figure AII.42. Parameters from BLAST search with SPD-160 sequence.  
 
 
                                                           Score     E 
                                                                  (Bits)  Value 
 
 emb|AL512662.8|  Human DNA sequence from clone RP11-479O17 on ...  1031   0.0   
 gb|AY216721.1|  Homo sapiens surfactant, pulmonary-associated ...  1023   0.0   
 gb|L05484.1|HUMSPD02  Human surfactant protein D (SP-D) gene, exo   735   0.0   
 gb|AY270843.1|  Homo sapiens clone SKT05-E10 putative promoter se   176   1e-41 
 gb|AY271192.1|  Homo sapiens clone SKG02-F03 putative promoter se   139   3e-30 
 ref|NM_003019.4|  Homo sapiens surfactant, pulmonary-associate...   119   3e-24 
 gb|BC022318.1|  Homo sapiens surfactant, pulmonary-associated ...   119   3e-24 
 emb|X65018.1|HSMRNAPD  H.sapiens mRNA for lung surfactant protein   119   3e-24 
 emb|CR541948.1|  Homo sapiens full open reading frame cDNA clo...   119   3e-24 
 gb|AC009974.10|  Homo sapiens BAC clone RP11-459I19 from 2, compl  46.1   0.032 
 
Figure AII.43. First ten sequences producing significant alignments with SPD-
160. 
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 Length=23538, Score = 1023 bits (516),  Expect = 0.0 
 Identities = 519/520 (99%), Gaps = 0/520 (0%) 
 Strand=Plus/Minus 
 
Query  19     ATCCCGGGGGTCCCCTGGCACCTGGACTTCCCTGGGGACCCATGGCTCCAGCAGACCCTG  78 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  10086  ATCCCGGGGGTCCCCTGGCACCTGGACTTCCCTGGGGACCCATGGCTCCAGCAGACCCTG  10027 
 
Query  79     GGGTAAAAGAAGAACTGGGTGAGCTATGTACTCATTTTATTTTTTTTGTTTTTAGCATTT  138 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  10026  GGGTAAAAGAAGAACTGGGTGAGCTATGTACTCATTTTATTTTTTTTGTTTTTAGCATTT  9967 
 
Query  139    TTACCTTCCCATACATGGACTAACTATCCTTATTGCCCAGAAATAGACAGATGGTCCCCA  198 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  9966   TTACCTTCCCATACATGGACTAACTATCCTTATTGCCCAGAAATAGACAGATGGTCCCCA  9907 
 
Query  199    GTACCCAGCCATGCAGCTCCCTGTACACTGACTGTCCCTGTCACCCAGCAATCAACCCCG  258 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  9906   GTACCCAGCCATGCAGCTCCCTGTACACTGACTGTCCCTGTCACCCAGCAATCAACCCCG  9847 
 
Query  259    CTGTGGAAAACTGCCCCGCCACCCAACAACTAACCTTCCCTGTATACAGACTTCTCCATT  318 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  9846   CTGTGGAAAACTGCCCCGCCACCCAACAACTAACCTTCCCTGTATACAGACTTCTCCATT  9787 
 
Query  319    GCTTGCGCCTCACTCTCCCTAGATAGGAACAGTCCCCAGAGCCCCCTCATGCACCCTTCT  378 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  9786   GCTTGCGCCTCACTCTCCCTAGATAGGAACAGTCCCCAGAGCCCCCTCATGCACCCTTCT  9727 
 
Query  379    TGGATACAGATTCTCTCCATGTTCCAGCGATACCACCTCTGCCTTTGTGGGTGGTGGAGG  438 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  9726   TGGATACAGATTCTCTCCATGTTCCAGCGATACCACCTCTGCCTTTGTGGGTGGTGGAGG  9667 
 
Query  439    GGGTGTAGGCATTGACAGCTCCAAGCAGGCACAGGAGAACTGGACCCAGCCCAGCCCAGC  498 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  9666   GGGTGTAGGCATTGACAGCTCCAAGCAGGCACAGGAGAACTGGACCCAGCCCAGCCCAGC  9607 
 
Query  499    TCTTTCCACTGCTCACCTGCTGCCCCTGTGTTTCCAGGGA  538 
              |||||||||||||||||||||||||||| ||||||||||| 
Sbjct  9606   TCTTTCCACTGCTCACCTGCTGCCCCTGCGTTTCCAGGGA  9567 
 
Figure AII.44. Alignment of Query sequence with: gb|AY216721.1| Homo 
sapiens surfactant, pulmonary-associated protein D (SFTPD) gene, complete 
cds. 
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AIII.1 RAOM/OME Population 
 
 
 
 
Table AIII.1. Sample information from the RAOM/OME diagnosed population 
(Part One). 
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Table AIII.2. Sample information from the RAOM/OME diagnosed population 
(Part Two). 
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Table AIII.3. Sample information from the RAOM/OME diagnosed population 
(Part Three). 
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Table AIII.4. Sample information from the RAOM/OME diagnosed population 
(Part Four). 
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Table AIII.5. Sample information from the RAOM/OME diagnosed population 
(Part Five). 
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    Key: 
ATE = Atelectasis M/P = Maori/Pacific Island 
A = Adenoidectomy OME = Otitis media with effusion 
CHO = Cholesteatoma RAOM = Reccurent acute otitis media 
E = Endoscopy RLG = Removal of left grommet 
ETD = Eustachian tube dysfunction RLT = Removal of left T-tube 
Euro = European-Caucasian RM = Right myringoplasty 
F = Female RMI = Right microinspection 
G = Grommets ROME = Recurrent OME 
L = Laryngoscopy RRG = Removal of right grommet 
LCM = Left cortical mastoidectomy T = Tonsillectomy 
LM = Left myringoscopy TT = T-tubes 
M = Male U = Unknown 
 
Table AIII.6. Sample information from the RAOM/OME diagnosed population 
(Part Six). 
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AIII.2 Control Population 
 
 
 
Sample 
Number Age Sex Ethnicity 
Sample 
Number Age Sex Ethnicity 
C1 28 F European C31 47 F European 
C2 43 F European C32 22 F Other 
C3 63 M European C33 30 M European 
C4 24 F European C34 50 F European 
C5 46 M European C35 39 F European 
C6 19 F Maori/Polynesian C36 37 M European 
C7 53 F European C37 53 M European 
C8 55 F European C38 48 M European 
C9 33 F European C39 38 M European 
C10 61 M European C40 36 M European 
C11 18 M European C41 56 M European 
C12 23 F European C42 22 F European 
C13 42 F European C43 51 M Maori/Polynesian
C14 53 M European C44 38 F European 
C15 48 M European C45 58 F European 
C16 59 M European C46 37 M European 
C17 27 F Maori/Polynesian C47 48 F European 
C18 20 F European C48 46 M European 
C19 52 F European C49 25 F European 
C20 40 M European C50 58 F European 
C21 40 F European C51 59 F European 
C22 21 F European C52 57 F European 
C23 27 F European C53 44 F European 
C24 43 F European C54 47 M European 
C25 48 M European C55 34 F European 
C26 41 M European C56 53 M European 
C27 55 M European C57 38 M Maori/Polynesian
C28 42 F Other C58 24 F Euro/other 
C29 17 M European C59 34 F European 
C30     Unknown  C60 45 M Maori/Polynesian
Continued next page… 
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Sample 
Number Age Sex Ethnicity 
Sample 
Number Age Sex Ethnicity 
C61 53 F European C99 26 M European 
C62 25 M European C100 48 M European 
C63 59 F European C101 25 M European 
C64 37 M European C102 25 F Other 
C65 46 F European C103 45 F Other 
C66 44 F European C104 36 M European 
C67 60 M European C105 25 F Maori/Polynesian
C68 46 F Other C106 37 M Euro/Other 
C69 41 F European C107 24 F European 
C70 49 M European C108 48 F Maori/Polynesian
C71 40 F European C109 46 F European 
C72 37 F European C110 43 M Maori/Polynesian
C73 48 M European C111 31 F European 
C74 33 F European C112 24 F European 
C75 31 F European C113 50 F Other 
C76 27 M European C114 47 M European 
C77 34 M Other C115 26 M European 
C78 34 M European C116 36 M European 
C79 37 M European C117 21 M Maori/Polynesian
C80 25 F European C118 38 F Unknown 
C81 38 F European C119 27 M European 
C82 44 M European C120 60 M European 
C83 41 M European C121 51 M European 
C84 52 F Maori/Polynesian C122 36 F European 
C85 54 M European C123 41 M European 
C86 44 M European C124 57 F Maori/Polynesian
C87 57 F European C125 24 M European 
C88 22 F European C126 53 M European 
C89 41 M European C127 45 M European 
C90 46 F European C128 21 F European 
C91 19 F Other C129    Unknown 
C92 57 F European C130 49 F Maori/Polynesian
C93 33 F European C131 67 M European 
C94 24 F European C132 67 F European 
C95 57 M European C133 48 F Other 
C96 29 F European C134 52 M European 
C97 51 F European C135 25 F European 
C98 23 F European  C136 18 M Maori/Polynesian
Continued next page… 
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Sample 
Number Age Sex Ethnicity 
C137 61 F European 
C138 47 F Other 
C139 19 M Maori/Polynesian
C140 38 M Other 
C141 41 M European 
C142 40 M European 
C143 22 F Other 
C144 61 F Other 
C145 48 F European 
C146 57 F European 
C147 45 F European 
C148 19 F European 
C149 23 M European 
C150 32 F Maori/Polynesian
C151 40 F European 
C152 33 F European 
C153 38 F European 
C154 52 M Other 
C155 38 F European 
C156  29 F  European 
C157  44 M   European 
C158  43 M  European 
C159  21 M   European 
C160  39 F   European 
 
Table AIII.7. Control population sample information. The control population 
consisted of volunteer blood donors from the New Zealand Blood Service, 
Hamilton. M = Male, F = Female. 
 
 
 
 
 
 
 
 
 
 
176 
APPENDIX IV 
 
GENOTYPING RESULTS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix IV: Genotyping Results  177
 
 
Table AIV. 1. Raw genotype data for RAOM/OME individuals in the case 
population (Part One). 
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Table AIV.2. Raw genotype data for RAOM/OME individuals in the case 
population (Part Two). 
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Table AIV.3. Raw genotype data for RAOM/OME individuals in the case 
population (Part Three). 
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Table AIV.4. Raw genotype data for RAOM/OME individuals in the case 
population (Part Four). 
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Table AIV.5. Raw genotype data for RAOM/OME individuals in the case 
population (Part Five). 
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Table AIV.6. Raw genotype data for the control population (Part One). 
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Table AIV.7. Raw genotype data for the control population (Part Two). 
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Table AIV.8. Raw genotype data for the control population (Part Three). 
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Table AIV.9. Raw genotype data for the control population (Part Four). 
 
 
 
 
Appendix IV: Genotyping Results  186
 
 
Table AIV.10. Raw genotype data for the control population (Part Five). 
 
 
 
 
Appendix IV: Genotyping Results  187
    
 
Table AIV.11. Raw genotype data for the control population (Part Six). 
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Table AIV.12. Raw genotype data for the (A) New Zealand Maori/Pacific Island 
population and the (B) meningococcal disease individuals. 
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